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Abstract: The complex hide-and-seek game between HIV-1 and the host immune system 
has impaired the development of an efficient vaccine. In addition, the high variability of 
the virus impedes the long-term control of viral replication by small antiviral drugs. For 
more than 20 years, phage display technology has been intensively used in the field of 
HIV-1  to  explore  the  epitope  landscape  recognized  by  monoclonal  and  polyclonal  
HIV-1-specific  antibodies,  thereby  providing  precious  data  about  immunodominant  and 
neutralizing epitopes. In parallel, biopanning experiments with various combinatorial or 
antibody fragment libraries were conducted on viral targets as well as host receptors to 
identify HIV-1 inhibitors. Besides these applications, phage display technology has been 
applied to characterize the enzymatic specificity of the HIV-1 protease. Phage particles 
also  represent  valuable  alternative  carriers  displaying  various  HIV-1  antigens  to  the 
immune system and eliciting antiviral responses. This review presents and summarizes the 
different studies conducted with regard to the nature of phage libraries, target display mode 
and biopanning procedures.  
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Abbreviations:  AA,  amino  acids;  Ab,  Antibody;  ADCC,  Antibody-Dependent  Cellular 
Cytotoxicity; AIDS, Acquired ImmunoDeficiency Syndrome; ARM, Arginine Rich Motif; BNtAb, 
Broadly  Neutralizing  Antibody;  BS,  Binding  Site;  BSA,  Bovine  Serum  Albumin;  CCR5,  CC 
chemokine Receptor 5; CD, Cluster of Differentiation; CDR, Complementarity Determining Region;  
CH,  Constant  Heavy  chain  domain;  CHR,  C-terminal  Heptad  Repeats;  CTL,  Cytotoxic  
T-Lymphocytes; CXCR4, CXC chemokine Receptor 4; DDDP, DNA-Dependent DNA Polymerase; 
ECL, ExtraCellular Loop; Fab, Fragment antigen-binding; FIV, Feline ImmunoDeficiency Virus; FR, 
Frameworks;  Gag,  group-specific  antigen;  gp,  glycoprotein;  HAART,  Highly  Active  
Anti-Retroviral  Therapy;  HB,  Helix  Bundle;  HcAb,  Heavy-chain  only  Antibody;  
HCDR,  Heavy-chain  Complementarity  Determining  Region;  HIV-1,  Human  ImmunoDeficiency 
Virus;  HLA,  Human  Leukocyte  Antigen;  HOC,  Highly  antigenic  Outer  Capsid  protein;  
IC50,  Inhibitory  Concentration  50;  ID,  Immuno  Dominant;  ID50,  Inhibitory  Dose  50;  
Ig, Immunoglobulin; IN, Integrase; KD, dissociation constant; KLH, Keyhole Limpet Hemocyanin; 
LTNP, Long-Term Non-Progressor; MAb, Monoclonal Antibody; MHC, Major Histocompatibility 
Complex;  MPER,  Membrane  Proximal  External  Region;  NC,  NucleoCapsid;  NCp,  Nucleocapsid 
protein; Nef, Negative factor; NHR, N-terminal Heptad Repeats; NLS, Nuclear Localization Signal; 
NNY, n-nonanoyl; NtAb, Neutralizing Antibody; PAb, Polyclonal Antibody; PBL, Peripheral Blood 
Lymphocytes;  PBMC,  peripheral  blood  mononuclear  cell;  PHI,  PreHairpin  Intermediate;  
PIC, PreIntegration Complex; PIE, Pocket-specific Inhibitor of Entry; PR, Protease; psi, packaging 
signal;  RDDP,  RNA-Dependent  DNA  Polymerase;  Rev,  Regulator  of  virion  expression;  
RPL, Randomized Peptide Library; RT, Reverse Transcriptase; ScFv, Single-chain variable fragment; 
SOC,  Small  Outer  Capsid  protein  ;  SPR,  Surface  Plasmon  Resonance;  TAR,  Transactivation 
Response element; TCR, T-Cells Receptor; TRM, Tat/TAR Recognition Motif; UDG, Uracyl DNA 
Glycosylase; VH, Variable Heavy chain domain; VHH, Variable Heavy-chain domains of Heavy-chain 
only Antibodies; Vif, Virion infectivity Factor; VL, Variable Light chain domain; vpr, Viral Protein of 
Regulation; VLP, Virus-Like Particle. 
1. Introduction 
In 1983, the human immunodeficiency virus (HIV-1) was identified as the causative agent of the 
Acquired ImmunoDeficiency Syndrome (AIDS) [1,2]. In 30 years of pandemic, HIV-1 has infected 
more than 60 million individuals and killed 25 million. Thirty-three million individuals are currently 
living with HIV-1 making this disease a major worldwide public health problem (UNAIDS 2010). 
Natural sterilizing immune response against HIV-1 has never been described and despite decades of 
intensive research, a vaccine against HIV-1 is still lacking, mainly due to the high ability of the virus 
to escape from the immune response.  
In the  absence of  a  vaccine, combinations  of small  antiviral  molecules are intensively used to 
control HIV-1 infection. The majority of these drugs are reverse transcriptase and protease inhibitors [3]. 
More recently, new molecules targeting the fusion step, CCR5 or integrase were licensed for clinical  
use [4–6]. Despite the increased life expectancy observed with the advent of these therapies, severe 
side effects, lack of adherence and emergence of drug-resistant virus strains still limit the long-term 
control of the infection [7].  Int. J. Mol. Sci. 2012, 13  4729 
 
HIV-1 is an enveloped virus whose genetic material consists of two identical RNA strands coding 
for the structural genes gag, pol and env as well as the accessory genes tat, rev, nef, vif, vpr and vpu. 
The gag gene codes for structural proteins p17 and p24, while pol codes for viral enzymes (reverse 
transcriptase,  integrase  and  protease)  and  env  for  the  gp160  envelope  protein  precursor  that  is 
subsequently cleaved into gp120 and gp41. Gp120 and gp41 proteins assemble at the surface of HIV-1 
into trimeric spikes composed of three monomers of membrane-embedded gp41 complexed to free 
gp120.  These  two  proteins  are  involved  in  virus  entry  and  represent  the  principal  targets  for  the 
humoral response. 
Upon CD4 receptor binding, glycoprotein gp120 undergoes conformational changes exposing the 
V3  loop,  a  region  that  further  interacts  with  the  chemokine  receptors  CCR5  or  CXCR4  thereby 
promoting viral entry [8] (Figure 1). Coreceptor binding leads to the insertion of the gp41 fusion 
peptide into the cell membrane, the creation of a hairpin loop intermediate and finally the fusion of 
both viral and cell membranes. The viral capsid then enters the cell and the genetic material is released 
in the cytoplasm. Most viral strains use only one coreceptor to enter host cells and are classified 
accordingly as CCR5- (R5 strains) or CXCR4-tropic (X4 strains), although viruses with broadened 
coreceptor  usage  (dual-tropic)  have  also  been  described.  R5  viruses  infect  macrophages  and  
CCR5-expressing T lymphocytes, and are mainly associated with transmission. In contrast, X4 viruses 
infect CXCR4-expressing T-cells and T-cell lines, and often appear at the later stages of infection. 
Figure 1. Model for HIV-1 entry. (A and B) Binding of Cluster of Differentiation (CD)4 to 
glycoprotein (gp)120 exposes a coreceptor binding site in gp120; (C and D) Coreceptor 
binding causes the exposure of the gp41 fusion peptide and its insertion into the membrane 
of the target cell in a triple-stranded coiled-coil; (E) Formation of a helical hairpin structure 
in which gp41 folds back on itself is coincident with membrane fusion.  
 
The  envelope  glycoprotein  gp120  is  composed  of  variable  and  more  constant  regions.  Several 
studies demonstrated that the elicitation or binding of effective neutralizing antibodies are impaired  
by  the  gp120  glycan  shield  or  steric  hindrance  of  its  constant  regions  [9].  Moreover,  variable 
immunodominant domains were shown to be recognized by non-neutralizing antibodies. Nonetheless, 
it is estimated that 10% to 30% of HIV-1-positive subjects develop neutralizing antibodies (NtAbs) 
appearing at least 1 year after infection. Only 1% of infected patients develop a broad neutralizing 
response against heterologous virus strains [10]. Among HIV-1-infected patients, such antibodies arise 
only rarely and tardily, thus inefficiently controlling viral replication. However, the recent identification Int. J. Mol. Sci. 2012, 13  4730 
 
of  broadly  neutralizing  antibodies  (BNtAbs)  and  mapping  of  their  epitopes  fueled  interest  in  the 
humoral immune response against HIV-1 (reviewed by Overbaugh [11]). 
To better understand the reasons underlying the persistance of viral infection despite the strong and 
sustained immune response on the one hand, and to identify new protective immunogens, numerous 
studies were conducted to map the epitope landscape of both HIV-1-neutralizing and non-neutralizing 
antibodies isolated from infected patients. In parallel, the development of new molecules or antibody 
fragments capable of blocking either viral proteins or host receptors has been widely investigated. 
To serve this purpose, the phage display technology has been extensively exploited in the field of 
HIV-1 as it represents one of the most powerful technologies for epitope mapping as well as for the 
identification of ligand binding to many types of targets.  
Bacteriophages (phages) are bacteria-infecting viruses whose DNA or RNA genome is packed in a 
capsid composed exclusively of surface proteins. The principle of phage display relies on cloning of 
exogenous DNA in fusion with the phage genetic material allowing the display of foreign peptides in 
an immunologically and biologically competent form at the surface of phage capsid proteins [12]. The 
significance of phage display was first demonstrated for filamentous phages such as M13, fd or related 
phagemids and later extended to lytic bacteriophages λ, T4 and T7 (reviewed by Beghetto [13]). The 
phage biopanning process consists of iterative cycles of binding, washing and elution steps leading to 
the progressive selection of phages displaying peptides/proteins binding to the target of interest [14]. 
The target is usually immobilized on a solid support which can be plastic, beads or even cells. 
A significant advantage of this technology is that phages may be used to display a collection of 
sequences  (phage  library),  reaching  up  to  billions  of  distinct  sequences.  Phage  libraries  can  be 
constructed to express combinatorial peptides or proteins/immunoglobulin fragments/variants that may 
be further screened for many different purposes including drug discovery, epitope mapping, diagnosis 
as well as identification of therapeutic antibodies. The phage display technology is versatile as it can 
be applied to different domains of research; it allows the easy handling and high-throughput screening 
of  billions  of  sequences.  It  is  affordable  and  enables  the  identification  of  linear  as  well  as 
conformational epitopes when applied to an antibody target. 
Numerous studies have described the use of the phage display technology in the field of HIV-1 
were reported. They can be classified in four main applications (Figure 2): 
I.  Epitope mapping, which relies on the screening of random peptide libraries on immobilized 
monoclonal or polyclonal antibodies to determine the linear and/or conformational epitopes 
recognized by these antibodies (linear epitope: sequence of continuous amino acids recognized 
by the paratope of a given antibody; conformational/discontinuous epitope: group of amino 
acids scattered along a protein sequence which come together in the folded protein and are 
recognized  by  the  paratope  of  a  given  antibody).  Such  screening  usually  results  in  the 
identification of sequences mimicking the natural epitope (mimotopes) and provides precise 
information about the location of residues forming the natural epitope. These mimotopes may 
in turn be used as valuable immunogens to elicit antibodies targeting the original epitope, an 
approach referred to as ―reverse vaccinology‖. 
II.  Inhibitor  discovery,  based  on  screening  of  phage  libraries  displaying  random  peptides  or 
antibody fragments against viral or host proteins critical for viral replication.  Int. J. Mol. Sci. 2012, 13  4731 
 
III.  ―Phage Substrate‖ approach in which potential substrate sequences are displayed at the phage 
surface to enzymes such as proteases. This approach not only allows for proteolysis specificity 
profiling, but provides information and data to develop specific inhibitors. 
IV.  Carrier phage, in which the phage functions as a ―carrier‖, ―vehicle‖ or ―virus-like particle‖ to 
display exogenous peptides such as mimotopes or even full size antigens to the immune system, 
to elicit specific humoral and/or cytotoxic T-cells responses.  
This review is intended as an overview of the different studies conducted using phages in the field 
of HIV-1, laying special emphasis on the nature of the phage libraries used, the target display mode, 
the biopanning procedure as well as the results obtained. These studies are classified according to the 4 
applications described above and the main results are presented in tables.  
Figure 2. Phage display applications in the field of HIV-1. (A) Epitope mapping (section 1): 
Randomized  Peptide  Library  (RPL)  or  antigen-fragment  libraries  are  used  to  map  the 
residues forming the epitope(s) recognized by either monoclonal or polyclonal antibodies 
immobilized on a solid support; (B) Inhibitor discovery (section 2): RPL, antibody-fragments 
or  ligand  variants  libraries  are  used  to  select  for  viral  or  host-cell  protein  inhibitors;  
(C)  Phage  substrate  (section  3):  phage  particles  immobilized  on  a  solid  support  are 
specifically eluted by the proteolytic activity of the HIV-1 protease; (D) Phage as carrier 
(section 4): phage particles or derived Virus-Like Particles (VLPs) are used to display 
immunogenic peptides or whole antigens to the immune system. 
 
2. Exploration of HIV-1 Epitope Landscape  
Monoclonal antibodies (MAbs) or polyclonal antibodies (PAbs) epitopes can be identified through 
screening  either  combinatorial  or  antigen-fragment  libraries  displayed  at  the  surface  of  phages. 
Antibodies may be derived from infected/immunized animals or from HIV seropositive patients with 
peculiar immunological profiles, such as the Long Term Non Progressors (LTNP) [15], leading to the 
identification and characterization of HIV mimotopes.  Int. J. Mol. Sci. 2012, 13  4732 
 
2.1. Antibodies Directed against Viral Proteins 
2.1.1. Monoclonal Antibodies Directed against Viral Epitopes 
2.1.1.1. Gp120 V3 Loop 
The seminal paper characterizing the epitope recognized by a MAb directed against HIV-1 using 
the  phage  display  technology  was  published  in  1993.  Keller  et  al.  screened  a  15-mer  Random  
Peptide  Library  (RPL)  against  the  BNtAb  447-52D  which  targets  the  V3  loop  of  gp120 
(KRKRIHIGPGRAFY)  [16]  (Figure  3)  and  identified  70  clones  presenting  a  GPxR  consensus 
sequence [17] (Table 1). These mimotopes were further used in rabbit immunization experiments and 
elicited neutralizing responses. Boots et al. later investigated the linear epitope recognized by the MAb 
447-52D  by  combining  gp120  competition  and  panning  of  V3-region  biased/constrained  libraries. 
Such a set-up favors the selection of mimotopes in which residues surrounding the GPGR crown motif 
are similar to those present in the gp120 used for competition, suggesting that the use of strain-specific 
competitors with a MAb of broad specificity can select for strain-specific mimotopes [18]. 
Figure 3. Epitope landscape of HIV-1 Env proteins. Monoclonal antibodies were mapped 
to different sites on the surface of the gp120 and gp41 proteins. 
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Table 1. Epitope mapping of monoclonal antibodies directed against viral epitopes. 
Target  Library  Target presentation  Mimotopes  Epitopes  Additional 
Vaccination 
attempts 
Results  Reference 
MAb447-52D 
(1) 15-mer RPL 
(2) 2 sublibraries 
(Cx5GPxRx5C, 
LLx5GPxRx5LL) 
(1) NA 
(2) Ab captured on 
polystyrene beads 
GPxR 
gp120 V3 
loop 
NA 
Rabbit 
immunization with 
1 peptide 
NAbs induced  [17,18] 
MAb 58.2  20-mer RPL 
(1) Biotinylated Ab 
captured on 
streptavidin-coated 
plates 
(2) Microwells 
(Y/L)(V/L/I)GPGRxF 
gp120 V3 
loop 
Characterization of  
non-essential 
aminoacids in the 
epitope using a peptide 
array 
NA  NA  [19] 
MAb 19B  15-mer RPL 
Ab captured on 
polystyrene beads 
xIx4GxxFYxT 
gp120 V3 
loop 
Type II ß  turn structure 
of the epitope 
NA  NA  [18,20] 
MAb 1001  30-mer RPL 
Ab coated onto 
microwells 
(R/K/H)xGR 
gp120 V3 
loop 
Peptides fused to E. 
coli AP. Affinities for 
the Ab determined by 
SPR 
NA  NA  [21] 
(1) MAb 110-A 
(2) MAb 19.26.4 
6-mer RPL  NA 
(1) HyxRGP 
(2) xQ(R/K)GP 
gp120 V3 
loop 
QR insertion 
characteristic of the 
LAI isolate 
NA  NA  [22] 
MAb 268  6-mer RPL 
Biotinylated Ab 
captured on 
streptavidin-coated 
beads 
268.1 (HLGPGR), 
268.2 (KAIHRI) 
gp120 V3 
loop 
NA 
Rabbit 
immunization 
gp120-specific Abs  [23] 
MAb 2F5  15mer 
Ab captured on 
polystyrene beads 
ELDKW, D(K/R)W 
ELDKWA 
(gp41 MPER) 
2F5 affinity for gp41 
and gp41 peptide 
determined by SPR 
NA  NA  [24] 
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Table 1. Cont. 
Target  Library  Target presentation  Mimotopes  Epitopes  Additional 
Vaccination 
attempts 
Results  Reference 
MAb 2F5 
17 constrained and 
linear RPL,  
x12-AADKW and 
AADKW-x12 
sublibraries 
Biotinylated Ab 
captured on 
streptavidin-coated 
beads 
 
3 peptides (AADKW-x12) 
ELDKWA 
(gp41 
MPER) 
Ala substitutions and 
deletions studies 
NA  NA  [25] 
MAb 2F5 
12-mer and 7-mer-c 
RPL 
Ab coated onto 
microwells 
DKWA, LDKWA 
ELDKWA 
(gp41 
MPER) 
Epitope specificity 
depends on the 
structural context of 
the library 
Mice and rabbit 
immunization 
Inhibition of cell 
fusion 
[26] 
(1) MAb 
GV1A8 
(2) MAb 
GV4D3 
20-mer RPL 
Rabbit anti-mouse 
IgG, Fc-specific Ab 
coated on Petri dishes 
(1) HxxIxxLW 
(2) Nx3WxxD 
C1 domain 
of gp120 
Pepscan analysis, 
quantitative binding 
analysis 
NA  NA  [27] 
MAb ID6 
12-mer, 7-mer,  
7-mer-c RPL 
Mab captured on rat 
anti-mouse Ab coated 
microwells 
TxxFxxWxxD, 
FxDWxF 
C1 domain 
of gp120 
ADCC-inducing Ab  NA  NA  [28] 
MAb b12 
(1) 11 RPL 
(2) 2 sublibraries 
(x7SDLx3CI and 
xCxxSDLx3CI) 
Biotinylated IgG1b12 
captured on  
avidin-coated 
microwells 
(1) REKRWIFSDLTHTCI, 
TCLWSDLRAQCI 
(2) B2.1 
(HERSYMFSDLENRCI) 
gp120 CD4 
binding site 
Competition with 
gp120 for the binding 
to IgG1b12, 
determination of the 
in-solution binding 
affinity. 
(2) Phage B2.1 
immunization of 
mice and rabbits 
Anti-peptide Abs 
elicited 
[29,30] 
MAb b12 
x10ALLRYx10, 
x3(M/V)WSDx3 
and xLXVWxDExx 
RPL 
Ab coated onto tubes  GLLVWSDEL 
gp120 CD4 
binding site 
NA  Mice immunization  Env-specific Abs  [31] Int. J. Mol. Sci. 2012, 13  4735 
 
 
Table 1. Cont. 
Target  Library  Target presentation  Mimotopes  Epitopes  Additional 
Vaccination 
attempts 
Results  Reference 
MAb b12  12-mer-c RPL 
Ab captured on 
Protein G-coated Petri 
dishes 
WSDL 
gp120 CD4 
binding site 
Prediction of epitope 
clusters with 
Mapitope 
NA  NA  [32] 
MAb 5145A 
9-mer and 
10-mer-c RPL 
Ab coated onto Petri 
dishes 
AECGPAEPRGAWVC, 
AECGPYEPRGDWTCC 
gp120 CD4 
binding site 
NA 
Rabbit 
immunization with 
peptides-HSP 
fusion constructs 
gp120-specific Abs 
elicited, recognizing a 
different epitope 
[33] 
MAb 803-15.6  7-mer RPL 
(1) Ab coated onto 
microwells 
(2) Ab coated onto 
microwells with 
gp120 
AxxKxRH 
gp120 
residues  
502–508 
Quantitative binding 
analysis 
NA  NA  [34] 
(1) MAb 17b 
(2) MAb 13b5 
(3) MAb CG10 
12-mer-c RPL 
Ab captured on 
Protein G-coated Petri 
dishes 
NA 
(1)(3) gp120 
CD4-induced 
epitope, 
(2) p24 
Prediction of epitope 
clusters with 
Mapitope 
NA  NA  [32] 
(1) MAb A32 
(2) MAb 50-69 
15-mer RPL 
Ab captured on 
polystyrene beads 
(1) W 
(2) WGCx(K/R)xLxC, 
FGxWFxMP 
(1) CD4-
induced 
epitope 
(2) gp41 ID 
GKLIC 
NA  NA  NA  [18] 
MAb 2G12  Set of RPL 
Ab captured on 
protein A-coated 
beads 
2G12.1 
(ACPPSHVLDMRSGTCL) 
Glycosylated 
gp120 
NA 
Rabbit 
immunization 
No HIV-specific Abs  [35] 
NA: data not available, Hy: any non-aromatic AA, underlined: AA tolerating substitutions, AP: alkaline phosphatase. Int. J. Mol. Sci. 2012, 13  4736 
 
In  the  same  year,  Jellis  et  al.  applied  the  phage  display  technology  to  the  MAb  58.2,  which 
recognizes the V3 loop of the HIV-1 MN strain [36,37]. In their study, a 20-mer RPL was constructed 
and panned against MAb 58.2 according to two different  protocols, either streptavidin  capture of  
phages mixed with biotin-labeled MAb 58.2 (SA-Bio) or panning against MAb 58.2 immobilized  
on  microwells  (micropan)  [19].  Phages  selected  with  the  SA-Bio  protocol  shared  a  consensus  
sequence (Y/L)(V/L/I)GPGRxF homologous to the V3 loop. The micropan protocol allowed for the 
identification of sequences sharing the same motif, of which two were also identified in the SA-Bio 
panning. Biopanning results were further validated in peptide array hybridization assays. Hybridization 
of MAb 58.2 to 14-mer peptides containing all possible point substitutions within the V3 loop sequence 
demonstrated that both phage display and peptide array experiments identified the same critical amino 
acids, thereby confirming the quality of the 20-mer RPL and the validity of the screenings performed. 
Epitope  mapping  was  also  performed  on  a  monoclonal  antibody  (MAb  19b)  isolated  from  an 
asymptomatic HIV-1-infected patient and recognizing the xxIx3PGRAFYTT motif within the V3 loop 
sequence (KRIHIGPGRAFYTT) [38]. Binding of MAb 19b to viral isolates presenting mutations in 
this sequence revealed that not all residues within this recognition motif were crucial for reactivity [20]. 
Biopanning with a 15-mer RPL resulted in the selection of sequences compatible with the minimal 
binding site (-I----G--FY-T) inferred from gp120 sequence alignment from clades A to F which bound 
MAb  19b.  Taken  together,  data  from  binding  assays  as  well  as  phage  biopanning  experiments 
demonstrated that the MAb 19b epitope spans both sides of the V3 loop. Substitutions within the 
residues located at the crown of the loop are however tolerated, provided that the formation of a β-turn 
induced by the GPGR crown motif is allowed. However, one exception was reported by Boots et al. 
who reported that the Phe to Trp substitution may be tolerated in the absence of a β-turn [18]. 
In  parallel,  Grihalde  et  al.  constructed  and  panned  a  30-mer  RPL  against  MAb  1001,  which 
recognizes  a  constrained  linear  epitope  on  the  V3  loop  [21].  Several  clones  were  obtained  and 
presented the common motif (R/K/H)xGR mimicking the crown of the V3 loop sequence, thereby 
confirming the epitope sequence of MAb 1001. To assess the reactivity of peptides deprived of the 
phage scaffold, the mimotope with the highest affinity for the MAb 1001 was expressed in fusion with 
the  E.  coli  alkaline  phosphatase.  Binding  of  the  phage  and  fusion  protein  to  the  MAb  1001  was 
assessed by ELISA, Western Blot and SPR assays and highlighted that binding was independent from 
the scaffold, although interactions were weaker when the peptide was displayed in the fusion protein 
format than in the phage scaffold. 
In  another  study,  Laisney  et  al.  investigated  the  minimal  epitopes  recognized  by  two  MAbs 
interacting with the V3 loop, 110-A and 19.26.4, whose specificity is strictly restricted to the X4-tropic 
LAI isolate [22]. The screening of a 6-mer RPL on the MAb 110-A allows the selection of numerous 
sequences with a consensus motif. Binding assays with synthetic peptides further showed that both 
MAbs reacted with residues 316-320 of the LAI gp120. In this narrow region, the minimal epitope 
deduced for the MAb 110-A was HyxRGP, whereas the MAb 19.26.4 recognized the xQ(R/K)GP 
motif (Hy: non-aromatic AA, underlined: AA tolerating substitutions). Interestingly, the essential QR 
residues located at positions 317–318 correspond to a QR insertion located upstream of the V3 loop 
GPGR  crown  motif  that  is  characteristic  of  the  LAI  isolate  and  may  thus  explain  the  restricted 
specificity of the two MAbs. The same authors screened a 6-mer RPL on the MAb 268, specific to the 
V3 loop of the MN isolate, and identified two groups of sequences [23]. A representative sequence Int. J. Mol. Sci. 2012, 13  4737 
 
 
from the first group (268.1, HLGPGR), corresponded to the crown of the V3 loop, a linear epitope, 
while  two  sequences  of  the  second  group  (268.2,  KAIHRI  and  268.3,  KSLHRH),  showed  no 
homology  to  linear  HIV-1  epitopes.  Both  peptides  268.1  and  268.2  nevertheless  inhibited  the 
interaction of MAb 268 with gp120, and were even able to compete with each other for binding to the 
antibody, indicating that peptide 268.2 was also a mimotope of peptide 268.1. When conjugated to 
KLH  and  injected  separately  into  rabbits,  both  peptides  268-1  and  268-2  were  able  to  elicit  
gp120-reacting antibodies that partially competed with the homologous peptide, confirming that 268.1 
and 268.2 peptides are both antigenic and immunogenic mimics of the gp120 MN V3 loop. 
2.1.1.2. Gp41 Membrane Proximal External Region (MPER) 
The isolation of the BNtAb 2F5, which interacts with an epitope (ELDKWA) located on the gp41 
MPER was reported in 1993 [39]. Conley et al. further characterized this epitope by biopanning a  
15-mer RPL on immobilized 2F5 Ab. Different sequences were obtained and classified in four groups, 
whose  consensus  motifs,  DKW,  LDxW,  ED(K/R)W  and  ELDKW,  revealed  information  on  the 
residues involved in 2F5 Ab recognition [24]. 
Immunization attempts with ELDKWA peptides failed to elicit 2F5-like NtAbs, suggesting that the 
epitope  necessitates  additional  residues  in  order  to  be  immunogenic.  Therefore,  Menendez  et  al. 
screened a panel of 17 libraries of linear and constrained peptides against the MAb 2F5 and deduced 
that residues flanking the DKW core at the C-terminal side region were important for high-affinity 
binding  to  the  MAb  [25].  They  subsequently  constructed  and  screened  two  phage  sublibraries 
displaying 12 random residues either upstream or downstream of the DKW core (x12-AADKW and 
AADKW-x12)  and  isolated  three  peptides  displaying  high  affinity  for  2F5  from  the  AADKW-x12 
library.  Ala  substitution  and  deletion  studies  revealed  that  each  clone  bound  2F5  according  to  a 
different mechanism. This data led the authors to postulate that the 2F5 paratope was composed of two 
binding domains either recognizing the DKW core with strong specificity or multispecifically binding 
to the residues located at its C-terminus.  
Based on this study, additional investigations were recently conducted on the BNtAb 2F5 epitope to 
assess the importance of structural constraints for MAb 2F5 recognition [26]. A linear 12-mer RPL and 
a constrained 7-mer RPL were screened against this antibody and all the sequences selected from the  
12-mer RPL contained the D(K/R)W core motif, with flanking residues L, A and S present at different 
frequencies.  Analysis  of  the  sequence  representation  compared  to  their  estimated  probability  of 
occurrence  indicated  a  trend  towards  enrichment  for  sequences  such  as  DKWA  or  LDKWA 
throughout panning of the 12-mer library, while all sequences selected from the constrained library 
contained  DKWA  or  LDKWA.  These  results  demonstrated  that  the  strong  epitope  specificity 
postulated by Menendez [25] is only displayed when the epitope sequence is presented in a certain 
structural context provided in the constrained 7-mer peptides. Immunization studies performed with 
both linear and constrained forms of the peptide in mice and rabbits resulted in the inhibition of cell 
fusion only with sera of rabbits immunized with the linear peptide. Int. J. Mol. Sci. 2012, 13  4738 
 
 
2.1.1.3. Gp120 C1 Domain 
RPL screening may also contribute to the elucidation of the antigen structure. To that purpose,  
Stern  et  al.  used  a  20-mer  RPL  to  analyze  two  different  mouse  MAbs  (GV1A8  and  GV4D3) 
recognizing non-overlapping sequences between residues 1 and 142 of gp120 [27,40]. Biopanning 
performed on GV1A8 allowed for identification of mimotopes sharing a (L/I)W motif identical to 
residues 111–112 of the gp120 C1 domain and highlighted a HxxIxxLW motif compatible with two 
turns of an α-helix. Computer modeling confirmed that such a structure placed the residues recognized 
by GV1A8 contiguously on one face of the helix while other secondary structures did not. Similarly, 
biopanning on MAb GV4D3 yielded sequences with a trend towards an Nx3WxxD motif. The epitope 
maps to the FNMWKND sequence satisfying the helical motif FxxWxxD. In this study, the use of 
phage display not only predicted the α-helix structure of the C1 domain of gp120, but also pinpointed 
the contact residues defining the surface of the helix. 
Phage display was also applied to epitope mapping of Antibody-Dependent Cellular Cytotoxicity 
(ADCC)-inducing MAbs since HIV-1 infected cells may be targets for Fc receptor-bearing effector 
cells interacting with HIV-1-specific Abs. Screening of 7-mer, 7-mer-c and 12-mer RPLs against the 
ADCC-inducing MAb ID6 resulted in the identification of phages with TxxFxxWxxD (12-mer RPL) 
and FxDWxF (7-mer and 7-mer-c RPLs) motifs homologous to the C1 domain of gp120 [28].  
Competition assays showed that binding of MAb ID6 to gp120 or gp160 was abrogated in the 
presence of 12-mer mimotopes. In contrast, heptapeptide mimics only slightly impaired this binding, 
supporting the hypothesis that the MAb-ID6 epitope probably encompasses residues additional to the 
FxDWxF motif. As this epitope is highly conserved among circulating HIV-1 subtypes, it might be 
useful to induce MAb ID6-like antibodies. 
2.1.1.4. Gp120 CD4-Binding Site 
The  BNtAb  IgG1  b12  was  the  first  neutralizing  MAb  selected  from  a  phage-displayed  Fab 
(antibody fragment composed of one constant and one variable domain of the heavy (CH1 and VH) 
and the light (CL and VL) chains linked together) library derived from an HIV-1-infected donor (See 
section  3.1.1.1.1.)  [41].  This  antibody  recognizes  a  conformational  epitope  overlapping  the  
CD4-binding site of gp120 [42]. Attempts to precisely map the residues interacting with the IgG1 b12 
MAb with 15-mer and 21-mer RPLs provided no consensus sequence [18]. As previous screening of 
11 cysteine-enriched peptide libraries resulted in the identification of two sequences bearing an SDL 
motif flanked by one or two cysteine residues (REKRWIFSDLTHTCI and TCLWSDLRAQCI) [30], 
Zwick et al. constructed two sublibraries (x7SDLx3CI and xCxxSDLx3CI) sharing the SDL motif and 
reflecting  the  cysteine  content  of  the  two  clones  [29].  A  B2.1  peptide  (HERSYMFSDLENRCI) 
containing a unique cysteine bound b12 in Fab as well as IgG1 formats with a much higher affinity 
than the other clones. Moreover, the phage-borne B2.1 peptide was used to screen the Fab library from 
which b12 was identified. This ―reverse panning‖ experiment showed that B2.1 was able to select only 
the Fab sequence corresponding to b12, confirming the specificity of the B2.1 mimotope towards the 
b12 Ab. B2.1 peptide was immunogenic in mice and rabbits but did not elicit significant anti-gp120 
cross-reactive Abs titers. Int. J. Mol. Sci. 2012, 13  4739 
 
 
Dorgham et al. attempted to map the b12 epitope with a RPL of two random 10-mers joined through 
an  ALLRY  spacer  (x10ALLRYx10)  [31].  Selection  resulted  in  the  identification  of  clones  sharing  a 
M/VArSD  consensus  motif  (Ar  standing  for  any  aromatic  residue)  as  previously  observed  [29].  A 
second- and a third-generation of semi-RPL containing fixed consensus motifs identified in the previous 
panning surrounded by randomized residues were constructed (x3(M/V)WSDx3 and xLXVWxDExx). 
Phagotopes (phage particle displaying a particular peptide sequence selected on a given target) obtained 
from  the  first,  second  and  third  generation  libraries  showed  increasing  binding  affinity  for  b12, 
respectively. Phagotopes were able to compete with gp160 for b12 binding and triggered the production 
of Abs capable of recognizing at least five distinct, unrelated HIV-1 strains. In contrast, the corresponding 
peptides were not able to compete for b12 binding and did not elicit anti-gp160 MAbs. Such discrepancies 
between phagotopes and peptides might be explained by constraints imposed by the phage scaffold.  
Detailed characterization of the BNtAb b12 was conducted with the Mapitope algorithm developed 
by Enshell-Seijffers et al. to facilitate the identification of discontinuous epitopes. This approach is 
based on the assumption that the collection of mimotopes recognized by a given antibody must in 
some manners reflect the antibody’s paratope [32]. A constrained 12-mer RPL was screened against 
b12 and selected sequences  were compared to those obtained from  previous panning  experiments 
performed  against  b12  [18,29,30,43].  Although  no  similarity  was  observed  with  the  mimotopes 
selected  by  Boots  et  al.  [18],  a  consensus  WSDL  motif  was  observed  in  the  newly  identified 
mimotopes and the sequences isolated by Bonnycastle et al. [29,30]. Mapitope analysis conducted on 
these sequences as well as on the peptide sets isolated by Boots and Bonnycastle resulted for each of 
the three panels in the prediction of two clusters located at the periphery of the CD4 binding site.  
At the same time, both a linear 9-mer RPL and a constrained 10-mer RPL were used in panning 
experiments against another gp120 CD4 binding site MAb (5145A) [33]. Screening of the 9-mer RPL 
resulted in selection of a single sequence (WKPVVIDFE), while screening of the 10-mer-c RPL on 5145A 
allowed for identification of a GPxEPxGxWxC consensus motif. Peptides were synthesized as peptide-pIII 
fusion proteins and their affinity for 5145A was assessed in phage/MAb and gp120/MAb binding 
inhibition assays. The two most affine peptides (AECGPAEPRGAWVC and AECGPYEPRGDWTCC) 
were used to  immunize rabbits  and  elicited  antibodies  binding to  recombinant  monomeric  gp120. 
Nevertheless, generated Abs seemed to target a different epitope since they were unable to compete 
with the 5145A CD4-binding site specific MAb. 
2.1.1.5. Other Domains 
The extreme C-terminus of gp120 forms a pocket which may interact with gp41 and was suggested 
to undergo conformational changes weakening the interaction between gp120 and gp41 upon CD4 
binding. In the absence of available crystallographic information, Ferrer et al. utilized the mouse MAb 
803–15.6 to analyze an epitope overlapping with this pocket region [34]. Epitope mapping of MAb 
803–15.6 achieved by cross-blocking experiments on gp120 suggested that the Ab recognized residues 
502–516 while the screening of an heptapeptide RPL against MAb 803–15.6 preincubated with gp120 
allowed for the recovery of phages presenting an AxxKxRH motif homologous to residues 502–508. 
Affinity studies confirmed that Ala was the N-terminal residue of the MAb 803–15.6 epitope and 
showed that affinity increased when C-terminal residues were added.  Int. J. Mol. Sci. 2012, 13  4740 
 
 
The Mapitope algorithm designed by Enshell-Seijffers et al. was initially developed to elucidate  
the CD4-induced epitope recognized by the MAb 17b [32]. Screening of a 12-mer-c RPL yielded 
sequences  with  no  homology  to  gp120.  Comparison  of  the  mimotopes  to  the  gp120  structure  in 
complex with MAb 17b and sCD4 predicted candidate epitopes that were in agreement with the actual 
17b contact residues. For further validation of the algorithm, RPL libraries were screened against the 
p24-specific MAb 13b5 and analysis of the selected sequences predicted four clusters, the largest of 
which corresponded to the genuine epitope. The algorithm was finally applied to the Mab CG10, an 
Ab with an unknown epitope competing with the Mab 17b for the binding to the CD4/gp120 complex. 
Mimotopes sequences were analyzed and produced seven clusters, one of them being in accordance 
with previous mutation analysis impeding Mab CG10 binding [44]. Noteworthingly, when reconstituted 
in a phage scaffold, the epitope was capable of binding Mab CG10. 
After having successfully identified linear or nearly linear epitopes [17,20,24], Boots et al. extended 
the use of the phage display technology to the identification of epitopes recognized by MAbs binding to 
discontinuous sequences [18]. One of these Abs (MAb A32) binds to a CD4-induced discontinuous epitope 
involving residues within the C1, C2 and C4 regions of isolates from clades B, C, D, E and F [45,46]. 
Panning of a 15-mer RPL yielded several phages which only shared a Trp residue. In the same study, 
panning of a 15-mer RPL against MAb 50–69, which reacts with the ID GKLIC region of gp41, 
resulted in the identification of sequences sharing a common Trp within motifs WGCx(K/R)xLxC and 
FGxWFxMP. The selected consensus sequences were however not further characterized. 
The  BNtAb  2G12  presents  the  typical  feature  of  recognizing  a  cluster  of  high-mannose 
oligosaccharides of gp120 [47–49]. In an attempt to identify peptidic immunogens capable of eliciting 
2G12-like Abs, Menendez et al. screened a set of previously described RPLs [30] against 2G12 and 
identified one phagotope specifically binding to 2G12 (2G12.1) [35]. The crystal structure of MAb 
2G12 complexed to the synthetic 2G12.1 peptide was compared to structures of 2G12-oligomannose 
epitopes and revealed that interactions with the Abs were different for the two ligands. These results 
showed that the peptide selected from RPL panning experiments is not a structural mimic of the 2G12 
oligomannose  epitope.  The  phagotope  2G12.1  was  used  in  rabbit  immunization  experiments  and 
elicited high titers of peptide-specific antibodies, but no cross-reactivity with gp120 was obtained, 
further supporting that peptide 2G12.1 is not an immunogenic mimic of the MAb 2G12 epitope.  
2.1.2. Polyclonal Antibodies Directed Against Viral Epitopes 
The first attempt at identifying epitopes recognized by HIV-specific PAbs was performed in 1999 
on plasma IgG from two LTNP patients (Table 2). Using linear and constrained 9-mer RPLs, Scala et al. 
identified mimotopes of the linear immunodominant (ID) GKLIC region of gp41 or the V1 and C2 
domains of gp120 [50]. These mimotopes were immunogenic when injected to mice and elicited an 
NtAb response against HIV-1. Moreover, the same mimotopes reduced viraemia to undetectable levels 
in immunized monkeys as shown in a subsequent study [51]. The same year, a similar study conducted 
on one LTNP with an RPL library of cysteine-constrained 12-mers selected for peptides defining the 
gp41 ID epitope CSGKLIC. The levels of reactivity of these phagotopes were further assessed against 
a panel of HIV positive plasma to evaluate the plasticity and polyclonality of the immune response 
mounted by 30 infected individuals [52]. Int. J. Mol. Sci. 2012, 13  4741 
 
Table 2. Epitope mapping of polyclonal antibodies directed against viral epitopes. 
Library 
Biopanning 
support 
Samples  Target 
Biopanning 
procedure 
Mimotopes  Epitopes  Additional 
Vaccination 
attempts 
Results  Reference 
9-mer, 9-mer-
c RPLs 
Tosylactivated 
beads coupled to 
Anti human IgG, 
Fc-specific Ab 
LTNP (serum)  IgG 
Panning on one 
LTNP, 
reactivities 
assessed on a 
second LTNP 
3 linear, 7 putative 
conformational 
Linear: gp41 
ID GKLIC 
region, 
gp120 V1 
and C2 
regions 
Reactivities of 
positive clones 
assessed on 22 
LTNP, 25 HIV, 50 
HD. Affinity 
purification of 
Nabs with phages 
Phage 
immunization of 
C57BL and  
BalB/c mice 
NAbs 
induced 
[50] 
12-mer-c RPL 
Protein G coated on 
Petri dishes 
HIV + (serum)  IgG 
Panning on 
HIV+ serum IgG 
4 linear, 2 unassigned 
Linear: gp41 
ID GKLIC 
region 
Reactivities of the 
clones assessed on 
the sera of 30 
HIV+ 
NA  NA  [52] 
12-mer, 7-
mer, 7-mer-c 
RPLs 
Microwells coated 
with purified IgG 
HIV+ 
(HAART) 
IgG 
Panning on 
purified HIV+ 
IgG, before and 
after HAART 
Linear, CxxKxxC 
Linear: gp41 
ID GKLIC 
region 
Reactivities of 1 
insert with IgG of 
22 HIV+ 
Phage 
immunization of 
C57BL/6J mice 
Abs 
against 
epitope 
[53] 
12-mer, 7-
mer, 7-mer-c 
RPLs 
Tosylactivated 
beads coupled to 
Anti human IgG, 
Fc-specific Ab 
LTNP 
(plasma) 
IgG 
Panning on pool 
of 8 LTNP 
plasma, negative 
selection on HIV 
- plasma pool 
160 linear, 
124 putative 
conformational, 
160 unassigned 
gp120 V3 
loop, gp41 
GKLIC, 
gp120 MPER 
Reactivities with 
plasma of 7 HIV+ 
plasma 
Phage 
immunization of 
mice 
NAbs 
induced 
[54] 
12-mer, 7-
mer, 7-mer-c 
RPLs 
Tosylactivated 
beads coupled to 
Anti monkey IgG 
Ab 
Clade C  
SHIV-infected 
rhesus 
macaque 
IgG 
Panning on one 
SHIV + plasma, 
negative 
selection on 
SHIV - monkey 
plasma pool 
72 linear, 6 putative 
conformational 
gp120 V2, 
V3, C-term, 
gp41 
GKLIC, 
MPER 
Reactivities of 
inserts tested as 
fusion proteins 
DNA prime-phage 
boost of BALB/c 
mice 
NAbs 
induced 
[55] Int. J. Mol. Sci. 2012, 13  4742 
 
 
Table 2. Cont. 
Library 
Biopanning 
support 
Samples  Target 
Biopanning 
procedure 
Mimotopes  Epitopes  Additional 
Vaccination 
attempts 
Results   Reference 
12-mer RPL 
Tosylactivated 
beads coupled to 
Anti human IgG, 
Fc-specific Ab 
HIV subtype 
CRF02AG-
infected 
plasma with 
4E10-like 
BNtAbs 
IgG 
Panning on 
pooled 
longitudinal 
samples of one 
HIV + plasma, 
negative 
selection on HIV 
- plasma pool 
Linear (SLxxLRL, 
KxWWxA, 
Kx3IGPHxxY) 
gp41 MPER 
and LLP2 
regions; 
gp120 C1 
and V3 
regions 
NA  NA  NA  [56] 
12-mer, 7-
mer, 7-mer-c 
RPLs 
Tosylactivated 
beads coupled to 
Anti human IgG, 
Fc-specific Ab 
HIV subtype  
A-infected 
plasma with 
4E10-like 
BNtAbs 
IgG 
Panning on 
pooled 
longitudinal 
samples of one 
HIV + plasma, 
negative 
selection on HIV 
- plasma pool 
38 linear, 22 putative 
conformational 
(Kx3Hx3Y, 
KxxHxGPx3F, 
CxGxLxCTxNxP) 
gp41 ID 
epitope; 
gp120 V2 
and V3 
regions 
Competition with 
rgp120/gp140 for 
antibodies binding; 
peptide 
neutralization 
inhibition assays 
NA  NA  [57] 
DNAse-
fragmented 
Gag DNA 
Purified IgG 
captured on 
microwells 
Serum of 
rabbits 
immunized 
with p24 
IgG 
Panning on 
rabbit anti p24 
IgG 
p24 fragments 
N- and  
C-terminus 
of p24 
Reactivities of 
inserts tested as 
proteins in fusion 
with GST 
NA  NA  [58] 
NA: data not available.  Int. J. Mol. Sci. 2012, 13  4743 
 
Later,  Palacios-Rodriguez  et  al.  evaluated  the  impact  of  factors  such  as  Highly  Active 
AntiRetroviral Treatment (HAART) or Ab titers on a selection of peptides mimicking the ID epitope 
CSGKLIC [53]. In their study, a mix of linear 12-mer as well as linear and constrained 7-mer RPL was 
screened against the individual plasma samples of four HIV-1 infected patients initiating HAART and 
presenting different titers of anti-GKLIC antibodies. A consensus motif CxxKxxC was obtained from 
the 12-mer linear RPL, and the percentage of occurrence of the motif in the selected sequences was 
proportional to the anti-GKLIC Ab titers of each sample, indicating that these Abs are involved in 
selection of the consensus motif. Mice immunization experiments with the two mimotopes resembling 
most  to  the  gp41  ID  parental  epitope  as  well  as  with  pools  of  phages  eluted  from  the  panning 
experiments showed that all phages elicited reactivity, and that immunization with the phage eluates 
induced  the  strongest  recognition.  These  findings  indicate  that  the  immunogenic  properties  of 
mimotopes are different and additive, opening the possibility of immunizing animals with different 
mimotope combinations (See Section 4). 
In  2007,  Humbert  et  al.  investigated  the  immune  response  of  eight  LTNP  patients  presenting 
BNtAbs. By using linear and constrained RPLs they identified epitopes recognized by plasma IgGs 
captured on tosylactivated beads [54]. Each panning round consisted of a positive selection performed 
on LTNP IgGs followed by a negative selection on the IgGs of healthy donors. Homologies of some 
selected sequences to immunodominant regions such as the gp120 V3 loop or the gp41 GKLIC region 
were observed, as reported in previous studies [50,52,53]. Further homologies to linear motifs located 
near the V3 loop (NNNT), downstream of the ID GKLIC region (AVPW motif) and overlapping with 
the 2F5 BNtAb epitope (PPWx3W motif) were also identified. Additionally, the authors applied the 
3DEX software to compare the phage insert sequences to HIV-1 protein structure files from the RCSB 
Protein Data Bank (www.pdb.org) [59,60]. Phage pools corresponding to the linear V3 loop, GKLIC 
domain and WxxxW motif, as  well as  pools representing potential  conformational epitopes,  were 
selected for mice immunization assays, and elicited plasma-associated neutralizing activity against 
primary HIV-1 strains. The highest neutralizing ability was obtained with mice immunized with the 
V3 mimotopes, although immunization with potential conformational epitopes also provided a modest 
neutralizing response. 
A similar approach was used by the same authors on a rhesus macaque infected with an SHIV 
chimera encoding the env of a clade C HIV-1 strain (SHIV1157ip) and presenting a broad neutralizing 
response against homologous SHIV-C as well as heterologous HIV-1 strains of different subtypes [61]. 
Biopanning yielded clones similar to gp120 (V2 and V3 loops or C-terminal domain) or to regions of 
gp41 (ID GKLIC region, other ID regions and MPER domain) [55]. Remaining clones showed no 
significant  homology to linear HIV-1 regions  and were analyzed with  the 3DEX software, which 
allowed  the  identification  of  a  discontinuous  mimotope  located  near  the  V3  loop  crown.  The 
antibodies binding to this phagotope were affinity-purified and subsequent assays demonstrated that 
recognition was conformation-dependent.  
An  immunofocused  immunization  of  mice  primed  with  a  DNA  vector  coding  for  the  gp160 
SHIV1157ip  and  boosted  with  pools  of  phage  particles  corresponding  to  the  V3  loop,  the  gp120  
C-terminus, the gp41 ID region, the GKLIC region and the MPER domain was set up. Almost all mice 
developed anti-env Abs and 59% of them presented a neutralizing activity.  Int. J. Mol. Sci. 2012, 13  4744 
 
 
In 2009, Dieltjens et al. applied the phage display technology to identify the epitopes potentially 
involved in the BNtAbs response of an HIV-1 CRF02AG-infected individual (ITM4) and to monitor 
the evolution of humoral response and viral escape through the course of infection [56]. Biopanning of 
a 12-mer RPL against plasma samples from ITM4 resulted in the identification of different peptide 
sequences. Half of these sequences were homologous to linear epitopes on gp41, i.e., the 4E10 epitope 
region in the MPER domain (NWFNLTQTLMPR) or the lentivirus lytic peptide 2 (LLP2) (SLxxLRL) 
while the other peptides shared homologies with the C1 domain (KxWWxA) and the crown of the V3 
loop (Kx3IGPHxxY) of gp120. Further analysis of the levels of reactivity of the phage groups against 
ITM4 six-year follow-up samples revealed different temporal patterns of recognition, confirming the 
dynamic  nature  of  the  immune  response.  Interestingly,  the  MPER  region  was  the  only  epitope 
retaining immunogenic properties during this period.  
In a more recent study, the same group investigated the antigenic landscape of an HIV-1 subtype  
A-infected individual with BNtAbs by screening an RPL library against a pool of sequential samples 
drawn from 1994 to 2005 [57]. The biopanning procedure yielded sequences predicted to represent 
autologous V2 sequence (Kx3Hx3Y), V3 loop (KxxHxGPx3F) and gp41 ID domain (CxGxLxCTxNxP). 
Again, follow-up sample recognition of the four phage groups showed different patterns. Antibody 
reactivity towards gp41 ID region fluctuated slightly in all plasma samples. Reactivity against the V3 
loop-like phages decreased over time. In contrast, the V2 loop mimotopes were not recognized before 
2001,  but  once  emerged,  reactivity  persisted  until  2005.  Env  sequence  analysis  of  the  follow-up 
samples showed that a Tyr to His mutation in the V2 loop sequence coincided with the emerging 
antibody response against this sequence. Additionally, the authors highlighted that the neutralizing 
activity observed in the samples was partially due to antibodies recognizing the V3 mimotopes.  
Besides the multiple reports on the use of RPL to characterize the humoral response against HIV-1 
Env proteins, Gupta et al. evaluated the reliability of using targeted antigen gene fragment libraries for 
the identification of epitopes recognized by antibodies elicited in rabbits immunized with p24. To this 
end, they constructed a phage library composed of DNAse-digested fragments of Gag DNA  [58]. 
Phagotopes obtained after the first panning round displayed mainly 30-40-mer peptides, 70% of which 
mapped to of the N-terminus of p24 (150–240 of Gag) and 30% corresponded to the C-terminal region 
of p24 (310–360 of Gag). Only one phagotope mapped to the central region of Gag (269–310). At the 
end of the second round, selected phages displaying longer inserts of 40 to 50 AA corresponding to the 
N- and C-terminal regions of Gag were identified, revealing the presence of two distinct antigenic 
regions in Gag. This study demonstrated that gene-fragment phage display could be used to identify 
epitopes targeted by polyclonal Abs. 
2.2. Antibodies Directed against Host Proteins 
Although they occur at a very low frequency in humans, antibodies targeting host proteins involved 
in HIV-1 infection have been reported in immunized animals. Given their potential value for viral 
entry inhibition and the general understanding of this mechanism, RPLs were screened on these MAbs 
to gain better knowledge of their epitopes (Table 3). Int. J. Mol. Sci. 2012, 13  4745 
 
 
Table 3. Epitope mapping of monoclonal antibodies directed against host proteins. 
Target  Library  Target presentation  Mimotopes  Epitopes  Additional 
Vaccination 
attempts 
Results   Reference 
MAbs 3A9, 
5C7 
7-mer, 7-mer-c,  
9-mer-c, 12-mer 
RPL 
Phage-antibody 
complexes captured on 
beads coated with  
anti-mouse IgG Ab 
CHASIYDFGSC, 
CPHWLRDLRVC 
CCR5 N-
terminus (SIYD) 
and  
ECL1 (FG) 
CCR5  
N-terminus (P), 
ECL1 (HW) and 
ECL3 (DLR) 
Reactivities assessed 
against inserts 
synthesized as peptides, 
binding and competition 
assays with peptides. 
Entry inhibitor 
NA  NA  [62,63] 
MAb 2D7  15-mer RPL 
Ab coated onto  
Petri dishes 
M23 
(FCALDGDFGWLAPAC) 
CCR5 ECL2 
Neutralization of HIV-1 
infection 
NA  NA  [64] 
MAb 2D7  12-mer RPL 
Ab coated onto 
microwells 
EWQKEGLVTLWL  CCR5 ECL2  NA  Rabbit immunization 
NAbs with  
2D7-like functions 
[65] 
MAb MHM23 
9-mer, 9-mer-c 
RPL 
Phages-Ab complexes 
captured on  
streptavidin-coated 
dishes 
PPFxYRK 
CD18  
(AA 200–206) 
Inhibition of  
HIV-1-induced 
syncytium formation 
NA  NA  [66] 
NA: data not available. 
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The  murine  MAbs  3A9  and  5C7  were  raised  against  cells  transfected  with  the  seven 
transmembrane-spanning domains chemokine receptor CCR5, one of the main coreceptors for HIV-1. 
They recognize a common epitope located near the CCR5 N-terminus [67,68]. Both MAbs were used 
to  screen  a  constrained  9-mer  RPL  [63].  Phagotopes  selected  on  3A9  displayed  the  sequence 
CHASIYDFGSC while CPHWLRDLRVC was the most prevalent sequence isolated on 5C7. These 
sequences showed homologies to residues located at the N-terminus but also within the first or third 
extracellular loop (ECL) of CCR5. Both reacted against the targeted MAb either in phage, cyclic 
peptide or linear peptide formats. Moreover, they were able to bind to gp120 and the peptide selected 
on 3A9 inhibited binding of the MAb to a cell line expressing CCR5. To further characterize the 
conformational  epitope  recognized  by  3A9,  additional  screening  rounds  of  12-mer,  7-mer  and  
7-mer-c RPLs were performed [62].  
Sequences with an HW motif homologous to the CPHWLRDLRVC motif selected on the MAb 
5C7 were identified, and Ala-scanning confirmed the importance of the HW motif and SIYD motifs 
previously identified for 3A9 binding [63].  
Another murine antibody (Mab 2D7) recognizing a conformational epitope on the second ECL of 
CCR5 [67] was explored by screening a linear 15-mer RPL [64]. Three phagotopes (M14, M23 and 
M71) were isolated and one of them (M23) was able to inhibit cell infection by the HIV-1 SF162 
isolate. The corresponding peptide (FCALDGDFGWLAPAC) fused to the pIII phage coat protein 
neutralized infection mediated by the JR-FL but not the IIIb strain. The fusion protein specifically 
bound 2D7 and was recognized in a dose-dependent manner by three CCR5 chemokine ligands, i.e., 
CCL5  (RANTES),  CCL3  (MIP1α)  and  CCL4  (MIP1ß),  confirming  its  CCR5  mimicry.  Six  years  
later,  another  screening  campaign  was  conducted  with  a  linear  12-mer  RPL  on  2D7  and  the 
EWQKEGLVTLWL sequence of a high-affinity binding peptide was obtained [65], revealing that 
this peptide presented homologies to the N-terminal (170-QKEGL-174) and C-terminal (195-TL-196) 
regions of the CCR5 ECL2. Ala substitutions of the TL residues confirmed their crucial role in 2D7 
binding. The selected peptide was used in rabbit immunization studies and elicited Abs with 2D7-like 
biological functions, i.e., which inhibited HIV-1-mediated cell fusion and PBMC infection.  
The  CD18  cell  surface  molecule,  a  part  of  the  LFA-1  molecule,  is  involved  in  the  syncytia 
formation  of  HIV-1-infected  lymphocytes  [69].  As  MAb  MHM23,  a  CD18  binder,  inhibits  
HIV-1-mediated cell fusion, Poloni et al. applied the phage display technology to map the MHM23 
epitope and thereby identify the CD18 domains which account for syncytia formation [66]. Linear and 
constrained 9-mer RPL were panned on the MHM23 MAb, to allow for the selection of linear and 
constrained sequences. A PPFxYRK consensus motif was inferred by sequence comparison, assigning 
the epitope recognized by MHM23 to residues 200–206 of CD18. Two phagotopes inhibited in vitro 
HIV-1-induced  syncytia  formation  and  one  of  them  retained  this  ability  in  the  peptide  format, 
confirming its role in syncytia formation and highlighting that mimics of this epitope could prevent 
cell-mediated viral propagation. Int. J. Mol. Sci. 2012, 13  4747 
 
 
3. Identification of HIV-1 Inhibitors by Phage Display  
As summarized in the first section of this review, phage-displayed RPLs are powerful tools to 
determine or to characterize MAbs as well as PAbs epitopes. Besides epitope mapping  the phage 
display technology was also widely applied to the identification of HIV-1 inhibitors. 
Screening of phage-displayed RPLs, antibody-fragment or ligand libraries on viral or host targets 
contributed  to  the  discovery  of  molecules  interacting  with  the  key  players  of  HIV-1  infection. 
Antibody libraries were particularly investigated, and repertoires of Fab, ScFv (antibody fragment 
corresponding to variable regions of the heavy (VH) and light (VL) chains of antibody connected by a 
short peptide linker), VHH/nanobodies (single domain antibody fragment (SdAb) corresponding to the 
variable heavy-chain domain of a camelid heavy-chain only antibody (HcAbs)) or CDR3 fragments 
from  naï ve or HIV-1 infected subjects  as  well as  from  immunized animals  were displayed  at  the 
surface of phages (Figure 4). 
Figure 4. Antibodies and antibody fragments used in phage display. (A) Whole human IgG; 
(B)  Fab  (Fragment  antigen  binding);  (C)  ScFv  (Single-chain  variable  Fragment);  
(D) Camelid HcAb (Heavy-chain only Antibody); (E) VHH/Nanobodies (Variable domain 
of HcAb).  
 
3.1. Inhibitors of HIV-1 Proteins 
Most of the HIV-1 inhibitors selected with the help of phage display were identified by targeting 
viral proteins (Table 4). 
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Table 4. HIV-1 protein inhibitors selected by phage display. 
Target  Library 
Target 
presentation 
Phagotopes 
Affinity 
(KD) 
Inhibition 
(IC50) 
Virus isolates/clades  Additional  Reference 
gp120 (CD4 BS)  LTNP Fab   Recombinant gp120  b12  <10 nM  ~20 nM  MN, IIIb   NA  [41,42,70] 
gp120 (CD4 BS) 
Fab (CDR walking of  
b12 Fab) 
Recombinant gp120  3D3  15 pM  ~0.1–0.9 nM  MN, IIIb 
3B3 ScFv engineered 
as fusion immunotoxin 
[71–73] 
gp120 (CD4 BS)  LTNP Fab   Recombinant gp120  L78  4–300 nM  ~2 ug/mL  MN, IIIb 
epitope-masking 
strategy 
[74] 
gp120 (CD4 BS) 
(1) ScFv (lupus 
patients) 
(2) Light chains (lupus 
patients) 
Recombinant gp120 
JL413 
SKL6 
NA 
(1) 0.1–25.6 
µ g/mL 
(2) NA 
(1) 23135, SF-162, 
ZA009, BR004, Ug246 
(2) NA 
gp120-hydrolyzing 
Abs 
[75,76] 
gp120 (CD4 BS) 
VHH (immunized 
llamas) 
Recombinant gp120 
A12 
D7 
C8 
0.1–1 nM  0.003–38 µ g/mL 
A, B, C, D, CFR02_AG 
and CRF07_BC 
sublibrary engineered 
to increase potency 
[77,78] 
gp120 (CD4 BS) 
CD4 V1 and V1-V2 
variants 
Recombinant gp120 
E6, B6, 22, F8, 
D11 
NA  0.2–1 µ g/mL  BH10  NA  [79] 
gp120 (V3 loop) 
MAb 447-52D-derived 
ScFv 
V3 loop peptide  402P5H7 
0.28–3.1 
nM 
NA  MN 
VL shuffling and 
HCDR3 ―spiking‖ of 
MAb 447-52D 
[80] 
gp120 (V3 loop)  LTNP Fab   Recombinant gp120 
DO142-10 
Fab loop 2 
11 nM 
1.9 nM 
0.2–8 µ g/mL 
1–5 µ g/mL 
MN, IIIb 
epitope-masking 
strategy 
[70,81] 
gp120 (CD4-i epitope) 
7-mer, 9-mer-c and  
12-mer RPL 
Recombinant gp120  12p1  NA  1.1–1.6 µ M  YU2  NA  [82] 
gp120 (CD4-i epitope) 
HIV-1 infected FDA-2 
patient FAb  
gp120-CD4-CCR5 
complexes 
X5  nanomolar  0.29–125 µ g/mL  A, B, C, D, F and G   NA  [83] 
gp120 (CD4-i epitope) 
7-mer, 7-mer-c and  
12-mer RPL 
sCD4-89.6 Env on 
retroviral particles  
XD3  NA  50 µ M  NL4-3, D117III  NA  [84] 
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Table 4. Cont. 
Target  Library 
Target 
presentation 
Phagotopes 
Affinity 
(KD) 
Inhibition 
(IC50) 
Virus 
isolates/clades 
Additional  Reference 
gp41 MPER 
(1) HIV-1 infected FDA-2 
patient FAb 
(2) Z13-derived Fab 
MPER peptide 
(1) Z13 
(2) Z13e1 
NA 
(1) >40–190 
µ g/mL 
(2) <2–190 nM 
B, C and E  NA 
[85] 
[86] 
gp41 Heptad 
Repeats 
(1) xxCDYPEWQWLCxx 
(2) naï ve human ScFv 
(3) Fab ―Tyr/Ser‖ 
(4) 7-mer and 12-mer RPL 
(1) IZN17 
(2) 5-Helix, IZN36 
(3) 5-Helix 
(4)N34(L6)C28 
(1) PIE12-trimer 
(2) D5 
(3) 13 clones 
(4) JCH-4 
 
NA 
(1) 0.5 nM 
(2) 93–1750 nM 
(3) – 
(4) 9 µ g/mL 
(1) A, B, C, D, F, 
G, CRF 
(2) at least 5 
isolates 
(3) – 
(4) HXB2 
(1) D-peptide 
[87–89] 
[90,91] 
[92] 
[93,94] 
 
gp41 Heptad 
Repeats 
(1), (2) Naï ve human Fabs 
(3) Fab 3674-derived Fabs 
(1) N35CCG-N13, 
NCCG-gp41 
(2) NCCG-gp41, 6-
HB 
(3) NCCG-gp41 
(1) 8 Fabs 
(2) Fab 3674 
(3) Fabs 8060, 8066 
and 8068 
(1) – 
(2) 97 nM 
(3) 7–25 
nM 
(1) 6–60 µ g/mL 
(2) 450–2100 
nM 
(3) 26–1400 nM 
(1) LAV 
(2) at least 5 
isolates 
(3) 7 isolates 
NA 
[95] 
[96–98] 
gp41 Heptad 
Repeats 
(1) Rabbit ScFv, 
HIV-1-infected FDA-2 
patient FAb 
(2) HIV-1-infected patient 
Ab library 
(1) N35CCG-N13 
(2) gp140, gp120 as 
competitor 
(1) 8K8, DN9 
(2) M44, M46, M48 
NA 
(1) 50–500 nM 
(2) NA,  
1.5–25 µ g/mL,  
9–22 µ g/mL 
(1) 13 isolates 
(2) 4 isolates 
(2) competitive antigen 
panning 
[99] 
[100–102] 
Vpr 
(1) 7-mer RPL 
(2) human ScFv 
(1) GST-Vpr 
(2) Vpr N-terminus  
(17–34) 
(1) WxxF consensus 
(2) ISSD, 
AFMKSGKRFIH, 
HFHYKGKLQTF 
NA  NA  NA 
(1) cotransfection of 
WxxF-CAT constructs  
and Vpr 
(2) inhibition of  
Vpr-mediated nuclear 
import 
[103] 
[104] 
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Table 4. Cont. 
Target  Library 
Target 
presentation 
Phagotopes 
Affinity 
(KD) 
Inhibition 
(IC50) 
Virus 
isolates/clades 
Additional  Reference 
Int  7-mer RPL  Recombinant Int  FHNHGKQ  NA  NA  NA 
Inhibition of strand 
transfer activity 
[105] 
(1) Tat 
(2) Cyclin T1 
(3) TAR RNA 
(1) HIV-1-infected patient 
Fab 
(2) naï ve human ScFv 
(3) 12-mer RPL 
(1) Tat AA  
22–33 
(2) cyclin box 
domain, TRM 
(3) TAR RNA 
(1) 3 Fabs 
(2) 3R6-1 
(3) 57-mers 
(1) 10–1000 
nM 
(2) 107 nM 
(3) 420–550 
nM 
NA  NA 
(2) inhibition of  
Tat-mediated 
transactivation and  
HIV-1 replication 
when transfected 
[106] 
[107] 
[108] 
(1) NCp7 
(2) Psi RNA 
(1) 9-mer-c RPL 
(2) RPLs 
(1) NCp7 AA 30–
52 
(2) psi RNA 
(1) PPx(D/E)R motif 
(2) HWWPWW motif, 
SYQWWWHSPQTL 
motif 
NA  NA  NA 
(2) reduction of virus 
release by infected 
cells 
[109] 
[110–112] 
(1) Nef 
(2) Vif 
(1) mouse ScFv, immunized 
llamas VHH, human ScFv 
(2) 12-mer RPL 
(1) recombinant 
Nef, Nef CTL 
138-10/A24 
(2) recombinant 
Vif 
(1) SdAb19, ScFV3, 
ScFv27 
(2) PxP motif 
(1) 2nM  NA  NA 
(2) inhibition of HIV-
1 replication 
[113–115] 
[116,117] 
RT 
(1) mouse Fab 
(2) human ScFv 
Recombinant RT 
(1) 5F, 5G 
(2) F-6, 6E9, 5B11 
NA  NA  NA 
Inhibition of RDDP 
and/or DDDP activity 
[118,119] 
[120] 
Rev 
(1) HIV-1-infected patient 
Fab 
(2) 15-mer RPL 
(3) immunized  
llamas VHH 
(4) chimeric rabbit/human 
Fab 
Rev 
(1) 2 Fabs 
(2) p1, p3, p19 
(3) Nb190 
(4) SJS-R1 
NA  NA  NA  NA  [106,121–124] 
Gag  12-mer RPL 
CA protein  
(AA 162–190) 
CAI  NA  NA  NA 
In vitro inhibition of 
capsid assembly 
[125] 
NA: data not available. Int. J. Mol. Sci. 2012, 13  4751 
 
 
3.1.1. Env Inhibitors 
3.1.1.1. Gp120 CD4 Binding Site 
The CD4 binding site represents one of the main Achille’s heels of the virus since it is involved in the 
earliest step of HIV-1 entry and is conserved in almost all HIV-1 strains [126,127]. Numerous phage 
display biopannings were performed on gp120 and are classified here according to the type of antibody 
libraries used. 
3.1.1.1.1. Fab Libraries 
Burton et al. were the first to report the construction of a phage-displayed Fab library from the bone 
marrow of an asymptomatic HIV-1-infected patient with high titers of gp120-specific Abs [41]. This 
library was screened against recombinant gp120 from the IIIb isolate and clones displaying high affinities 
(<10 nM)
 for gp120 were selected [42]. One Fab (b12) (See Section 2.1.1.4.) was able to neutralize the 
MN and IIIb strains in different set-ups. This Ab is the most potent neutralizing Ab isolated to date, 
featuring neutralizing activity against 75% of 36 primary isolates of HIV-1 tested at concentrations that 
could be achieved by passive immunization [73].  
To  improve  its  affinity,  the  b12  Fab  was  submitted  to  CDR  walking,  a  procedure  involving 
randomization  of  its  CDR  and  expression  of  the  derived  libraries  expressed  on  phages,  followed  by 
screening against on gp120  [73]. Sequential CDR walking of the HCDR1 and HCDR3 domains was 
performed and four clones were chosen for detailed analysis of their binding affinity and neutralization 
potency against the IIIb and MN isolates. A Pro96Glu mutation of the HCDR3 was identified in the clone 
with highest affinity, 3B3, which bound IIIb gp120 with an 8-fold improved affinity (0.77 nM) compared 
to the parental b12 Fab. 
Similarly, Fab 3B3 was able to neutralize four isolates that were insensitive to the parental b12 Fab. 
The  CDR  walking  mutagenesis  strategy  was  pursued  in  a  subsequent  study  and  a  further  420-fold 
improvement of the binding affinity of 3B3 for gp120 was achieved, reaching 15 pM [72]. 
These  studies  were  the  first  to  demonstrate  that  recombinant  Fabs  (devoid  of  the  typical  IgG 
contamination residual of calpain cleavage) featured neutralizing activities similar to those of whole IgG. 
As the Fabs fragments were easier to produce and their smaller size allowed them to target binding sites 
that were not accessible to full-length Igs, this led to the construction of many Fab libraries to elucidate 
the immune response to HIV-1 and to identify therapeutic antibodies. 
The extremely high binding affinity of 3B3 was also applied to develop an immunotoxin which could 
specifically kill HIV-1-infected lymphocytes [71]. The authors engineered 3B3 ScFv fused to a truncated 
form of Pseudomonas exotoxin A. The 3B3(Fv)-PE38 fusion immunotoxin bound to the MN strain of 
gp120 with the same affinity as the parental Fab antibody and specifically killed a gp120-expressing cell 
line and a chronically HIV-infected lymphocytic cell line. This study provided the proof-of-concept that 
high affinity anti-HIV-1 antibodies have a dual application since they may be used for their neutralizing 
potency but also as carriers for antiviral compounds. Int. J. Mol. Sci. 2012, 13  4752 
 
 
Most antibodies obtained through screening Fab libraries against monomeric gp120 targeted epitopes 
related to the CD4-binding domain of gp120, pointing to it as an immunodominant epitope  [70]. To 
expedite the identification of NtAbs directed against weakly immunogenic epitopes,  a strategy called 
epitope-masking was applied in several studies. This biopanning approach is designed to mask a particular 
epitope with antibodies or ligands directed against the region of interest prior to addition of the phage 
library. Ditzel et al. panned a Fab library from an asymptomatic HIV-1-infected patient on immobilized 
recombinant gp120 and identified two dominant clones targeting the CD4-binding site [74]. These two 
Fabs were then incubated with gp120 to mask their respective epitopes and the panning of the library  
was repeated, highlighting (based on sequence similarities) four groups of Fabs recognizing gp120 with 
affinities in the range of 50 to 100 nM. Epitope mapping of one representative Fab for each group showed 
that gp120 binding of three clones was influenced by the V2 loop and the CD4-binding site and was not 
affected by the glycosylation status of gp120. Furthermore, one of these Fabs (L78) featured a broad 
neutralization spectrum against various HIV-1 strains. The authors performed further epitope masking  
by using different selection strategies with the same Fab phage library [81]. The first strategy involved 
masking the CD4-binding site (CD4BS) epitopes either with soluble CD4 or with a CD4BS Ab. All Fabs 
selected on sCD4-bound gp120 recognized the C1 region,  while the Fabs  isolated from  the CD4-BS  
Ab-captured gp120 were classified in four different groups: (i) Fabs targeting the C1 region, similarly to 
Fabs isolated on sCD4-bound gp120; (ii) Fabs directed against the C1–C5- region; (iii) Fabs
 recognizing 
the V2 loop; and (iv) Fabs directed against a CD4BS/V2 loop region, similar to the neutralizing FAb 
isolated  by  Ditzel  et  al.  [74].  Multiple  epitope  masking  was  then  conducted  by  masking  the  
CD4BS-MAb-captured gp120 with one of the C1-specific Fabs selected on the sCD4-bound gp120 prior 
to phage addition, leading to the identification of two C1/C2-dependent Fabs. All isolated Fabs bound 
their targets with affinities ranging from 4 to 300 nM. However, these FAbs targeting weakly immunogenic 
regions were not or poorly neutralizing.  
More  recently,  Koefoed  et  al.  investigated  the  anti-gp120  Ab  repertoire  of  the  circulating  
gp120-binding IgG-bearing B cells of 22 HIV-1-infected patients by constructing phage displayed Fabs 
libraries from unselected cells or from cells preselected with immobilized gp120 [128]. Panning against 
gp120  selected  for  a  higher  number  of  phagotopes  from  the  preselected  library.  Clones  from  the 
unselected library recognized the V3 loop, while clones from the preselected library targeted the CD4 BS 
or a CD4-induced epitope encompassing the C1 region. These Fabs displayed no significant differences 
with respect to epitope specificity, affinity and neutralization ability compared to Fabs obtained from bone 
marrow libraries, and most of them were unable to neutralize HIV-1. These results were in accordance 
with  previous findings  by Parren  et  al. (1997) concluding that the majority of the circulating HIV-1 
specific antibodies were elicited by viral debris and were therefore devoid of neutralizing activity [129]. 
3.1.1.1.2. ScFvs Hydrolyzing gp120  
Antibodies recognizing the amino acids 421–436 of the gp120 CD4BS were isolated from patients 
suffering from the systemic lupus erythematosus autoimmune disease [130,131]. However, whether these Int. J. Mol. Sci. 2012, 13  4753 
 
 
antibodies neutralized HIV-1 was not known, which prompted Karle et al. to quantify gp120-recognizing 
Abs  in  an  existing  ScFv  phage-displayed  library  from  the  PBMCs  of  lupus-suffering  patients  [132]. 
Biopanning selected for clones binding both gp120 and the 421–436 region of the gp120-CD4-binding site. 
One of these clones (JL413) neutralized R5 and X4-tropic HIV-1 primary isolates from clades B, C and D 
with IC50 ranging from 0.1 to 25.6 µg/mL.  
A subset of gp120-binding antibodies was shown to hydrolyze gp120 by a mechanism analogous to 
serine protease [133], As the nucleophilic region responsible for this activity was localized in the light 
chain [134,135], a library of light chains prepared from three lupus patients [132] was screened with an 
electrophilic analogue of gp120 residues 421–433 to isolate antibodies capable of binding and hydrolyzing 
gp120 [75]. One of the light chain clones selected (SKL6) cleaved a gp120 421–433-reporter substrate as 
well as full-length gp120. Engineering of Abs composed of such a light chain coupled to a gp120-binding 
heavy chain might provide Abs with anti-viral proteolytic activities. 
3.1.1.1.3. Nanobodies 
The  advantages  of  reduced  antibody  formats  were  also  explored  with  naturally  occurring  smaller 
antibodies. In addition to conventional antibodies, camelids also produce antibodies devoid of light chains 
(Figure  3D).  These  heavy-chain  only  antibodies  (HcAbs)  lack  the  CH1  domain  and  their  binding 
specificity is provided by the variable heavy-chain domains of HcAbs (VHH or nanobodies) [136]. The 
CDR regions of nanobodies are on average longer CDR than those of conventional Abs and display a 
protruding  conformation,  thereby  more  easily  binding  clefts  and  active  sites.  Nanobodies  were 
successfully used for panning against various pathogens (reviewed by Vanlandschoot [137]). Forsman et al. 
immunized  llamas  with  a  recombinant  gp120  of  subtype  B/C  (CN54)  [78].  Three  different  panning 
strategies against various gp120 resulted in the selection of three nanobodies (A12, D7 and C8) with 
neutralizing activity against a limited panel of clade B and C strains (IC50 values ranging from 0.003 to  
38 µg/mL). These nanobodies bound gp120 with affinities from 0.1 to 1 nM and inhibited its binding to 
CD4 as well as to MAbs known to recognize the gp120 CD4 binding site and, last but not least, competed 
with each other for gp120 binding. In a follow-up study, Koh et al. described a family-based approach to 
produce nanobodies similar to A12 and D7 [77]. They used a degenerated oligonucleotide annealing to the 
last six codons of CDR3 and framework (FR) 4 and an FR1-specific primer to amplify a sublibrary of 
related VHH clones with properties similar to the parental A12 or D7 VHH. More than 30 phagotopes were 
tested for their ability to neutralize 3 clade B and 3 clade C strains. All tested VHH displayed similar 
neutralizing activity against the clade B viruses. Three different neutralization profiles (Broad A12-like, 
Intermediate and Narrow D7-like potency) were observed against the clade C type strains and the breadth 
of neutralization potency appeared to be correlated to the presence of an YYD motif in the C terminus of 
A12 CDR3. When the CDR3 YDD motif from A12 was introduced within D7, gp120 binding affinity 
increased by 10-fold and neutralization of clade C strains increased by 5-fold. These studies were the first 
to  demonstrate BNtAbs elicited in  immunized animals.  As VHH are stable and can be produced at  a 
relatively low cost, they are promising HIV-1 inhibitors. Int. J. Mol. Sci. 2012, 13  4754 
 
 
3.1.1.1.4. CD4 Mimics 
The CD4 receptor recognizes gp120 through residues located within its V1 region, and engineering of 
this cell receptor was applied to identify CD4 variants with a better affinity for gp120, thereby displaying 
HIV-1 inhibitory properties. In 1997, Krykbaev et al. constructed a phage-displayed library of CD4 V1 
and V1-V2 variants generated by error-prone PCR and screened it against gp120 [79]. Five clones with 
increased affinity for gp120 and presenting mutations within the CD4 V1 domain were identified. All of 
these clones inhibited HIV-1 entry with IC50 ranging from 0.2 to 1 µg/mL.  
3.1.1.2. Gp120 V3 Loop 
The phage display technology was used to improve the affinity of the Mab 447-52D for its V3 loop 
epitope,  which  had  also  been  identified  through  phage  display  [16,17].  In  1996,  Thompson  et  al. 
expressed  MAb  447-52D  as  ScFv  on  phages  and  combined  its  VH  with  λ  and  κ  chains  from  a  
non-immunized PBL repertoire prior to  panning on  a peptide containing the  V3 loop  sequence  [80]. 
Additional shuffling of the HCDR1 and HCDR2 regions was combined to HCDR3 ―spiking‖, i.e., the 
introduction  of  random  mutations,  resulting  in  the  identification  of  four  key  residues  that  could  be  
mutated to improve Ab affinity. A sublibrary in which all four codons were simultaneously mutated was 
constructed and biopanning allowed to select for one ScFv (402P5H7) with improved KD against the MAb 
447-52D epitope. Two neutralizing Fabs (Fab loop 2 and Fab DO142-10) were obtained by screening a 
Fab library against recombinant gp120 reaching IC50 ranging from 0.2 to 8 µg/mL [70,81]. 
3.1.1.3. Gp120 CD4-Induced Epitope 
In 1999, Ferrer and Harrison screened 7-mer, 12-mer and constrained 9-mer RPL against gp120 and 
identified two peptides from the 12-mer RPL [82]. The first sequence RINNIPWSEAMM (12p1) inhibited 
CD4 as well as NtMAb17b binding while the second peptide, TSPYEDWQTYLM (12p2) did not affect 
the CD4 interaction and rather enhanced 17b binding. The 12p1 peptide was further investigated and 
shown to inhibit binding of monomeric YU2 gp120 to both sCD4 and 17b with IC50 values of 1.1 and 1.6 
µM  respectively.  The  12p1  peptide  also  inhibited  binding  of  these  ligands  to  trimeric  envelope 
glycoproteins, blocked binding of gp120 to the native coreceptor CCR5, and specifically inhibited HIV-1 
infection of target cells in vitro [138]. 
HIV-1  entry  is  a  multi-step  process  requiring  the  successive  binding  of  gp120  to  CD4  and  to  a 
coreceptor,  CCR5  or  CXCR4,  and  triggers  successive  conformational  changes  that  expose  transient 
epitopes. Targeting of these epitopes with NtAbs could therefore prevent HIV-1 infection, as has been 
proven  with  the  clinically  approved  fusion  inhibitor  Enfuvirtide.  To  identify  such  receptor-induced 
epitopes, Moulard et al. screened a Fab library constructed from an HIV-1 infected patient (FDA-2) with 
high  NtAb  titers  against  gp120-CD4-CCR5  complexes  [83].  One  Fab  clone,  X5,  bound  gp120  from 
several strains with a low nanomolar affinity. Furthermore, binding affinity was significantly increased in 
the presence of CD4 and slightly enhanced by CCR5. Competition assays with a panel of antibodies Int. J. Mol. Sci. 2012, 13  4755 
 
 
targeting different HIV-1 epitopes revealed that X5 recognized an epitope located in close vicinity to the 
CD4 and coreceptor binding sites. Neutralization assays with isolates from clades A, B, C, D, F and G 
demonstrated that X5 neutralized all isolates with potency comparable to that of b12. X5 is the first 
BNtAb recognizing a receptor-induced epitope identified to date.  
To select  for ligands  for CD4-induced epitopes, murine leukemia virus  particles  carrying the  Env 
protein of the dual-tropic 89.6 strain pre-incubated with sCD4 were recently used to screen 7-mer, 7-mer-c 
and 12-mer RPLs [84]. One of the selected phagotopes (XD3: HKQPWYDYWLLR) displaying sequence 
similarities (in bold) with the N-terminal extracellular part of the CCR5 and CXCR4 coreceptors was 
identified, suggesting novel potential leads for tyrosine sulfation. Both the XD3 phagotope and XD3 
peptides  strongly  and  specifically  bound  to  89.6  gp120  regardless  of  CD4  and  XD3  competed  with  
MAb 17b for binding to a CD4-induced epitope. The sulfated form of the XD3 peptide recognized X5, R4 
and dual-tropic strains and inhibited HIV-1 entry in the high micromolar range. 
3.1.1.4. Gp120 C1 Domain 
The Salp15 salivary protein of Ixodes scapularis inhibits CD4+ T cells activation by binding to the 
CD4 molecule in a region that may overlap with the gp120 binding site. This inhibition is mediated by the 
C-terminal  95–114  GPNGQTCAEKNKCVGHIPGC  sequence  [139].  Juncadella  et  al.  thus  analyzed 
Salp15 as a potential HIV-1 inhibitor and demonstrated that Salp15 inhibited gp120-CD4 interaction and 
subsequent cell fusion and that the GPNGQTCAEKNKCVGHIPGC peptide also interacted with gp120 [140]. 
To identify which gp120 amino acids interacted with peptide 95–114 of Salp15, the authors screened a  
7-mer RPL against Salp15 and isolated a HVITPLW sequence homologous to an (I/L)TPL motif of the 
gp120  C1/V1  domain  which  is  highly  conserved  across  HIV-1  isolates.  Finally,  they  mapped  the 
interaction site of full-length Salp15 protein or of its 95–114 C-terminal domain were able to bind to the 
PCVKLTPLCVTLNCT peptide within the gp120 C1/V1 region. 
3.1.1.5. Phage Display as a Tool to Unravel the HIV-1-Specific Humoral Response 
In addition to epitope mapping and inhibitor identification, phage display was also widely applied to 
elucidating  the  determinants  of  the  initial  response  to  HIV-1  antigens  and  more  particularly  the 
importance and different roles of IgM and IgG during the establishment of infection. Indeed, all known 
BNtAbs are IgGs that are somatically hypermutated and are thus more difficult to elicit. In contrast, IgMs 
are closer to germline antibodies and the identification of HIV-1 specific IgM could be relevant for the 
development  of vaccine immunogens.  The studies  listed in this  section explored and emphasized the 
importance  of  the  initial  IgM  response  against  HIV-1  and  viral  strategies  to  skew  it  towards  
non-neutralizing or infection-enhancing antibodies.  
Screening  against  gp120  with  IgM  and  IgG  Fab  repertoires  constructed  from  a  healthy  donor 
demonstrated  that  only  Fabs  isolated  from  IgM  were  able  to  recognize  gp120,  although  they  were 
polyreactive, displayed low affinities and no neutralizing properties [141]. Sequence analysis evidenced 
that selected gp120-binding Fabs originated from different VH germline genes. Several studies reported Int. J. Mol. Sci. 2012, 13  4756 
 
 
that gp120 displays superantigenic properties giving it the ability to bind and stimulate non-immune B 
cells to secrete VH3 Ig in vitro [142]. Interestingly, the VH3 antibody family is the most represented 
immunoglobulin gene family in healthy adults (54% of peripheral repertoire) and HIV-1 infection leads to 
altered VH3 production through selective depletion of the anti-HIV-1 VH3 antibodies [143]. Toran et al. 
further applied the phage display technology to examine and compare the human VH3 genes involved in 
IgM and IgG responses to gp120 to identify the correlates of long-term non progression. Two IgM and 
IgG phage-displayed Fab libraries from an HIV-1-infected LTNP with high gp120-specific IgM and IgG1 
titers were constructed and screened [144]. Several clones were selected from the IgM library (M02, 
M025, 4M26 and 4M40) and three clones from the IgG library (S20, S19 and S8). All IgM Fabs were 
polyreactive and had a binding affinity for gp120 in the micromolar range while the IgG Fabs were 
specific and bound gp120 with affinities in the nanomolar range, as expected. Sequence analysis showed 
that IgG Fabs originated from the same germline Ab. The IgM Fab M025 displayed the same VH region 
nucleotide substitutions as those of IgG Fab S8 and used similar DH and JH segments, suggesting that S8 
arose from M025 by isotype switching. In addition, a four aminoacid difference in the HCDR3 sequence 
of M025 (TGQWE) and S8 (RGGSI) was proposed to be associated with the 100-fold affinity increase for 
gp120  and  to  the  higher  neutralizing  activity  of  IgG  Fab  S8  (ID50  = 23  ng/mL)  than  of  IgM  M025  
(ID50 = 3 µg/mL). In a follow-up study conducted two years later, the three IgG Fabs were submitted to 
reverse  mutations  to  reconstitute  the  germline  amino  acid  residues  [145].  The  higher  affinity  and 
neutralizing ability of S20 were due to the Ala30Arg and Ala31Asp somatic mutations in the HCDR1 
region  of  the  germline  gene  sequence,  providing  clues  for  rational  modifications  of  CDR  in  human 
antibodies to improve affinity and HIV-1 neutralization capacity.  
The IgM to IgG isotypic switch generating high affinity neutralizing or non-neutralizing antibodies  
is  triggered  by  the  activation  of  IgM-producing  B  cells.  To  characterize  the  epitopes  recognized  by  
HIV-1-specific IgM and to assess the effects of these Abs on HIV-1 infection, Chen et al. constructed a 
Fab library from blood, lymph nodes and spleen from 59 healthy donors [146]. The library was panned 
against  gp140  (Env  ectodomain  containing  both  gp120  and  a  truncated  gp41  lacking  transmembrane 
domain and cytoplasmic tail) of a clade B isolate and allowed for the selection of one Fab clone (R3H1m) 
with a relatively high binding affinity for gp140 from different strains. A sublibrary derived from this 
clone was panned against gp140 from different isolates, resulting in the selection of clones (m19, m19a, 
m19b, m19c and m19d) binding with high affinity to clade B and F gp140 (EC50 ranging from 2 nM to  
80 nM). While these antibodies had weak neutralizing properties against X4-tropic isolates, they did not 
inhibit and in some cases even enhanced infection with R5-tropic isolates. The m19 Ab, whose sequence 
is relatively similar to the germline Ab, targeted highly conserved epitopes located near the CD4 binding 
site or the coreceptor binding site. The high immunogenic capacity of the conserved non-neutralizing 
epitopes of such antibodies could divert the immune system from  actually neutralizing epitopes. The 
authors  suggested  that  these  newly  identified  MAbs  could  be  used  as  probes  to  further  characterize 
conserved non-neutralizing or enhancing epitopes and to modify or remove them from candidate vaccine 
immunogens. The epitope masking strategy (section 3.1.1.1.) might be applied to these epitopes to redirect 
the immune system to elicitation of antibodies targeting neutralizing epitopes. Int. J. Mol. Sci. 2012, 13  4757 
 
 
To select for antibodies closely resembling the germline antibodies as a candidate source of BNtAbs, 
the same authors constructed a cord-blood-derived IgM library which they submitted to parallel screening 
against HIV-1 Env, SARS coronavirus protein binding domain (RBD) and soluble Hendra virus G protein 
(sG) [147]. Although RBD and sG antigens provided enriched IgM, the library could not be enriched in 
HIV  Env-binding  phagotopes.  These  results  are  in  accordance  with  the  hypothesis  that  HIV-1  could  
have evolved strategies based on weak or absent binding to antibodies of the germline repertoire [146]. 
Presenting epitopes unsuitable for binding of somatically hypermutated antibodies would enable the virus 
to escape from strong immune responses. 
3.1.1.6. Gp41 MPER Inhibitors 
In 2001, Zwick et al. constructed a phage-displayed Fab library from an HIV-1 positive patient with 
exceptionally BNtAbs (FDA-2 patient). This library was screened on the MN2031 peptide encompassing 
the  2F5  epitope  ELDKWA,  and  led  to  the  identification  of  the  Z13  MAb  [85].  Epitope  mapping 
experiments based on synthetic peptides and recombinant proteins showed that the epitope targeted by 
MAb Z13 was located downstream of the 2F5 epitope and centered on the NFWDIT sequence. MAb Z13 
neutralized primary isolates from HIV-1 B, C and E subtypes. To enhance binding potency, Fabs sublibraries 
of Z13 variants were engineered and screened against an MPER peptide and gp41 [86]. The selected 
Z13e1 variant displayed an over 100-fold increase in neutralization breadth and potency compared to the 
parental Z13 MAb. Binding experiments coupled to competition assays revealed that the Z13e1 MAb 
bound to a WASLWNWFDITN minimal epitope overlapping the 2F5 epitope and that the Asn and Asp 
residues were essential for peptide recognition as well as HIV-1 neutralization. 
Very recently, phage- and yeast-displayed Abs libraries constructed from an HIV-1-infected patient 
with 2F5-like BNtAbs were panned against peptides containing the 2F5 epitope and against the HIV-1  
JR-FL gp140 [148]. Two MAbs (M66 and M66.6) were identified and the most mutated variant (M66.6) 
neutralized HIV-1 with a higher potency than M66. Ala substitutions indicated that both Abs recognized 
the DKW core of the 2F5 epitope and two additional Leucine residues located upstream (L(660,663)).  
3.1.1.7. Gp41 Heptad Repeat Inhibitors 
Fusion of viral and host membranes, the last step of HIV-1 entry, requires the initiated by the insertion 
of  the  gp41-encoded  fusion  peptide  into  the  host  cell  membrane  and  the  formation  of  an  extended 
prehairpin intermediate (PHI). The gp41 N- and C-terminal heptad repeats (NHR, CHR) then collapse to 
form a six-helix bundle (6-HB) in which the NHR form a trimeric coiled-coil, creating grooves where the 
CHR bind. The viral and cellular membranes are thereby brought into close proximity, enabling fusion 
(Figure 1). During PHI formation, the NHR and CHR do not interact and may thus be transiently targeted 
by compounds which prevent the formation of the six-helix bundle in a dominant-negative manner. One 
such compound is the synthetic CHR mimic Enfuvirtide (T20) [4,149]. A hydrophobic pocket located on 
the N-terminal peptide trimer groove of the 6-HB is highly conserved among HIV-1 sequences and plays a 
critical role in membrane fusion, and therefore represents a select target for inhibitors.  Int. J. Mol. Sci. 2012, 13  4758 
 
 
Eckert et al. used the particular approach called ―mirror-image phage display‖ to identify D-peptides 
targeting the gp41 hydrophobic pocket [89]. In this approach, a phage library of natural  L peptides is 
screened against the mirror image of a target synthesized as D-peptide [150]. By symmetry, the selected  
D-peptide  phagotope  sequences  will  bind  the  natural  L-form  of  the  target.  The  main  advantage  of  
D-peptides  over  L-peptide inhibitors  is  their resistance to  natural  proteases  which enhances  their oral 
bioavailability and serum half-life. In a first study, the authors screened a constrained 10-mer RPL against 
the D-peptide sequence of the gp41 hydrophobic pocket fused to a soluble trimeric coiled-coil (IZN17). 
Pocket-specific binders with a consensus motif Cx5EWxWLC were identified and inhibited cell fusion or 
HIV-1 entry into cells with an IC50 in the micromolar range when synthesized using D-amino acids. In a 
second study, the same authors constructed a sublibrary based on the consensus sequence identified in 
their first study [89] which allowed the selection of sequences with a fourfold potency increase [87]. 
Surprisingly,  the  most  potent  peptide  was  a  8-mer  with  a  Cx3EWxWLC  motif  which  was  probably 
selected from the 10-mer sublibrary because its smaller size favored a more compact hydrophobic core 
upon binding to the gp41 hydrophobic pocket. Screening of second generation D-peptides from a 8-mer 
CX4WXWLC library led to the selection of pocket-specific inhibitor of entry (PIE) 7 with an IC50 of 620 nM. 
Dimeric and trimeric forms of PIE7 had respective IC50 values of 1.9 nM and 250 pM. In a third study, the 
same authors constructed a phage library based on the PIE7 core sequence flanked by two randomized 
amino  acids  (xxCDYPEWQWLCxx)  and  obtained  phages  with  the  H(A/P)-[PIE7  core]-(R/K/E)L 
consensus  sequence  [88].  A  peptide  (PIE12,  HPCDYPEWQWLCEL)  exhibited  a  broad  neutralizing 
spectrum and was even more efficient than T20, reaching an IC50 of 0.5 nM, when trimerized. Moreover, 
this third generation PIE12-trimer displays broadened inhibitory potency and resistance to viral variants, 
as escape mutants required over 65 weeks of selection in vitro to emerge. The PIE12 trimer is thus a 
promising entry inhibitor and may be used as a topical microbicide in its D conformation. 
In 2005, there was no evidence of Abs capable of binding the highly conserved NHR region targeted 
by the T20 inhibitor. To determine whether antibody fragments could target this determinant on the gp41 
protein, Miller et al. constructed a phage-displayed naï ve ScFv library and screened it against a synthetic 
protein mimicking the 6-HB [90]. This construct, named 5-Helix, lacks one of the three CHRs and the 
NHR trimer is partially exposed, presenting a single binding site for a CHR mimic [151]. The ScFv library 
was also panned against the IZN36 compound, a homotrimerized form of 36 NHR amino acids fused to a 
coiled-coil peptide, therefore representing a 6-HB mimic devoid of the CHR trimer [91]. The authors 
identified a ScFv (D5), which blocks HIV-1 entry and inhibits infection in a single-cycle infectivity assay. 
This ScFv retained its properties when produced as a whole IgG1. The antibody was found to bind the 
hydrophobic pocket of the NHR trimer and Ala scan experiments revealed the crucial role of residues 
L568, W571, and K574 located in the hydrophobic pocket for this interaction. IgG1 D5 was  able to 
neutralize at least five HIV-1 isolates with IC50 ranging from 93 to 1750 nM, thereby demonstrating that 
the hydrophobic pocket of the NHR trimer is accessible for binding of HIV-1 inhibitors as large as IgGs.  
The same year, another study demonstrated that antibodies binding with high affinity and specificity to 
heptad repeats can be isolated from synthetic Fab minimalist libraries presenting Tyr/Ser randomization of 
their CDR [152]. Very recently, Liu et al. took advantage of these results and constructed a minimalist Int. J. Mol. Sci. 2012, 13  4759 
 
 
Fab library where the LCDR3 and HCDR1-3 domains were randomized with Tyr and Ser [92]. Screening 
of this library on the 5-Helix mimic selected for Fabs with affinity and specificity values comparable  
to  those obtained with  the ScFv of the previously described D5 Ab  [90,153]. Huang  et  al. used the 
N34(L6)C28  polypeptide  mimicking  the  6-HB  [154]  to  screen  7-mer  and  12-mer  RPLs  and  selected 
sequences  bearing  a  Hxx(N/D)PF  motif  [93].  This  consensus  motif  synthesized  as  peptide  (JCH-4) 
inhibited HIV-1-mediated syncytia formation [94]. 
Fusion inhibitors  were  also  identified by screening non-immune human Fab libraries.  Louis  et  al. 
screened such a library [155] against antigens comprising the trimeric coiled-coil NHR fused or not to the 
gp41 six-helix bundle (N35CCG-N13 and NCCG-gp41, respectively) [156,157]. They identified Fabs 
targeting (i) the 6-HB; (ii) the NHR trimeric coiled-coil or (iii) both 6-HB and trimeric coiled-coil [95]. 
These antibodies were tested in a cell fusion inhibition assay and the two more potent MAbs, belonging to 
the third group, featured an IC50 of 6–7 µg/mL. Two years later, the same library was screened against 
NCCG-gp41 and 6-HB antigens [96]. Two clones, Fabs 3663 and 3670, inhibited cell fusion while one 
Fab 3674 clone selected against NCCG-gp41 was also effective in infection neutralization assays. Fab 
3674 bound the 6-HB as well as stable NHR trimers, and recognized an epitope that partially overlapped 
the hydrophobic pocket targeted by the D5 Ab. The same authors subsequently demonstrated that the 
N36
Mut(e,g) peptide presenting mutations within the 5
th and 7
th AA residues of the heptad repeat [158] 
increased the temporal window of viral sensitivity to Fab 3674 and thereby synergistically enhanced the 
neutralizing activity of Fab 3674 as well as of the BNtAbs 2F5 and 4E10 [98]. A Fab sublibrary was 
created by affinity maturation of the Fab 3674 HCDR2 loop and screened against NCCG-gp41, selecting 
for three Fabs (Fabs 8060, 8066 and 8068) with enhanced potency (average 5-fold decrease in IC50) and 
neutralization breadth [97]. 
To  follow-up  a  study  demonstrating  that  affinity-purified  IgGs  from  rabbits  immunized  with 
N35CCGN13 inhibited HIV-1-mediated fusion [156], Nelson et al. rescued a ScFv antibody library from 
these animals [99]. Three N35CCGN13 binders were selected, and one of them, 8K8, displayed neutralizing 
activity against HXB2. In parallel a more complex Fab library was constructed from the FDA-2 HIV-1-
positive patient from whom Z13 Ab had previously been isolated  [85]. Screening this library against 
N35CCGN13 allowed for the isolation of Fab DN9 [99]. Both ScFv 8K8 and Fab DN9 neutralized HIV-1 
infection with a panel of viral strains with IC50 ranging from 50 to 500 nM and targeted the NHR trimeric 
coiled-coil, presumably close to the hydrophobic pocket. Three additional gp41-specific Abs (M44, M46 
and  M48)  were  obtained  by  screening  antibody  phage  libraries  from  asymptomatic  seropositive  
patients [159] against gp140 [100–102]. A recombinant gp140 (gp140 R2) isolated from an asymptomatic 
seropositive patient with BNtAbs was reported to elicit BNtAbs in monkeys, further demonstrating that 
immunogenic epitopes were exposed on this recombinant antigen  [101]. Competitive antigen panning 
(CAP) (biopanning approach designed to outcompete phagotopes binding to an immunodominant region 
of  a  multi-domain  target  through  concomitant  addition  of  an  excess  of  soluble  forms  of  this 
immunodominant domain) using a mixture of gp140R2 as antigen and gp120R2 as competitor resulted in 
the  selection  of  a  gp41-specific  M46  Ab  [101].  M46  displayed  broad  neutralization  properties  and 
recognized a conformational epitope and bound weakly to 5-Helix antigen but not to the trimeric NHR nor Int. J. Mol. Sci. 2012, 13  4760 
 
 
to 6-HB. In two other studies, the same libraries were panned against gp140/120 from three different 
isolates (89.6, cm243 and R2), which led to the identification of the M48 Ab recognizing a conformational 
epitope of gp140 [102] and the M44 Ab, which binds gp140, 5-Helix and 6-HB but not to the NHR 
trimeric coiled-coil. M44 recognized a conserved conformational epitope and neutralized isolates from 
different clades with a significantly higher potency than 4E10 or Z13 [100]. The competitive antigen 
panning approach against gp140/120 thus allows the selection of Abs recognizing conformational epitopes 
on gp41, which are not properly folded when gp41 is used as a target. 
3.1.2. Other HIV-1 Proteins  
Most of the studies found in the literature that apply the phage display technology to the discovery of 
HIV-1 inhibitors target the Env protein. However, reports about the identification of peptides directed 
against other HIV-1 proteins involved in viral replication as well as interfering with RNA sequences have 
been published and are summarized in this section.  
3.1.2.1. Viral Protein of Regulation (Vpr) 
Vpr is  involved in  the nuclear import of the viral  preintegration complex (PIC)  as  well as  in the 
induction of apoptosis after cell cycle arrest and can be packaged into virions in quantities similar to the 
structural proteins [160–163]. Vpr was also reported to be associated with numerous cellular proteins such 
as glucocorticoid receptors, transcription factors or the uracyl DNA glycosylase (UDG) [160,164–166].  
To investigate whether Vpr may be used as a docking protein to deliver anti-viral compounds into 
virions, BouHamdan et al. used a 7-mer RPL to determine a common motif involved in the interaction 
between Vpr and its various ligands  [103]. Screenings rounds against Vpr fusion proteins pinpointed 
sequences sharing a WxxF motif. Since UDG contains a WxxF sequence, mutants were constructed and 
confirmed the importance of this motif for Vpr binding. Cotransfection experiments indicated that the WxxF 
motif might be used to deliver a fusion protein into the HIV-1 virion through a new docking strategy. 
In 2003, Krichevsky et al. conducted a study to elucidate the exact role of Vpr and its contribution to 
the nuclear import process of the HIV-1 PIC [104]. To that aim, a semi-synthetic ScFv library [167] was 
screened against the N-terminal (AA 17–34) part of Vpr (VprN) conjugated to BSA (VprN-BSA). Purified 
ScFvs fragments featuring their strong and specific binding to the VprN sequence recognized full-length 
Vpr and inhibited Vpr-mediated nuclear import, indicating that targeting Vpr may lead to the development 
of new peptides to fight viral infection. 
3.1.2.2. Integrase (IN) 
The  phage  display  technology  has  also  been  applied  to  the  identification  of  the  HIV-1  integrase 
inhibitors.  In 2004, Desjobert  et  al. screened a 7-mer RPL against recombinant  HIV-1 integrase and 
identified a high affinity phagotope displaying the FHNHGKQ sequence [105]. In peptide format, this Int. J. Mol. Sci. 2012, 13  4761 
 
 
sequence inhibited the strand transfer activity of IN by competing with the target DNA, providing the 
proof-of-concept that IN is also a valuable target for phage display.  
3.1.2.3. Transactivator of Transcription (Tat)/Transactivation Response element (TAR)  
Interaction of the viral transcription activator Tat with the human cyclinT1 subunit of the positive 
transcription elongation factor (P-TEFb) complex and the cooperative binding of this complex to the 
transactivation response element (TAR) RNA are prerequisites of HIV-1 transcription [168]. Screening 
RPLs  or  Fab  libraries  against  Tat,  cyclinT1  or  TAR  elements  using  the  phage  display  technology 
identified peptides impairing Tat-mediated HIV-1 replication. 
The first study was conducted in 1996, when Pilkington et al. screened a Fab library constructed from 
the Ab repertoire of  an HIV-1-infected  asymptomatic patient  and selected Fabs  recognizing a  region 
comprised between amino acids 22 to 33 of the Tat protein in a conformation-dependent manner [106].  
Many  years  later,  a  non-immune  human  ScFv  phage-displayed  library  was  explored  to  identify 
peptides binding to cyclinT1 [107]. Clones recognizing the cyclin box domain of cyclinT1 or interacting 
with the Tat/TAR recognition motif (TRM) were isolated after panning against the 272 N-terminal amino 
acids of cyclinT1. When expressed as intrabodies (antibody or antibody fragment expressed intracellularly), 
one of these ScFvs inhibited Tat-mediated transactivation without impairing cellular basal transcription or 
inducing apoptosis and partially inhibited HIV-1 replication in cultured cells.  
The TAR RNA sequence adopts a specific structure  recognized by the basic Arginine Rich Motif 
(ARM) of Tat  and thus  represents  a potential target  for phage display  screening.  In 2005, Kolb and 
Boiziau screened a 12-mer RPL against TAR RNA molecules and selected 12-mer and unexpectedly  
57-mer sequences from the library [108]. The latter were proposed to  arise from incomplete enzyme 
restriction  during  the  construction  of  the  initial  library.  Clones  were  further  characterized  in  peptide 
format and displayed TAR-specific binding. The authors suggested that the surprisingly long peptides 
might have been selectively retrieved from the library because they presented a conformation that shorter 
12-mer peptides were unable to adopt. 
3.1.2.4. Nucleocapsid (NC)/Packaging Signal (psi) Sequence 
The HIV-1 nucleocapsid protein p7 (NCp7) is processed from the Gag precursor and is involved in the 
protection and encapsidation of viral RNA leading to viral assembly through interaction with a specific 
secondary structure of the 125-base long psi RNA [169–172]. Lener et al. screened a constrained 9-mer 
RPL against NCp7 and selected phagotopes sharing a PPx(D/E)R consensus motif [109]. Further binding 
experiments  suggested  that  the  NCp7-phage  interactions  involved  amino  acids  30  to  52  of  NCp7, 
encompassing a zinc finger domain.  
Studies to identify inhibitors of viral packaging were also conducted. RPLs were screened on the psi 
RNA immobilized onto a streptavidin-coated surface by annealing its 5'-end to a biotinylated oligomer, 
leading  to  the  selection  of  peptides  characterized  by  an  HWWPWW  motif  [110].  Peptide  variants 
presenting this motif were subsequently synthesized and the most efficient binder was shown to strongly Int. J. Mol. Sci. 2012, 13  4762 
 
 
reduce virus release by infected cells, suggesting that it could serve as a lead compound to develop new 
anti-HIV-1 drugs [111].  
A  similar  screening  campaign  was  conducted,  where  the  5'-end  of  the  psi  RNA  was  covalently 
immobilized, leaving the secondary structure intact and fully accessible [112]. Screening of a 12-mer RPL 
selected  for  four  clones  with  either  WHxT  or  HSSxY  motifs  which  were  assessed  for  specific  and  
dose-dependent binding to psi RNA. The most prevalent sequence (SYQWWWHSPQTL) was expressed 
in fusion with the maltose-binding protein and was able to compete with NCp7 for binding to psi RNA, 
confirming the value of the peptide as a potential HIV-1 inhibiting compound.  
3.1.2.5. Negative Factor (Nef)/Virion Infectivity Factor (Vif) 
HIV-1 accessory proteins Nef and Vif have an important role in HIV-1 viral replication and infectivity 
and, as such, represent as such interesting targets for inhibitors. In 2001, Yang et al. demonstrated that Vif 
was able to multimerize and that its 151-AALIKPKQIKPPLP-164 domain was critical for multimerization 
pointing to it as an interesting target to impair Vif-mediated viral replication [116]. The authors therefore, 
screened a 12-mer RPL library against Vif and selected phages sharing a common PxP motif [117]. Four 
of these sequences synthesized as peptides bound the C-terminus of Vif with high affinity and were able 
to inhibit Vif-Vif as well as Vif-Hck tyrosine kinase interactions. Moreover, these peptides inhibited  
HIV-1 replication in cultured cells.  
Besides  the  identification  of  inhibitors  from  RPL,  the  discovery  of  Abs  targeting  Nef  and  Vif 
applicable to intrabody-based therapy may represent an alternative way to impede viral replication [72].  
In a very recent study, Yoshikawa et al. evaluated the effect of two different schedules of Nef and Vif 
administration for mice immunization prior to the construction of ScFvs phage-displayed libraries [113]. 
Results  demonstrated  that  the  immunization  protocol  influenced  the  complexity  of  the  elicited  Ab 
repertoire and thus the successful identification of Abs specifically recognizing the target.  
A  nanobody  (sdAb19)  recognizing  a  conformational  epitope  and  reacting  with  a  high  affinity  
(KD: 2 nM) with Nef proteins from a panel of HIV-1 M, N, O and P groups was isolated through phage 
displaying the VHH repertoire of a llama immunized with a purified recombinant Nef protein (fragment  
57–205) [114]. When expressed as an intrabody, this anti-Nef sdAb inhibited important biologic functions 
of Nef both in vitro and in vivo in CD4C/HIV-1Nef transgenic mice. 
The first step in cytotoxic T lymphocytes (CTL) activation is the recognition by a T cell receptor (TCR) 
of the antigen-derived peptide/MHC class I complex (pMHC). To date, few studies were undertaken to 
examine  antigen  presentation  at  a  cellular  and  molecular  level.  Nunoya  et  al.  screened  pooled  ScFv 
libraries [173] on an immunodominant HLA-A*2402(A24) restricted CTL epitope within the Nef protein 
(Nef138-10; RYPLTFGWCF) [115]. The panning procedure yielded clones binding specifically to Nef 
138-10/A24. Clones ScFv3 and ScFv27 were able to bind to Nef 138-10/A24 expressed at the cell surface 
and retained this specificity when expressed as reconstituted whole IgGs. This recent study was the first to 
address the identification of monoclonal antibodies binding specifically to an immunodominant HIV-1 
CTL epitope loaded on an HLA class I molecule. Int. J. Mol. Sci. 2012, 13  4763 
 
 
3.1.2.6. Reverse Transcriptase (RT) 
Reverse transcriptase is a valuable target for anti-HIV-1 compounds, as illustrated by the success of the 
multiple small compounds used in HAART. In 1996, Gargano et al. panned a phage-displayed library of 
synthetic combinatorial human Fab fragments against recombinant HIV-1 RT [174]. Two Ab fragments 
that specifically inhibited the RNA-dependent DNA polymerase (RDDP) activity of RT were identified. 
Both fragments also inhibited the activities of avian and murine retroviral RTs as well as the human DNA 
polymerase α and prokaryotic DNA polymerases. Because of their lack of specificity, these Abs fragments 
were not exploited further as anti-HIV-1 molecules. 
To develop a panel of recombinant MAbs reacting with different epitopes of the RT, Ohba  et al. 
immunized mice with recombinant RT expressed in a vaccinia virus vector and constructed a phage-displayed 
mice Fab fragments library [118]. Biopanning against recombinant RT led to the identification of two Fab 
fragments (5F and 5G) able to strongly inhibit the RDDP activity of HIV-1 RT. Epitope mapping and 
competitive ELISA showed that 5F and 5G recognized an epitope similar or closely related to the epitope 
targeted by the mouse MAb (7C4) previously described by the same authors [119].  
Two years later, a semisynthetic phage display library of human ScFvs with randomized heavy and 
light chain CDR3 was screened against recombinant RT [120]. Five different ScFv Abs directed against 
RT were isolated, of which three (F-6, 6E9, 5B11) inhibited the RDDP activity of RT; of note, (F-6) also 
inhibited RT DNA-dependent DNA polymerase (DDDP) activity. Synthesis of the peptides corresponding 
to the CDR3 regions of the heavy and light chains showed that the heavy chain CDR3 inhibited RDDP 
activity  while  the  light  chain  peptide  had  no  effect.  These  HCDR3  peptides  represent  the  smallest 
antibody fragments inhibiting the RT identified to date and demonstrated that HCDR3 repertoire is a 
potential source of bioactive molecules (see Section 3.2.1.2.). 
3.1.2.7. Regulator of Virion Expression (Rev) 
Rev is a key regulatory protein. Oligomerized Rev binds to unspliced or singly spliced viral mRNA 
and ensures its transport to the cytoplasm, thereby allowing the translation of viral gene products. Despite 
considerable efforts, the structure of Rev is poorly characterized since Rev is refractory to crystallization, 
mainly because of its tendency to form insoluble aggregates [175]. In the absence of structural information, 
the phage display technology was used by different authors to map the domains involved in the interaction 
of Rev with its network of partners. Pilkington et al. identified two Rev-specific Fabs from a Fab library 
derived  from  the  Ab  repertoire  of  an  HIV-1-infected  asymptomatic  patient  [106].  These  Fabs  were 
directed against sites adjacent to the Rev basic nuclear localization signal (NLS) (residues 52–64) and to 
the activation domain (residues 75–88). Two years later, Jensen et al. screened a 15-mer RPL to identify 
potential Rev peptidic antagonists [121]. Three groups of sequences sharing a SRLxG(x)2–3R motif (group 
I),  sharing  a  RVV(x)2–4RG/A  motif  (group  II)  or  featuring  no  sequence  similarity  (group  III),  were 
obtained. Three clones were selected based on their high frequency of occurrence (p1 and p3, group I) or on 
their strong binding affinity for Rev (p19, group III). They were synthesized as peptides and were shown 
to retain Rev binding specificity. More recently, llama nanobody libraries from animals immunized with Int. J. Mol. Sci. 2012, 13  4764 
 
 
recombinant Rev allowed the identification of 12 Rev-binding nanobodies [123]. One of them (Nb190) 
prevented  or  disrupted  Rev  multimerization  by  interacting  with  Lys20  and  Tyr23  of  the  Rev  
N-terminal  α-helix  [122].  Besides  inhibitor  discovery,  Fabs  were  recently  proposed  as  ―crystal 
chaperones‖ to support crystallization of their partners by locking them in specific conformations and 
blocking aggregation [124]. Stahl et al. described the preparation, characterization, and crystallization of 
an equimolar complex formed between Rev and a chimeric rabbit/human Fab (SJS-R1) selected through 
phage display [124]. The Rev/SJS-R1 Fab complex was successfully crystallized and the Fab SJS-R1 was 
shown to recognize a conformational epitope in the N-terminal half of Rev. Structural characterization of 
the crystallized Fab/Rev complex is ongoing and a corresponding ScFv has been engineered and may have 
anti-HIV-1 properties.  
3.1.2.8. Group-Specific Antigen (Gag) 
To identify peptides interfering with HIV-1 capsid assembly, Sticht et al. screened a 12-mer RPL 
against  the  capsid  (CA)  protein  generated  by  the  proteolysis  of  the  Gag  precursor  and  identified 
phagotopes whose sequences could be classified in four groups  [125]. One of these sequences (CAI, 
capsid assembly inhibitor) competed with phagotopes for binding to CA and inhibiting capsid assembly  
in  vitro.  Interaction  with  CAI  was  mapped  to  CA  amino  acids  162–190,  with  additional  contacts  in  
helix 4. CAI did not inhibit capsid assembly in vivo, but may nevertheless serve as tool for drug screening 
and as a starting point for drug design based on its CA-binding properties. 
3.1.3. Diagnostic Applications  
Peptides and antibody fragments selected by means of phage display may also be used for diagnostic 
purposes or to assess the diversity of the immune response against HIV-1-specific antigens. 
De  Haard  et  al.  constructed  a  ScFv  library  from  PBLs  of  an  HIV-1  positive  patient  presenting 
antibodies  against  gp120,  gp41  and  p24  and  screened  the  library  against  gp160  and  p24  [176].  
One phagotope recognizing an epitope within the 2F5 and 4E10 BNtAbs epitopes on gp41 (AB#31) with 
affinities in the nanomolar range was isolated. Importantly, it was shown to compete with 41 out of  
42 gp160-reactive plasma samples from North-American and African HIV-1 positive patients, indicating 
that this antibody recognizes an epitope conserved in a large panel of isolates and might be suitable for 
diagnostic applications. 
Since all vaccine candidates elicited antibodies reacting positively in HIV tests, Khurana et al. applied 
the  phage  display  technology  to  identify  HIV-1  epitopes  susceptible  to  help  discriminate  between 
successfully immunized vaccinees and seroconverters [177]. They constructed a phage library displaying 
the full HIV-1 genome and screened it against the sera of newly seroconverted HIV-1 positive individuals. 
They identified conserved epitopes present in gp41 and in Gag p6 that were not part of the vaccine used at 
that moment and established a new detection test, named SELECTEST, that demonstrated over 99% 
selectivity and sensitivity for the early detection of seroconversion. HIV SELECTEST was able to detect 
antibodies against these epitopes in newly infected patients as early as 2 to 4 weeks after infection. Int. J. Mol. Sci. 2012, 13  4765 
 
 
3.2. Inhibitors of Host Proteins  
In parallel to the targeting of viral proteins, many efforts were undertaken to identify peptides, antibody 
fragments or modified ligands binding to the HIV-1 host proteins and impairing their interactions with the 
viral proteins (Table 5).  
3.2.1. Host receptors inhibitors 
The HIV-1 host receptors CD4, CCR5 and CXCR4 are involved in the early steps of HIV-1 infection 
and  thus  represent  valuable  targets  for  the  identification  of  antiviral  peptides  or  neutralizing  Abs. 
Moreover, these receptors display very low variability compared to the viral Env proteins facilitating the 
identification of neutralizing antibodies. Although the CD4 receptor plays a crucial  role in  the entry 
process,  the only phage display biopanning  assays  reported to  date targeted the chemokine receptors 
CCR5 and CXCR4. However, to circumvent the difficulties of purifying and immobilizing such complex 
receptors on a solid support without losing their native structure, biopanning procedures had to be adapted. 
In this regard, screening strategies using biopanning on living cells [178,179], proteoliposomes [180] or 
peptides derived from the receptors extracellular parts [181,182] were particularly successful. 
3.2.1.1. CCR5 Coreceptor 
The CC chemokine receptor 5 (CCR5) is one of the two major HIV-1 coreceptors and binds three 
different endogenous chemokines CCL5 (RANTES), CCL4 (MIP-1β) and CCL3 (MIP-1α) which were 
reported to prevent R5-tropic HIV-1 entry. Interestingly, inhibition of CCR5 binding to HIV-1 provides an 
almost complete protection against R5-tropic viruses with only minor effects on the normal physiological 
functions of the cells [183].  
The  first  biopanning  experiment  targeting  CCR5  was  performed  using  receptor  embedded  in 
paramagnetic proteoliposomes [180]. To create such proteoliposomes, magnetic beads were added to a 
mixture of synthetic lipids, a detergent-solubilized C9-tagged CCR5 receptor and a capture antibody, 
reconstituting membrane bilayers containing pure, native and properly oriented CCR5 receptor. These 
proteoliposomes were used in biopanning experiments with a human ScFv antibody library and several 
antibody  fragments  specifically  binding  to  CCR5-expressing  cells  were  identified.  The  same  year, 
Steinberger  et  al.  used  the  phage  display  technology  to  select  and  to  humanize  rabbit  anti-CCR5 
antibodies preventing the export of CCR5 to the cell surface [184]. Following rabbit immunization with a 
GST-Nterm CCR5 fusion protein, the authors constructed a phage displayed Fab library that was screened 
against  the  antigen  initially  used  for  the  immunization.  A  phagotope  (ST6)  binding  strongly  and 
specifically to the immobilized antigen as well as to CCR5-positive cells was identified, expressed as a 
ScFv and humanized by successive replacements of the rabbit light and heavy chains by their human 
counterparts. One humanized antibody fragment, ST6/34, that retained the strong CCR5-binding capacity 
of  the  parental  ST6  antibody  was  isolated  from  the  screening  of  the  intermediate  libraries.  When 
expressed as intrabody the ST6/34 scFV efficiently blocked the CCR5 expression at the cell surface. Int. J. Mol. Sci. 2012, 13  4766 
 
 
Table 5. Host protein inhibitors selected by phage display. 
Target  Library 
Target 
presentation 
Biopanning procedure  Phagotope  Affinity  Inhibition 
Virus 
isolates
/clades 
Additional  Reference 
CCR5  Human ScFv  Liposome  Five rounds  NA  NA  NA  NA  NA  [180] 
CCR5 
Human VH-Rabbit ST6 
HCDRs 
CCR5 Nterm-GST 
fusion 
Four rounds, acidic 
elution 
Rabbit ST6 
Human ST6/34 
2.7 nM 
8.5 nM 
NA  NA 
Inhibit CCR5 export 
when expressed as 
intrabodies 
[184] 
CCR5 
Randomized and 
extended CCL5 
chemokine 
HEK-CCR5,  
CHO-CCR5 
Recovery of internalized 
phages, acidic elution 
CCL5 
P1-CCL5 
P2-CCL5 
IC50 = 4.1 nM 
IC50 = 2 nM 
IC50 = 0.2 nM 
NA 
IC50 = 7.0 
nM 
IC50 = 0.6 
nM 
BaL 
P1: triggers reduced 
signaling 
P2: superagonist 
inducing CCR5 
sequestration 
[185] 
CCR5 
Randomized and 
extended CCL5 
chemokine 
HEK-CCR5,  
CHO-CCR5 cells 
Recovery of internalized 
phages, acidic elution 
6P4-CCL5 
5P12-CCL5 
5P14-CCL5 
NA 
NA 
NA 
IC50 = 21 pM 
IC50 = 28 pM 
IC50 = 26 pM 
BaL 
Superagonist + 
sequestration 
No signaling + no 
sequestration 
Internalization + no 
signaling 
[186] 
CCR5  Mice and rats ScFV 
ECL1, ECL2, 
ECL3 biotinylated 
peptides 
Alkaline elution 
A1 (ECL1) 
B7 (ECL2) 
L9 (ECL2) 
 
NA 
NA 
NA 
25% 
a 
35% 
a 
25% 
a 
BaL 
All active ScFv were 
selected on cyclic 
peptides 
[181] 
CCR5  12-mer RPL  CHO-CCR5 cells 
Four rounds, acidic 
elution 
AFDWTFVPSLIL  IC50 = 2.5 μM  NA  NA  Antagonist of CCR5  [179] 
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Table 5. Cont. 
Target  Library 
Target 
presentation 
Biopanning procedure  Phagotope  Affinity  Inhibition 
Virus 
isolates/
clades 
Additional  Reference 
CCR5 
Partially randomized 
(1) 
CDx3KPCALLRYx10 
(2) 
x10ALLRYNPFYYLSF
SP 
CHO-CCR5 cells 
(1) Four rounds, 
competitive elution 
(2) Four rounds, 
preselection, alkaline and 
competitive elutions 
(1) 
ALLRYNPFYYLSFSP 
(2) LLDSTFFTADALL 
RYNPFYYLSFSP 
NA 
No inh 
IC50 = 2.5 
μM 
ADA 
Does not act as CCR5 
agonist or antagonist 
[178] 
CXCR4  Llamas immunized VHH  HEK-CXCR4 cells 
Two rounds and 
counterselection 
238D2 
238D4 
238D2-15GS-238D4 
KI = 10 nM 
KI = 6 nM 
KI = 0.3 nM 
IC50 = 30 nM 
IC50 = 40 nM 
IC50 = 0.2 
nM 
NL4.3 
Inhibit chemotaxis and 
mobilize stem cells 
[187] 
CXCR4 
Non immunized 
HCDR3 
Linear ECL2 
peptide 
Four rounds, acidic 
elution 
YYCARDRGGTYPGR
YWCQG 
KD = 5 μM  NA  NA  Antagonist of CXCR4  [182] 
CD40  Human ScFv 
Biotinylated  
CD40-Fc fusion 
protein 
Four rounds, trypsin 
elution 
B44  KD = 60 nM 
3–4 fold 
reduction of 
infection 
R5-
tropic 
Activates normal B cells, 
Does not block CD40-
CD40L binding 
[188,189] 
DDX3 
Mix of 12-mer and 7-
mer RPL 
His tagged 
ALRAMKENGR 
peptide 
Acidic elution 
INS1: SDVPTQV-
GGRRRRRRRRR 
NA  IC50 = 20 μM  LAI 
Homologies to 
XPO1/CRM1 
[190] 
NA: data not available. A: tested at a unique concentration of 100 μg/mL. 
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In  2003,  Hartley  et  al.  developed  another  innovative  and  efficient  strategy  to  identify  CCR5  
HIV-1  entry inhibitors  based on CCR5 ligand  variants  selected by phage display  [185] (reviewed in  
Chevigné  et al. [191]. In this strategy, a phage library displaying randomly mutated and N-terminally 
extended CCL5 chemokine variants (xS#xSSx###-CCL5, where # represents either A, P, S or T) was 
constructed  and  screened  on  CCR5-expressing  cells.  Only  intracellular  phagotopes  that  had  induced 
CCR5  receptor  internalization  were  recovered.  Two  CCL5  variants  (P1  =  LSPVSSQSSA-CCL5  and  
P2 = FSPLSSQSSA-CCL5) were identified. These variants displayed a higher selectivity for CCR5 and 
had more potent HIV-1 inhibitory abilities than the wild-type CCL5 chemokine. Further characterization 
demonstrated that P2 acted as a CCR5 superagonist and potently induced intracellular CCR5 sequestration. 
P1 was less potent but significantly reduced CCR5-dependent intracellular calcium signaling. In a subsequent 
study, P1 and P2 variants were optimized by phage display biopanning to select for variants that retained 
the high anti HIV-1 potency of P1 and P2 but reduced CCR5-agonist activity [186]. Three successive 
generations of libraries (xxPx3Q#TP-CCL5, QGPPLMx4-CCL5 and QGPΨ$x5-CCL5 where Ψ represents 
G, L or P and $ represents G, L or M) were constructed and screened as previously described [185]. The 
three most interesting candidates (5P12-CCL5, 5P14-CCL5 and 6P4-CCL5) produced as soluble proteins 
displayed  highly  potent  antiviral  activities.  Analogue  6P4-CCL5  acted  as  an  agonist  and  sequestered 
CCR5,  5P12-CCL5  induced  no  signaling  or  receptor  sequestration  while  5P14-CCL5  induced  CCR5 
internalization without triggering G-protein signaling. Altogether these data demonstrated that antiviral 
activities of similar molecules identified through phage display screening can rely on various mechanisms 
of action.  
Shortly  after  the  identification  of  the  P1  and  P2  variants,  Zhang  et  al.  reported  an  alternative 
biopanning  methodology  relying  on  the  use  of  small  cyclic  biotinylated  peptides  mimicking  CCR5 
extracellular  loops  (ECL1,  ECL2  and  ECL3)  for  the  identification  of  CCR5-binding  ScFvs  [181].  
A mouse phage-displayed ScFv library was incubated with biotinylated-ECL peptides and ECL-binding 
phages were specifically recovered using streptavidin-coated beads. Among the CCR5-binding ScFv identified, 
three clones (A1, B7 and L9) selected on cyclic ECL1 or ECL2 peptides inhibited R5- tropic HIV-1. 
Screening of RPL was also applied to the discovery of small CCR5-blocking peptides through the 
targeting  of  receptor-expressing  cells  [178,179].  Vyroubalova  et  al.  screened  a  partially  randomized  
10-mer  phage  library  (CDx3KPCALLRYx10-PIII)  using  competitive  elution  with  a  CCL5  analogue  
(NNY-CCL5, 100 nM) and selected a unique peptide (ALLRYNPFYYLSFSP). This peptide was further 
optimized  through  N-terminal  extension,  exon  shuffling  and  biopanning.  By  applying  successive 
treatments  consisting  of  a  preselection  using  a  low  amount  of  NNY-CCL5  (100  pm)  to  discard  
low-affinity binding phages followed by classical alkaline elution using TEA and a competitive elution 
containing NNY-CCL5 (1 µM) they identified an extended peptide (LLDSTFFTADALLRYNPFYYLS-
FSP) inhibiting R5-tropic HIV-1 cell fusion with an IC50 of 5 μM. In parallel, Wang et al. screened a fully 
randomized  12-mer  RPL  using  acidic  elution  and  identified  phagotopes  binding  specifically  to  
CCR5-expressing cells and sharing the AFDWTFVPSLIL sequence [178]. In peptide and phage formats 
this sequence blocked the binding of the anti-CCR5 neutralizing 2D7 MAb and completely inhibited 
binding of the chemokine CCL5 to the receptor [179]. Int. J. Mol. Sci. 2012, 13  4769 
 
 
3.2.1.2. CXCR4 Coreceptor 
The CXC chemokine receptor 4 (CXCR4) is the second major HIV-1 coreceptor. CXCR4 binds only to 
one endogenous chemokine ligand (CXCL12) and is also expressed at the surface of numerous cancer cell 
types underlining its high value as therapeutic target [192,193]. Despite this importance and the relative 
success of phage biopanning on CCR5, only two recent studies reported the use of phage display to search 
CXCR4 inhibitors [182,187]. 
In 2010, Jahnichen et al. isolated llama-derived VHH binding specifically to CXCR4 and inhibiting the entry 
of X4-tropic virus [187]. To select VHH binding exclusively to functional and properly folded receptor, llamas 
were immunized with CXCR4-expressing HEK293T cells. A phage library was subsequently constructed 
from the PBMCs of immunized camelids and several phage clones inhibiting the binding of labeled CXCL12 
chemokine to the receptor were identified. In particular, two VHHS (238D2 and 238D4) showed low nanomolar 
affinity for the receptor and inhibited entry of X4 and X4/R5-viruses into different CXCR4
+ cell types with 
IC50 values ranging from 10 to 100 nM. Dimerization of 238D2 and 238D4 to form biparatopic proteins 
increased their antiviral properties to IC50 values in the picomolar range. Epitope mapping revealed that the 
two VHHs inhibited CXCR4 mainly through binding to the second extracellular loop. 
Very recently, we used a peptide corresponding to this particular extracellular loop (ECL2) as target to 
identify short CXCR4 antagonists [182]. By screening a non-immune phage library displaying the human 
HCDR3 peptide repertoire [194], several small peptides binding to the ECL2 peptide that specifically 
recognized CXCR4-expressing cells were identified. Notably, one of these HCDR3 peptides (TYPGRY) 
acted as a CXCR4 antagonist with potency in the micromolar range. 
3.2.2. Other Host Protein Inhibitors 
In addition to targeting host receptors, a few studies reported the identification of peptides or antibody 
fragments  directed against other host proteins  such as  cell surface determinants  (CD) or intracellular 
enzymes  [188,190,195,196].  The  CD40  receptor,  a  member  of  the  tumor  necrosis  factor  receptor 
superfamily, and its CD40L ligand are involved in several biological processes including cell proliferation, 
activation and production of cytokines and chemokines. During HIV-1 infection, viruses were proposed to 
selectively downregulate or even deplete the pool of CD40L-expressing CD4+ T cells. In this context, 
antibodies binding to CD40 and restoring the HIV-1-induced CD40L downregulation might be of interest. 
In 2002, Ellmark et al. identified a set of anti-CD40 antibody fragments through biopanning of a human 
ScFv phage library against a biotinylated CD40 antigen [189]. When expressed as full-length IgG1 one 
antibody (clone B44) suppressed HIV-1 infection by a R5-tropic virus, most probably through induction of 
CC chemokine production [188]. More recently, the DDX3 protein, a cellular RNA helicase involved in 
RNA unwinding was shown to play important roles in HIV-1 replication. This protein presents a unique 
region (ALRAMKENG) responsible for high affinity binding to the HIV-1 RNA. Garbelli et al. carried 
out a biopanning experiment with a mix of linear 12-mer and linear and constrained 7-mer RPL against a 
peptide mimicking the DDX3 region interacting with HIV-1. They identified a 7-mer peptide (SDVPTQV) 
blocking the replication of an X4-tropic virus with an IC50 of 20 μM [190]. Int. J. Mol. Sci. 2012, 13  4770 
 
 
Besides therapeutic purposes, the phage display technology has also been applied for fundamental 
studies of host proteins. In particular, a study focusing on the roles and the diversity of the anti-CD34 
autoimmune repertoire in the myelosuppression appearing in HIV-1 infected individuals was reported by 
Rubinstein et al. [195]. Using a substractive biopanning procedure from the immune repertoire of a HIV-1 
seropositive  patient,  the  authors  selected  Fab  fragments  binding  specifically  to  the  CD34  receptor. 
Sequencing and binding analyses of these antibody fragments demonstrated the heterogeneous origin of 
the anti-CD34 autoimmune repertoire and suggested that these autoantibodies might be generated through 
antigen-specific driven processes.  
4. Phage Substrate 
The use of phages for protease cleavage specificity profiling was first described by Matthews and 
Wells in 1993 [197]. This ―phage substrate‖ approach relies on the use of phage particles to screen for 
enzyme substrates instead of classical binder selection. Protease cleavage profiling using phage takes 
advantage of the natural resistance of phage particles to proteolysis. Phage particles displaying random 
peptides are immobilized on a solid support and submitted to proteolytic elution to specifically liberate 
phages presenting peptides corresponding to the protease cleavage site. The phage substrate approach 
allows thus to rapidly determine the cleavage profile of a given protease and provides optimized substrate 
candidates which can be further used as leads for the development of specific inhibitors. Over the last two 
decades, phage substrate has been applied to a large variety of proteases including the HIV-1 protease (PR) 
[198,199]. The HIV-1 PR is a homodimeric aspartic protease responsible for nine critical cleavage steps 
within  both  the  structural  (Gag)  and  the  non-structural  (Gag/pol)  polyproteins.  The  HIV-1  protease 
recognizes substrate residues encompassing P4 to P3' positions (Schechter and Berger’s nomenclature), 
with the primary determinants from positions P2 to P2' positions [200,201]. Interestingly, alignment of the 
nine natural substrate cleavage sites of the HIV-1 PR shows a high sequence diversity suggesting a broad 
proteolytic specificity. In 2000, Beck et al. reported the use of hexapeptide phage library to unravel the 
HIV-1 PR specificity and develop new protease inhibitors (Table 6) [199]. This library was constructed by 
fusing the Mab 3-E7 epitope upstream of the randomized sequences. Phages were first incubated with the 
HIV-1 PR and uncleaved phages were removed by addition of pansorbin cells. Biopanning selected for 
highly diverse sequences consistent with the suggested broad substrate specificity of the HIV-1 protease. 
However, none of the selected peptides corresponded to the HIV-1 polyproteins cleavage sites.  
Nonetheless, several phage-displayed peptides were very efficiently cleaved by the HIV-1 protease.  
In  peptide  format,  most  of  them  displayed  a  Km  value  lower  than  the  one  determined  for  a  peptide 
mimicking the natural substrate at the matrix/capsid junction (IRKIL↓FLDG) (Table 6, italic). The most 
potent selected substrate (GSGIF↓LETSL) was cleaved 60 times more efficiently and had a Km value of  
5 μM i.e., 260 times lower than the natural substrate (Km = 1300 μM). Interestingly, the GSGIF↓LETSL 
substrate displayed only two residues (in bold) of the optimal cleavage site model designed based on the 
most frequently selected residues for each position (SGVY↓FVTS) (Table 7). Int. J. Mol. Sci. 2012, 13  4771 
 
 
Table 6. Phage substrate analysis of the HIV-1 protease cleavage specificity. 
Target  Library  Biopanning 
Natural substrates 
P4-P3-P2-P1--P1'-P2'-P3'-P4' 
Selected 
substrates 
Kcat/Km 
(μM
−1s
−1) 
Derived Inhibitors  KI (nM)  Reference 
HIV-1 
protease Q7K 
Random 
hexapeptides 
fused to the 
MAb 3-E7 
epitope and 
displayed on Fd 
phage 
5 rounds with 
progressive 
decrease of the 
protease 
concentration and 
contact time 
(RT/IN) RKIL↓FLDG 
(MA/CA) SQNY↓PIVQN 
(CA/P2) ARVL↓AEAM 
(P2/NC) ATIM↓MQRG 
(P1/P6) PQNF↓LQSR 
(in P6) KELY↓PLTS 
(TF/PR) SFNF↓PQIT 
(PR/RT) TLNF↓YVDG 
(in RT) AETF↓YVDG 
GSGIF↓LETSL 
GSGVF↓VEMPL 
GSGVF↓VVNGL 
GSGLF↓TEYGL 
IRKIL↓FLDG 
1.3  
3.9 
18 
0.002 
0.002 
GSGIFΨ(CH2NH)LETSL 
GSGVFΨ(CH2NH)VEMPL 
GSGVFΨ(CH2NH)VVNGL 
GSGLFΨ(CH2NH)TEYGL 
5 
18 
100 
200 
 
[199] 
HIV-1/FIV 
proteases 
4 rounds with 
progressive 
decrease of the 
protease 
concentration 
SGNF↓VVNGLVK 
KSGVF↓VENGLVK 
KSGVF↓VQNGLVK 
KSGNFVVN↓GLVK 
KSGV↓SVNGK 
KSGVFHVN↓GLVK 
KSGVFQVN↓GLVK 
KSGVF↓VVNGLVK 
KSFVF↓VVNGLVK 
KSGIF↓VVNGLVK 
KSGVF↓HVNGK 
KSGVF↓QVNGLVK 
KSGVF↓VVQGLVK 
KSGVF↓VVTGLVK 
Protease 
GSGVF Ψ(CH2OH)VVNGL 
GSGVF Ψ(CH2NH)VVNGL 
IC50 
(nM) 
[198] 
HIV-1 only 
HIV-1 only 
HIV-1 only 
FIV only 
FIV only 
FIV only 
FIV only 
HIV-1/FIV 
HIV-1/FIV 
HIV-1/FIV 
HIV-1/FIV 
HIV-1/FIV 
HIV-1/FIV 
HIV-1/FIV 
 
 
 
 
 
HIV/FIV 
160/5000 
700/400 
Arrow denotes cleavage sites in the natural or the selected substrates sequences. Underlined substrates correspond to sequences used to derived inhibitors. Italic sequences 
correspond to natural substrate (matrix/capsid junction) used as reference for the assessment of the cleavage efficiently. Ψ: amid-reduced bound. Int. J. Mol. Sci. 2012, 13  4772 
 
 
Table 7. HIV-1 protease specificity model. 
P4  P3  P2  P1  P1'  P2'  P3'  P4' 
S11  G11  V5  Y5  F4  V5  T4  S3 
    I3  F4  V3  E4  S3  T2 
    N3  M2  L3  A1  M1  G2 
        H1  Q1  E1  P1 
            N1  N1 
            Q1  D1 
              A1 
The model was build based on the 11 most efficiently cleaved phage substrates. Underscript numbers represent 
the frequency of appearance of the amino acid at a given position. 
Sequences corresponding to the four most potent substrates were synthesized as peptidic transition 
state analogues and presented inhibitory activity in the nanomolar range (Table 6, underlined sequences). 
In 2001, the same authors applied the phage substrate approach to compare the relative specificities of the 
human (HIV-1) and feline (FIV) Immunodeficiency virus PRs [198]. Hexapeptides specifically processed 
by  each  of  the  two  proteases  as  well  as  peptides  cleaved  by  both  enzymes  were  identified.  Further 
mutational analysis of synthetic peptides derived from a sequence processed with the same efficiency by 
the two proteases (KSGVF↓VVNG) was performed to assess the influence of amino acid substitutions on 
the catalytic process of each PR (Table 6, underlined sequence). They showed that substitutions for a Val 
at position P2 or P2' increased the cleavage by the HIV-1 protease whereas the introduction of a Val at 
position P1 was more favorable to FIV protease activity. In particular, the GSGVFΨ(CH2NH)VVNGL 
inhibitor identified in the first study was active against both PRs with different potencies and replacement 
of its amide group by a hydroxyethylene group resulted in a peptide with equivalent inhibitory activity 
towards both the HIV-1 and the FIV proteases. 
5. Phage particles as HIV-1 Antigen Carriers 
In parallel to epitope mapping, inhibitor discovery and enzyme profiling applications, bacteriophage 
particles  were  exploited  as  carriers  for  the  development  of  anti-HIV-1  vaccines.  For  this  particular 
purpose, phages are not used as affinity selection tools but rather to display antigens to the immune system, 
aiming to elicit specific neutralizing antibodies or/and efficient cytotoxic T-cell responses. Indeed, phages 
can also be considered as biologically inert particles characterized by a dense and repetitive organization 
capable of displaying a wide range of exogenous proteins at a precise valency and in a controlled manner. 
Moreover,  phages  were  shown  to  be  naturally  immuno-stimulatory  [202,203]  and  are  particularly 
affordable, easy and rapid to produce and to administer in many animal models [204]. Altogether these 
characteristics  make  bacteriophages  a  suitable  and  valuable  carrier  for  HIV-1  
vaccine development. 
Anti-HIV-1 vaccination trials to elicit humoral and cellular responses against various HIV-1 proteins 
such as the envelope proteins gp120 and gp41 as well as the RT and the p17 proteins [205–209] were Int. J. Mol. Sci. 2012, 13  4773 
 
 
conducted with a large diversity of bacteriophages including M13, T4, MS2 and lambda phages [205,210–213] 
(Table 8).  
Numerous phage-vaccination trials using mimotopes identified on anti-HIV-1 antibodies were reported 
(See Tables 1–3). All these attempts aimed mainly at eliciting antibodies directed against the genuine 
epitope of an existing antibody. Besides these descriptions, a few studies were exclusively dedicated to the 
use of phage particles as vehicles to display fragments or complete HIV-1 proteins to the immune system 
to prime new immune responses.  
Table 8. Use of phage particle as HIV-1 antigen carrier. 
Phage  Type 
Carrier 
protein 
HIV-1 antigen  Display level 
Animal 
Model 
Reference 
M13  Filamentous  pIII  p17 (GEDRW) 
3 to 5 
copies/phage 
Rabbit  [205] 
fd  Filamentous  pIII  V3 loop of gp120 
3 to 5 
copies/phage 
Mice  [207] 
fd  Filamentous  pIII  V3 loop of gp120 
3 to 5 
copies/phage 
Mice  [210] 
fd  Filamentous  pVIII  RT (ILKEPVHGV) 
2700 
copies/phage 
Human 
cells 
[206,214] 
M13  Filamentous  pVIII  V3 loop variants 
2700 
copies/phage 
Mice  [215] 
T4  Lytic/Icosahedral  SOC  V3 loop of gp120 
960 
copies/phage 
Mice  [214] 
T4  Lytic/Icosahedral  HOC  p24 
150 
copies/phage 
Mice  [216] 
MS2  VLP/Icosahedral  A-B loop  V3 loop of gp120  90 copies/VLP  Mice  [212] 
PP7  VLP/Icosahedral  A-B loop  V3 loop of gp120  -  Mice  [217] 
Lambda  Lytic/Icosahedral  gpD  gp140 trimer  30 copies/phage  Rabbit  [213] 
The pioneer attempt was reported by Minenkova  et al. in 1993 [205]. Immunization of rabbits with 
filamentous M13 phage particles displaying a small peptide (GEDRW) derived from the p17 Gag protein 
in fusion with pIII minor coat protein elicited the production of specific IgGs reacting with the natural p17 
antigen as well as with the Gag precursor protein. Shortly afterwards, two studies reported that mice 
immunization with fd phages displaying the gp120 V3 loop fused to the pIII protein induced high titers of 
antibodies cross-reacting with V3 loops of different strains and featuring neutralizing activity [207,210]. 
The major coat protein pVIII of the fd phage (2700 copies per particles) was also investigated as scaffold 
protein for vaccination.  Immunization with  phages  displaying a pVIII-fused peptide corresponding to 
residues 309–317 of the HIV-1 RT resulted in the induction of a specific cytotoxic T- cell response (CTL) 
against the displayed peptide. Priming nevertheless required a co-immunization with a T-helper epitope 
from  the  same  protein  (KDSWTVNDIQKLVGK)  provided  by  either  the  same  or  a  separate  phage  
particle  [206].  More  recently  attempts  to  prime  CTL  response  were  conducted  with  M13  phages Int. J. Mol. Sci. 2012, 13  4774 
 
 
displaying a mixture of thousands of variants of CTL epitopes (RGPGxAx4 or xGxGxAxVxI) derived 
from the gp120 V3 loop (residues 311–320; RGPGRAFVTI) presented in an immunoglobulin VH domain 
scaffold  [215].  Mice  immunization  provided  potent  and  broad  epitope-specific  long  lasting  response  
(12 months) and effector memory T cells were induced. Moreover, recent studies demonstrated that mice 
immunized with these variable epitope libraries are capable of neutralizing half of the subtype B viral 
isolates used for challenge, including HIV-1 isolates which are known to be resistant to neutralization by 
several potent monoclonal antibodies [218]. 
Although  they  are  versatile  and  easy  to  manipulate,  filamentous  phages  present  limitations  for 
vaccination,  and  namely  low  display  level  and  the  limited  size  of  the  foreign  peptides  that  can  be 
incorporated  without  interfering  with  the  natural  functions  of  the  phage  coat  proteins.  Therefore, 
alternative  bacteriophage  models  were  explored.  T4  phage  and  its  two  accessory  capsid-decorating 
proteins SOC and HOC were demonstrated to be particularly efficient for high copy display of various 
large HIV-1 antigens [211,214,216]. In contrast to pIII and pVIII proteins, SOC and HOC present the 
major advantage of being dispensable for phage assembly yet of being able to strongly bind to the outer 
surface of the capsid, if added subsequently [219]. SOC and HOC self-associate to the capsid at a display 
level of 960 and 150 copies per capsid, a far higher density than that of filamentous minor coat protein  
(3 to 5 copies). HOC protein provides high-density display of single as well as multiple antigens and 
immunization of mice with the p24-HOC-T4 elicits strong humoral and cellular responses.  
Moreover,  fusion  of  different  antigens  to  SOC  and  HOC  offer  the  possibility  to  develop 
multicomponent HIV-1 vaccine particles [216] T4 phage displaying V3 loop of the gp120 protein fused to 
SOC protein was reported to elicit antibodies capable of recognizing the native antigen [214]. Further 
study demonstrated that HOC protein can also be used to display various HIV-1 antigens including the 
p24, Nef or a trimeric peptide derived from the C-terminus of gp41 [216]. More recently, lambda phage 
and its decorating capsid protein were used for dense display of glycosylated mammalian cell-derived 
trimers of gp140 protein [213]. Lambda phage provided a display level of 30 copies of gp140 trimer per 
particle, a 20-fold higher display than observed on native HIV-1 virions (14 ±  7 spikes per virion) [220]. 
Rabbit immunization trials were rather disappointing and higher antibody titers were elicited in animals 
receiving soluble oligomeric gp140. These results were proposed to be due to the sequential immunization 
process and to the strong and immunodominant response against phage capsid proteins, which is most 
probably boosted upon sequential immunization, and could lead to a decrease of the humoral immune 
response to the displayed antigen. 
Virus like particles (VLP) derived from the MS2 bacteriophage coat protein displaying the V3 loop of 
gp120 and devoid of phage genome were also reported [212]. Although characterized by a low display 
level (90 copies per VLP) these particles were nevertheless able to elicit high titers of specific antibodies 
when  injected  in  mice  and  provided  neutralizing  activity  at  1/10  sera  dilution.  More  recently,  PP7  
phage-derived VLPs displaying the V3 loop of gp120 were used to immunize mice providing high-titer 
antibody response [217].  Int. J. Mol. Sci. 2012, 13  4775 
 
 
6. Conclusions and Future Challenges 
AIDS was first described in 1981 [1], and two years later HIV-1, its causative agent, was isolated [2]. 
The phage display technology was first published almost concomitantly in 1985 [12]. Both protagonists 
lived parallel lives until 1991, when Burton et al. identified a human Fab recognizing the CD4-binding 
site of HIV-1 gp120 through phage display [41]. This first antibody, b12, turned out to be one of the rare 
BNtAbs characterized to date, and many studies are still ongoing to set up scaffolds presenting its epitope 
in a conformation capable of eliciting Abs with b12-like HIV-1 inhibiting properties. This article was the 
starting point of a dense literature exploiting the different applications of the phage display technology to 
gain as much knowledge as possible on the HIV-1 infection process.  
The complex hide-and-seek game between HIV and the host immune system and the absence of an 
efficient vaccine candidate emphasizes the need to better comprehend the HIV-1-related immune response 
and to identify antiviral molecules. HIV-1 is to the best of our knowledge the only pathogen to which all 
four applications of the phage display technology described in this review—i.e., epitope mapping, inhibitor 
discovery,  substrate  presentation  and  carrier  phage-  have  been  applied.  Parallel  improvements  in  the 
technology on one hand, and crucial discoveries in the HIV-1 field on the other hand, most likely account 
for such a tight interplay. The phage display technology applied to HIV-1 has provided precious knowledge 
concerning  the  regions  recognized  by  the  Ab  repertoire  of  immune  patients,  and  allowed  to  identify 
immunodominant regions. It has also allowed to map the epitopes of numerous monoclonal antibodies 
directed against viral and host proteins, and, most importantly, discontinuous epitopes. Alternative phage 
display biopanning substractive procedures such as epitope masking or competitive antigen panning also 
precisely highlighted non-immunodominant regions of the HIV-1 antigen, which had remained occult 
using classical biopanning approaches. Although the antibodies identified through epitope-masking are 
mostly devoid of neutralizing activity, this strategy led to the identification of Fabs binding with high 
affinity to specific targets. Taking advantage of this affinity, approaches aiming at engineering bispecific 
antibodies, coupling these inhibitors to toxins, or multimerizing them to increase their binding avidity 
could lead to the development of antiviral compounds or more efficient vaccine candidates. 
Although  highly  informative,  immunization  trials  performed  with  mimotopes/phagotopes  selected 
through phage display remained altogether rather disappointing as no long-lasting neutralizing response was 
reported, and provided yet further proof that antigenicity does not necessarily imply immunogenicity [221]. 
Among the bottlenecks in the field of HIV-1 vaccine research and development are the weak immunogenic 
properties  of  the  identified  mimotopes  or  native  antigens.  Whether  the  difficulty  of  eliciting  and/or 
isolating strong or broad neutralizing antibodies from HIV-1-infected patients, be they normal Progressors 
or LTNPs, is a caveat of phage display or a real reflect of the restricted humoral response in fighting HIV, 
or  to  both,  remains  to  be  established.  Nevertheless,  these  discrepancies  are  not  exclusive  of  HIV-1 
mimotopes and were observed with other antigens. 
From a fundamental prospect, the use of phage-displayed IgM libraries to model Abs close to the 
germline Abs allowed to elegantly expore the poorly characterized determinants of the initial antiviral 
immune response. Phage display also contributed to a better knowledge on the structure of the diverse Int. J. Mol. Sci. 2012, 13  4776 
 
 
HIV-1 proteins as well as a gain of insight on non-structural proteins involved in replication mechanisms. 
A highlight example would be the phage substrate approach which allowed the precise characterization of 
the HIV-1 protease cleavage specificity and thereby provided valuable inhibitor candidates. Unraveling 
viral replication steps or protein interactions led to exploit phage display to engineer various types of 
inhibitors targeting either viral or host proteins.  
In parallel, phage display allowed the identification of various types of inhibitors targeting either viral 
or host proteins. Nevertheless, only a few strong antiviral candidates with broad neutralizing activities 
and/or  potencies  in  the  nanomolar  or  even  picomolar  range  were  identified  with  the  phage  display 
technology while most of them presented inhibiting activities that ranged at the best in the micromolar 
range and could not be further exploited.  
Some  of  the  most  potent  inhibitors  originated  from  Fab  libraries  derived  from  asymptomatic  
HIV-1-infected patients whose reactivity against HIV-1 was previously assessed (b12, X5, Z13) or from 
immunized camelids (VHH anti CXCR4). Other inhibitors were identified from semi-synthetic (ligand 
analogues of CCL5) or randomized peptide libraries (D-peptides: PIE123) and their affinity was improved 
through  secondary  libraries.  These  inhibitors  were  selected  against  different  targets  (Env  proteins, 
coreceptors)  by  biopanning  carried  out  using  different  types  of  support  (immobilized  proteins,  cells, 
peptides), illustrating the power and versatility of the phage display technology [41,83,85] (Figure 5).  
Figure 5. HIV-1 entry inhibitors identified by phage display and their target. Potent HIV-1 
inhibitors blocking key  steps in the entry process were identified using the phage display 
technology. These inhibitors target: the CD4 binding site (Fab b12 and Z13), the coreceptors 
CCR5 (CCL5 variants) or CXCR4 (VHH 238D2 and 238D4), the CD4-induced epitope of 
gp120 (Fab X5) or the heptad repeat region of gp41 (peptide PIE123). 
 
Despite the variable success of the phage display technology per se in developing a direct antiviral 
agent or immune response, this technology continues to contribute precious and otherwise inaccessible Int. J. Mol. Sci. 2012, 13  4777 
 
 
developments in the field of HIV-1 research, mainly owing to the ability of phages to display a high 
density of either single antigens or libraries of antigens/mimotopes.  To this regard, phages are being 
extensively explored to increase immune responsiveness. The latest developments include exploiting the 
phage  as  DNA  vaccine  carrier  or  hybrid  phage  and  pursuing  the  symbiotic  interplay  between  phage 
display and HIV-1.  
Acknowledgements 
This  manuscript  is  supported  by  the  ―Centre  de  Recherche  Public-Santé‖,  Luxembourg  (Grants 
20100708 GPCR47 and 20101002 EUMIMO). The authors are grateful to Danielle Perez-Bercoff for 
thorough reading and helpful discussions. The authors also want to thank Carole Devaux, Virginie Fievez, 
Marie-Eve Dumez and Martyna Szpakowska for critically reading the manuscript.  
References 
1.  Gottlieb,  M.S.;  Schroff,  R.;  Schanker,  H.M.;  Weisman,  J.D.;  Fan,  P.T.;  Wolf,  R.A.;  Saxon,  A. 
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: 
Evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 1981, 305, 1425–1431. 
2.  Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J.; Dauguet, C.; 
Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; et al. Isolation of a t-lymphotropic retrovirus from a 
patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868–871. 
3.  Naeger,  L.K.;  Struble,  K.A.;  Murray,  J.S.;  Birnkrant,  D.B.  Running  a  tightrope:  Regulatory 
challenges in the development of antiretrovirals. Antiviral Res. 2010, 85, 232–240. 
4.  Kilby, J.M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; 
Hunter, E.; Lambert, D.; Bolognesi, D.; et al. Potent suppression of HIV-1 replication in humans by  
T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 1998, 4, 1302–1307. 
5.  Dorr,  P.;  Westby,  M.;  Dobbs,  S.;  Griffin,  P.;  Irvine,  B.;  Macartney,  M.;  Mori,  J.;  Rickett,  G.;  
Smith-Burchnell, C.; Napier, C.; et al. Maraviroc (uk-427,857), a potent, orally bioavailable, and 
selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human 
immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49, 4721–4732. 
6.  Summa,  V.;  Petrocchi,  A.;  Matassa,  V.G.;  Gardelli,  C.;  Muraglia,  E.;  Rowley,  M.;  Paz,  O.G.;  
Laufer,  R.;  Monteagudo,  E.;  Pace,  P.  4,5-dihydroxypyrimidine  carboxamides  and  
N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with 
good pharmacokinetic profiles in preclinical species. J. Med. Chem. 2006, 49, 6646–6649. 
7.  Tozzi, V.; Bellagamba, R.; Castiglione, F.; Amendola, A.; Ivanovic, J.; Nicastri, E.; Libertone, R.; 
D’Offizi, G.; Liuzzi, G.; Gori, C.; et al. Plasma HIV RNA decline and emergence of drug resistance 
mutations among patients with multiple virologic failures receiving resistance testing-guided haart. 
AIDS Res. Hum. Retrovir. 2008, 24, 787–796. 
8.  Dragic, T. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. 
Virol. 2001, 82, 1807–1814. Int. J. Mol. Sci. 2012, 13  4778 
 
 
9.  Pantophlet, R.; Wang, M.; Aguilar-Sino, R.O.; Burton, D.R. The human immunodeficiency virus 
type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J. Virol. 
2009, 83, 1649–1659. 
10.  Mahalanabis, M.; Jayaraman, P.; Miura, T.; Pereyra, F.; Chester, E.M.; Richardson, B.; Walker, B.; 
Haigwood,  N.L.  Continuous  viral  escape  and  selection  by  autologous  neutralizing  antibodies  in 
drug-naive human immunodeficiency virus controllers. J. Virol. 2009, 83, 662–672. 
11.  Overbaugh, J.; Morris, L. The antibody response against HIV-1. Cold Spring Harb. Perspect. Med. 
2012, 2, a007039. 
12.  Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the 
virion surface. Science 1985, 228, 1315–1317. 
13.  Beghetto, E.; Gargano, N. Lambda-display: A powerful tool for antigen discovery. Molecules 2011, 
16, 3089–3105. 
14.  Parmley, S.F.; Smith, G.P. Antibody-selectable filamentous fd phage vectors: Affinity purification 
of target genes. Gene 1988, 73, 305–318. 
15.  Poropatich, K.; Sullivan, D.J., Jr. Human immunodeficiency virus type 1 long-term non-progressors: 
The viral, genetic and immunological basis for disease non-progression. J. Gen. Virol. 2011, 92, 
247–268. 
16.  Gorny,  M.K.;  Xu,  J.Y.;  Gianakakos,  V.;  Karwowska,  S.;  Williams,  C.;  Sheppard,  H.W.;  
Hanson,  C.V.;  Zolla-Pazner,  S.  Production  of  site-selected  neutralizing  human  monoclonal 
antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope 
glycoprotein. Proc. Natl. Acad. Sci. USA 1991, 88, 3238–3242. 
17.  Keller,  P.M.;  Arnold,  B.A.;  Shaw,  A.R.;  Tolman,  R.L.;  van  Middlesworth,  F.;  Bondy,  S.;  
Rusiecki,  V.K.;  Koenig,  S.;  Zolla-Pazner,  S.;  Conard,  P.;  et  al.  Identification  of  HIV  vaccine 
candidate peptides by screening random phage epitope libraries. Virology 1993, 193, 709–716. 
18.  Boots,  L.J.;  McKenna,  P.M.;  Arnold,  B.A.;  Keller,  P.M.;  Gorny,  M.K.;  Zolla-Pazner,  S.;  
Robinson,  J.E.;  Conley,  A.J.  Anti-human  immunodeficiency  virus  type  1  human  monoclonal 
antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from 
recombinant phage peptide display libraries. AIDS Res. Hum. Retrovir. 1997, 13, 1549–1559. 
19.  Jellis, C.L.;  Cradick, T.J.; Rennert, P.; Salinas, P.;  Boyd, J.;  Amirault, T.;  Gray, G.S.  Defining 
critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and 
peptide array technologies. Gene 1993, 137, 63–68. 
20.  Moore, J.P.; Trkola, A.; Korber, B.; Boots, L.J.; Kessler, J.A., 2nd; McCutchan, F.E.; Mascola, J.; 
Ho, D.D.; Robinson, J.; Conley, A.J. A human monoclonal antibody to a complex epitope in the V3 
region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside 
clade b. J. Virol. 1995, 69, 122–130. 
21.  Grihalde, N.D.; Chen, Y.C.; Golden, A.; Gubbins, E.; Mandecki, W. Epitope mapping of anti-HIV 
and anti-HCV monoclonal antibodies and characterization of epitope mimics using a filamentous 
phage peptide library. Gene 1995, 166, 187–195. Int. J. Mol. Sci. 2012, 13  4779 
 
 
22.  Laisney, I.L.; Benjamin, H.; Gefter, M.; Strosberg, A.D. Permissive residues within the minimal 
epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1. Eur. J. Immunol. 1996, 26, 
1634–1640. 
24.  Conley, A.J.; Kessler, J.A., 2nd; Boots, L.J.; Tung, J.S.; Arnold, B.A.; Keller, P.M.; Shaw, A.R.; 
Emini, E.A. Neutralization of divergent human immunodeficiency virus type 1 variants and primary 
isolates by iam-41-2f5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 1994, 
91, 3348–3352. 
25.  Menendez,  A.;  Chow,  K.C.;  Pan,  O.C.;  Scott,  J.K.  Human  immunodeficiency  virus  type  
1-neutralizing  monoclonal  antibody  2F5  is  multispecific  for  sequences  flanking  the  DKW  core 
epitope. J. Mol. Biol. 2004, 338, 311–327. 
26.  Palacios-Rodriguez, Y.; Gazarian, T.; Huerta, L.; Gazarian, K. Constrained peptide models from 
phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mab 2f5. 
Immunol. Lett. 2011, 136, 80–89. 
27.  Stern, B.; Denisova, G.; Buyaner, D.; Raviv, D.; Gershoni, J.M. Helical epitopes determined by  
low-stringency antibody screening of a combinatorial peptide library. FASEB J. 1997, 11, 147–153. 
28.  Gomez-Roman, V.R.; Cao, C.; Bai, Y.; Santamaria, H.; Acero, G.; Manoutcharian, K.; Weiner, D.B.; 
Ugen, K.E.; Gevorkian, G. Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 
gp120 murine monoclonal antibody. J. Acquir. Immune Defic. Syndr. 2002, 31, 147–153. 
29.  Zwick,  M.B.;  Bonnycastle,  L.L.;  Menendez,  A.;  Irving,  M.B.;  Barbas,  C.F.,  3rd;  Parren,  P.W.; 
Burton, D.R.; Scott, J.K. Identification and characterization of a peptide that specifically binds the 
human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J. Virol. 2001, 
75, 6692–6699. 
30.  Bonnycastle, L.L.; Mehroke, J.S.; Rashed, M.; Gong, X.; Scott, J.K. Probing the basis of antibody 
reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J. Mol. Biol. 
1996, 258, 747–762. 
31.  Dorgham, K.; Dogan, I.; Bitton, N.; Parizot, C.; Cardona, V.; Debre, P.; Hartley, O.; Gorochov, G. 
Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes. AIDS Res. Hum. Retrovir. 
2005, 21, 82–92. 
32.  Enshell-Seijffers, D.; Denisov, D.; Groisman, B.; Smelyanski, L.; Meyuhas, R.; Gross, G.; Denisova, 
G.;  Gershoni,  J.M.  The  mapping  and  reconstitution  of  a  conformational  discontinuous  
b-cell epitope of HIV-1. J. Mol. Biol. 2003, 334, 87–101. 
33.  Wilkinson, R.A.; Evans, J.R.; Jacobs, J.M.; Slunaker, D.; Pincus, S.H.; Pinter, A.; Parkos, C.A.; 
Burritt, J.B.; Teintze, M. Peptides selected from a phage display library with an HIV-neutralizing 
antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope. AIDS Res. Hum. 
Retrovir. 2007, 23, 1416–1427. 
34.  Ferrer,  M.;  Sullivan,  B.J.;  Godbout,  K.L.;  Burke,  E.;  Stump,  H.S.;  Godoy,  J.;  Golden,  A.;  
Profy, A.T.; van Schravendijk, M.R. Structural and functional characterization of an epitope in the 
conserved C-terminal region of HIV-1 gp120. J. Pept. Res. 1999, 54, 32–42. Int. J. Mol. Sci. 2012, 13  4780 
 
 
35.  Menendez, A.; Calarese, D.A.; Stanfield, R.L.; Chow, K.C.; Scanlan, C.N.; Kunert, R.; Katinger, H.; 
Burton, D.R.; Wilson, I.A.; Scott, J.K. A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is 
not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J. 2008, 22, 1380–1392. 
36.  Rusche,  J.R.;  Javaherian,  K.;  McDanal,  C.;  Petro,  J.;  Lynn,  D.L.;  Grimaila,  R.;  Langlois,  A.;  
Gallo,  R.C.;  Arthur,  L.O.;  Fischinger,  P.J.;  et  al.  Antibodies  that  inhibit  fusion  of  human 
immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. 
Proc. Natl. Acad. Sci. USA 1988, 85, 3198–3202. 
37.  Javaherian,  K.;  Langlois,  A.J.;  McDanal,  C.;  Ross,  K.L.;  Eckler,  L.I.;  Jellis,  C.L.;  Profy,  A.T.; 
Rusche,  J.R.;  Bolognesi,  D.P.;  Putney,  S.D.;  et  al.  Principal  neutralizing  domain  of  the  human 
immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 1989, 86, 6768–6772. 
38.  Scott, C.F., Jr.; Silver, S.; Profy, A.T.; Putney, S.D.; Langlois, A.; Weinhold, K.; Robinson, J.E. 
Human monoclonal antibody that recognizes the v3 region of human immunodeficiency virus gp120 
and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc. Natl. Acad. Sci. USA 1990, 
87, 8597–8601. 
39.  Muster, T.; Steindl, F.; Purtscher, M.; Trkola, A.; Klima, A.; Himmler, G.; Ruker, F.; Katinger, H.  
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 
67, 6642–6647. 
40.  Denisova, G.; Stern, B.; Raviv, D.; Zwickel, J.; Smorodinsky, N.I.; Gershoni, J.M. Humoral immune 
response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res. Hum. Retrovir. 1996, 12, 
901–909. 
41.  Burton, D.R.; Barbas, C.F., 3rd; Persson, M.A.; Koenig, S.; Chanock, R.M.; Lerner, R.A. A large 
array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial 
libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 1991, 88, 10134–10137. 
42.  Barbas, C.F., 3rd; Bjorling, E.; Chiodi, F.; Dunlop, N.; Cababa, D.; Jones, T.M.; Zebedee, S.L.; 
Persson, M.A.; Nara, P.L.; Norrby, E.; et al. Recombinant human fab fragments neutralize human 
type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 1992, 89, 9339–9343. 
43.  Bublil,  E.M.;  Yeger-Azuz,  S.;  Gershoni,  J.M.  Computational  prediction  of  the  cross-reactive 
neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific 
for HIV-1 gp120. FASEB J. 2006, 20, 1762–1774. 
44.  Rizzuto,  C.D.;  Wyatt,  R.;  Hernandez-Ramos,  N.;  Sun,  Y.;  Kwong,  P.D.;  Hendrickson,  W.A.; 
Sodroski, J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. 
Science 1998, 280, 1949–1953. 
45.  Moore, J.P.; McCutchan, F.E.; Poon, S.W.; Mascola, J.; Liu, J.; Cao, Y.; Ho, D.D. Exploration of 
antigenic variation in gp120 from clades a through f of human immunodeficiency virus type 1 by 
using monoclonal antibodies. J. Virol. 1994, 68, 8350–8364. 
46.  Thali,  M.;  Moore,  J.P.;  Furman,  C.;  Charles,  M.;  Ho,  D.D.;  Robinson,  J.;  Sodroski,  J. 
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes 
exposed upon gp120-CD4 binding. J. Virol. 1993, 67, 3978–3988. Int. J. Mol. Sci. 2012, 13  4781 
 
 
47.  Scanlan, C.N.; Pantophlet, R.; Wormald, M.R.; Ollmann Saphire, E.; Stanfield, R.; Wilson, I.A.; 
Katinger,  H.;  Dwek,  R.A.;  Rudd,  P.M.;  Burton,  D.R.  The  broadly  neutralizing  anti-human 
immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2 mannose residues on 
the outer face of gp120. J. Virol. 2002, 76, 7306–7321. 
48.  Trkola, A.; Purtscher, M.; Muster, T.; Ballaun, C.; Buchacher, A.; Sullivan, N.; Srinivasan, K.; 
Sodroski, J.;  Moore,  J.P.;  Katinger,  H.  Human  monoclonal  antibody  2G12  defines  a  distinctive 
neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 
1996, 70, 1100–1108. 
49.  Sanders,  R.W.;  Venturi,  M.;  Schiffner,  L.;  Kalyanaraman,  R.;  Katinger,  H.;  Lloyd,  K.O.;  
Kwong,  P.D.;  Moore,  J.P.  The  mannose-dependent  epitope  for  neutralizing  antibody  2G12  on 
human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76, 7293–7305. 
50.  Scala, G.; Chen, X.; Liu, W.; Telles, J.N.; Cohen, O.J.; Vaccarezza, M.; Igarashi, T.; Fauci, A.S. 
Selection  of  HIV-specific  immunogenic  epitopes  by  screening  random  peptide  libraries  with  
HIV-1-positive sera. J. Immunol. 1999, 162, 6155–6161. 
51.  Chen, X.; Scala, G.; Quinto, I.; Liu, W.; Chun, T.W.; Justement, J.S.; Cohen, O.J.; van Cott, T.C.; 
Iwanicki, M.; Lewis, M.G.; et al. Protection of rhesus macaques against disease progression from 
pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat. Med. 2001, 7, 
1225–1231. 
52.  Enshell-Seijffers,  D.;  Smelyanski,  L.;  Vardinon,  N.;  Yust,  I.;  Gershoni,  J.M.  Dissection  of  the 
humoral immune response toward an immunodominant epitope of HIV: A model for the analysis of 
antibody diversity in HIV+ individuals. FASEB J. 2001, 15, 2112–2120. 
53.  Palacios-Rodriguez, Y.; Gazarian, T.;  Rowley,  M.; Majluf-Cruz, A.; Gazarian, K. Collection of 
phage-peptide probes for HIV-1 immunodominant loop-epitope. J. Microbiol. Methods 2007, 68, 
225–235. 
54.  Humbert, M.; Antoni, S.; Brill, B.; Landersz, M.; Rodes, B.; Soriano, V.; Wintergerst, U.; Knechten, H.; 
Staszewski, S.; von Laer, D.; et al. Mimotopes selected with antibodies from HIV-1-neutralizing 
long-term non-progressor plasma. Eur. J. Immunol. 2007, 37, 501–515. 
55.  Humbert,  M.;  Rasmussen,  R.A.;  Ong,  H.;  Kaiser,  F.M.;  Hu,  S.L.;  Ruprecht,  R.M.  Inducing  
cross-clade  neutralizing  antibodies  against  HIV-1  by  immunofocusing.  PLoS  One  2008,  3, 
doi:10.1371/journal.pone.0003937. 
56.  Dieltjens, T.; Heyndrickx, L.; Willems, B.; Gray, E.; Van Nieuwenhove, L.; Grupping, K.; Vanham, G.; 
Janssens, W. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG 
infected patient with 4E10-like antibodies. Retrovirology 2009, 6, doi:10.1186/1742-4690-6-113. 
57.  Dieltjens,  T.;  Willems,  B.;  Coppens,  S.;  Van  Nieuwenhove,  L.;  Humbert,  M.;  Dietrich,  U.; 
Heyndrickx,  L.;  Vanham,  G.;  Janssens,  W.  Unravelling  the  antigenic  landscape  of  the  HIV-1 
subtype a envelope of an individual with broad cross-neutralizing antibodies using phage display 
peptide libraries. J. Virol. Methods 2010, 169, 95–102. Int. J. Mol. Sci. 2012, 13  4782 
 
 
58.  Gupta, S.; Arora, K.; Sampath, A.; Singh, S.S.; Gupta, A.; Chaudhary, V.K. Mapping of HIV-1 gag 
epitopes  recognized  by  polyclonal  antibodies  using  gene-fragment  phage  display  system.  
Prep. Biochem. Biotechnol. 2001, 31, 185–200. 
59.  Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; 
Bourne, P.E. The protein data bank. Nucleic. Acids Res. 2000, 28, 235–242. 
60.  Schreiber,  A.;  Humbert,  M.;  Benz,  A.;  Dietrich,  U.  3d-epitope-explorer  (3dex):  Localization  of 
conformational epitopes within three-dimensional structures of proteins. J. Comput. Chem. 2005, 26, 
879–887. 
61.  Song, R.J.; Chenine, A.L.; Rasmussen, R.A.; Ruprecht, C.R.; Mirshahidi, S.; Grisson, R.D.; Xu, W.; 
Whitney,  J.B.;  Goins,  L.M.;  Ong,  H.;  et  al.  Molecularly  cloned  SHIV-1157IPD3N4:  A  highly 
replication-  competent,  mucosally  transmissible  R5  simian-human  immunodeficiency  virus 
encoding HIV clade c env. J. Virol. 2006, 80, 8729–8738. 
62.  O’Connor,  K.H.;  Konigs,  C.;  Rowley,  M.J.;  Irving,  J.A.;  Wijeyewickrema,  L.C.;  Pustowka,  A.; 
Dietrich, U.; Mackay, I.R. Requirement of multiple phage displayed peptide libraries for optimal 
mapping of a conformational antibody epitope on CCR5. J. Immunol. Methods 2005, 299, 21–35. 
63.  Konigs, C.; Rowley, M.J.; Thompson, P.; Myers, M.A.; Scealy, M.; Davies, J.M.; Wu, L.; Dietrich, U.; 
Mackay, C.R.; Mackay, I.R. Monoclonal antibody screening of a phage-displayed random peptide 
library reveals mimotopes of chemokine receptor CCR5: Implications for the tertiary structure of the 
receptor and for an N-terminal binding site for HIV-1 gp120. Eur. J. Immunol. 2000, 30, 1162–1171. 
64.  Meta, A.; Torigoe, N.; Ito, Y.; Arakaki, R.; Nakashima, H.; Sugimura, K. Inhibition of M-tropic  
HIV-1 infection by the fd phage-gene 3 protein with MIP-1α-binding activity. Mol. Immunol. 1999, 
36, 1249–1254. 
65.  Khurana, S.; Kennedy, M.; King, L.R.; Golding, H. Identification of a linear peptide recognized by 
monoclonal  antibody  2D7  capable  of  generating  CCR5-specific  antibodies  with  human 
immunodeficiency virus-neutralizing activity. J. Virol. 2005, 79, 6791–6800. 
66.  Poloni, F.; Puddu, P.; Moretti, F.; Flego, M.; Romagnoli, G.; Tombesi, M.; Capone, I.; Chersi, A.; 
Felici, F.; Cianfriglia, M. Identification of a LFA-1 region involved in the HIV-1-induced syncytia 
formation through phage-display technology. Eur. J. Immunol. 2001, 31, 57–63. 
67.  Wu, L.; LaRosa, G.; Kassam, N.; Gordon, C.J.; Heath, H.; Ruffing, N.; Chen, H.; Humblias, J.; 
Samson,  M.;  Parmentier,  M.;  et  al.  Interaction  of  chemokine  receptor  CCR5  with  its  ligands: 
Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 
1997, 186, 1373–1381. 
68.  Wu, L.; Paxton, W.A.; Kassam, N.; Ruffing, N.; Rottman, J.B.; Sullivan, N.; Choe, H.; Sodroski, J.; 
Newman, W.; Koup, R.A.; et al. CCR5 levels and expression pattern correlate with infectability by 
macrophage-tropic HIV-1, in vitro. J. Exp. Med. 1997, 185, 1681–1691. 
69.  Pantaleo, G.; Butini, L.; Graziosi, C.; Poli, G.; Schnittman, S.M.; Greenhouse, J.J.; Gallin, J.I.; Fauci, 
A.S. Human immunodeficiency virus (HIV) infection in CD4+ t lymphocytes genetically deficient 
in  LFA-1:  LFA-1  is  required  for  HIV-mediated  cell  fusion  but  not  for  viral  transmission. 
J. Exp. Med. 1991, 173, 511–514. Int. J. Mol. Sci. 2012, 13  4783 
 
 
70.  Barbas, C.F., 3rd; Collet, T.A.; Amberg, W.; Roben, P.; Binley, J.M.; Hoekstra, D.; Cababa, D.; 
Jones, T.M.; Williamson, R.A.; Pilkington, G.R.; et al. Molecular profile of an antibody response to 
HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 1993, 230, 812–823. 
71.  Bera,  T.K.;  Kennedy,  P.E.;  Berger,  E.A.;  Barbas,  C.F.,  3rd;  Pastan,  I.  Specific  killing  of  
HIV-infected  lymphocytes  by  a  recombinant  immunotoxin  directed  against  the  HIV-1  envelope 
glycoprotein. Mol. Med. 1998, 4, 384–391. 
72.  Yang, W.P.; Green, K.; Pinz-Sweeney, S.; Briones, A.T.; Burton, D.R.; Barbas, C.F., 3rd. CDR 
walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the 
picomolar range. J. Mol. Biol. 1995, 254, 392–403. 
73.  Barbas, C.F., 3rd; Hu, D.; Dunlop, N.; Sawyer, L.; Cababa, D.; Hendry, R.M.; Nara, P.L.; Burton, D.R. 
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance 
affinity and broaden strain cross-reactivity. Proc. Natl. Acad. Sci. USA 1994, 91, 3809–3813. 
74.  Ditzel, H.J.; Binley, J.M.; Moore, J.P.; Sodroski, J.; Sullivan, N.; Sawyer, L.S.; Hendry, R.M.; Yang, 
W.P.;  Barbas,  C.F.,  3rd;  Burton,  D.R.  Neutralizing  recombinant  human  antibodies  to  a 
conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an 
epitope-masking procedure. J. Immunol. 1995, 154, 893–906. 
75.  Nishiyama, Y.; Karle, S.; Planque, S.; Taguchi, H.; Paul, S. Antibodies to the superantigenic site of 
HIV-1 gp120: Hydrolytic and binding activities of the light chain subunit. Mol. Immunol. 2007, 44, 
2707–2718. 
76.  Karle, S.; Planque, S.; Nishiyama, Y.; Taguchi, H.; Zhou, Y.X.; Salas, M.; Lake, D.; Thiagarajan, P.; 
Arnett, F.; Hanson, C.V.; et al. Cross-clade HIV-1 neutralization by an antibody fragment from a 
lupus phage display library. AIDS 2004, 18, 329–331. 
77.  Koh, W.W.; Steffensen, S.; Gonzalez-Pajuelo, M.; Hoorelbeke, B.; Gorlani, A.; Szynol, A.; Forsman, 
A.; Aasa-Chapman, M.M.; de Haard, H.; Verrips, T.; et al. Generation of a family-specific phage 
library of llama single chain antibody fragments that neutralize HIV-1. J. Biol. Chem. 2010, 285, 
19116–19124. 
78.  Forsman, A.; Beirnaert, E.; Aasa-Chapman, M.M.; Hoorelbeke, B.; Hijazi, K.; Koh, W.; Tack, V.; 
Szynol, A.; Kelly, C.; McKnight, A.; et al. Llama antibody fragments with cross-subtype human 
immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.  
J. Virol. 2008, 82, 12069–12081. 
79.  Krykbaev,  R.;  McKeating,  J.;  Jones,  I.  Mutant  CD4  molecules  with  improved  binding  to  HIV 
envelope protein gp120 selected by phage display. Virology 1997, 234, 196–202. 
80.  Thompson,  J.;  Pope,  T.;  Tung,  J.S.;  Chan,  C.;  Hollis,  G.;  Mark,  G.;  Johnson,  K.S.  Affinity 
maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of 
human  immunodeficiency  virus:  Use  of  phage  display  to  improve  affinity  and  broaden  strain 
reactivity. J. Mol. Biol. 1996, 256, 77–88. 
81.  Ditzel, H.J.; Parren, P.W.; Binley, J.M.; Sodroski, J.; Moore, J.P.; Barbas, C.F., 3rd; Burton, D.R. 
Mapping  the  protein  surface  of  human  immunodeficiency  virus  type  1  gp120  using  human 
monoclonal antibodies from phage display libraries. J. Mol. Biol. 1997, 267, 684–695. Int. J. Mol. Sci. 2012, 13  4784 
 
 
82.  Ferrer, M.; Harrison, S.C. Peptide ligands to human immunodeficiency virus type 1 gp120 identified 
from phage display libraries. J. Virol. 1999, 73, 5795–5802. 
83.  Moulard, M.; Phogat, S.K.; Shu, Y.; Labrijn, A.F.; Xiao, X.; Binley, J.M.; Zhang, M.Y.; Sidorov, I.A.; 
Broder, C.C.; Robinson, J.; et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal fab 
selected  for  binding  to  gp120-CD4-CCR5  complexes.  Proc.  Natl.  Acad.  Sci.  USA  2002,  99,  
6913–6918. 
84.  Dervillez,  X.;  Klaukien,  V.;  Durr,  R.;  Koch,  J.;  Kreutz,  A.;  Haarmann,  T.;  Stoll,  M.;  Lee,  D.; 
Carlomagno, T.; Schnierle, B.; et al. Peptide ligands selected with cd4-induced epitopes on native 
dualtropic  HIV-1  envelope  proteins  mimic  extracellular  coreceptor  domains  and  bind  to  HIV-1 
gp120 independently of coreceptor usage. J. Virol. 2010, 84, 10131–10138. 
85.  Zwick, M.B.; Labrijn, A.F.; Wang, M.; Spenlehauer, C.; Saphire, E.O.; Binley, J.M.; Moore, J.P.; 
Stiegler,  G.;  Katinger,  H.;  Burton,  D.R.;  et  al.  Broadly  neutralizing  antibodies  targeted  to  the 
membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.  
J. Virol. 2001, 75, 10892–10905. 
86.  Nelson, J.D.; Brunel, F.M.; Jensen, R.; Crooks, E.T.; Cardoso, R.M.; Wang, M.; Hessell, A.; Wilson, 
I.A.;  Binley,  J.M.;  Dawson,  P.E.;  et  al.  An  affinity-enhanced  neutralizing  antibody  against  the 
membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an 
epitope between those of 2F5 and 4E10. J. Virol. 2007, 81, 4033–4043. 
87.  Welch, B.D.; VanDemark, A.P.; Heroux, A.; Hill, C.P.; Kay, M.S. Potent D-peptide inhibitors of 
HIV-1 entry. Proc. Natl. Acad. Sci. USA 2007, 104, 16828–16833. 
88.  Welch,  B.D.;  Francis,  J.N.;  Redman,  J.S.;  Paul,  S.;  Weinstock,  M.T.;  Reeves,  J.D.;  Lie,  Y.S.; 
Whitby, F.G.; Eckert, D.M.; Hill, C.P.; et al. Design of a potent d-peptide HIV-1 entry inhibitor with 
a strong barrier to resistance. J. Virol. 2010, 84, 11235–11244. 
89.  Eckert,  D.M.;  Malashkevich,  V.N.;  Hong,  L.H.;  Carr,  P.A.;  Kim,  P.S.  Inhibiting  HIV-1  entry: 
Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999, 99, 103–115. 
90.  Miller,  M.D.;  Geleziunas,  R.;  Bianchi,  E.;  Lennard,  S.;  Hrin,  R.;  Zhang,  H.;  Lu,  M.;  An,  Z.; 
Ingallinella, P.; Finotto, M.; et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates 
by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. USA 2005, 102, 14759–14764. 
91.  Eckert, D.M.; Kim, P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. 
Proc. Natl. Acad. Sci. USA 2001, 98, 11187–11192. 
92.  Liu, Y.; Regula, L.K.; Stewart, A.; Lai, J.R. Synthetic fab fragments that bind the  HIV-1 gp41 
heptad repeat regions. Biochem. Biophys. Res. Commun. 2011, 413, 611–615. 
93.  Huang, J.H.; Liu, Z.Q.; Liu, S.; Jiang, S.; Chen, Y.H. Identification of the HIV-1 gp41 core-binding 
motif—HXXNPF. FEBS Lett. 2006, 580, 4807–4814. 
94.  Huang, J.H.; Yang, H.W.; Liu, S.; Li, J.; Jiang, S.; Chen, Y.H. The mechanism by which molecules 
containing the HIV gp41 core-binding motif hxxnpf inhibit HIV-1 envelope glycoprotein-mediated 
syncytium formation. Biochem. J. 2007, 403, 565–571. Int. J. Mol. Sci. 2012, 13  4785 
 
 
95.  Louis, J.M.; Bewley, C.A.; Gustchina, E.; Aniana, A.; Clore, G.M. Characterization and HIV-1 fusion 
inhibitory properties of monoclonal fabs obtained from a human non-immune phage library selected 
against diverse epitopes of the ectodomain of HIV-1 gp41. J. Mol. Biol. 2005, 353, 945–951. 
96.  Gustchina, E.; Louis, J.M.; Lam, S.N.; Bewley, C.A.; Clore, G.M. A monoclonal fab derived from a 
human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human 
immunodeficiency virus type 1 strains. J. Virol. 2007, 81, 12946–12953. 
97.  Gustchina, E.; Louis, J.M.; Frisch, C.; Ylera, F.; Lechner, A.; Bewley, C.A.; Clore, G.M. Affinity 
maturation by targeted diversification of the CDR-H2 loop of a monoclonal fab derived from a 
synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 
yields a set of fabs with improved HIV-1 neutralization potency and breadth. Virology 2009, 393, 
112–119. 
98.  Gustchina, E.; Bewley, C.A.; Clore, G.M. Sequestering of the prehairpin intermediate of gp41 by 
peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of 
monoclonal antibodies directed against the N-terminal helical repeat of gp41. J. Virol. 2008, 82, 
10032–10041. 
99.  Nelson,  J.D.;  Kinkead,  H.;  Brunel,  F.M.;  Leaman,  D.;  Jensen,  R.;  Louis,  J.M.;  Maruyama,  T.; 
Bewley, C.A.; Bowdish, K.; Clore, G.M.; et al. Antibody elicited against the gp41 N-heptad repeat 
(NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also 
bind to NHR mimetics. Virology 2008, 377, 170–183. 
100.  Zhang, M.Y.; Vu, B.K.; Choudhary, A.; Lu, H.; Humbert, M.; Ong, H.; Alam, M.; Ruprecht, R.M.; 
Quinnan, G.; Jiang, S.;  et  al. Cross-reactive human immunodeficiency  virus type 1-neutralizing 
human  monoclonal  antibody  that  recognizes  a  novel  conformational  epitope  on  gp41  and  lacks 
reactivity against self-antigens. J. Virol. 2008, 82, 6869–6879. 
101.  Choudhry, V.; Zhang, M.Y.; Sidorov, I.A.; Louis, J.M.; Harris, I.; Dimitrov, A.S.; Bouma, P.; Cham, F.; 
Choudhary, A.; Rybak, S.M.; et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected 
by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated 
from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007, 363, 79–90. 
102.  Zhang, M.Y.; Choudhry, V.; Sidorov, I.A.; Tenev, V.; Vu, B.K.; Choudhary, A.; Lu, H.; Stiegler, G.M.; 
Katinger,  H.W.;  Jiang,  S.;  et  al.  Selection  of  a  novel  gp41-specific  HIV-1  neutralizing  human 
antibody by competitive antigen panning. J. Immunol. Methods 2006, 317, 21–30. 
103.  BouHamdan, M.; Xue, Y.; Baudat, Y.; Hu, B.; Sire, J.; Pomerantz, R.J.; Duan, L.X. Diversity of 
HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins. J. Biol. Chem. 1998, 
273, 8009–8016. 
104.  Krichevsky, A.; Graessmann, A.; Nissim, A.; Piller, S.C.; Zakai, N.; Loyter, A. Antibody fragments 
selected by phage display against the nuclear localization signal of the HIV-1 Vpr protein inhibit 
nuclear import in permeabilized and intact cultured cells. Virology 2003, 305, 77–92. 
105.  Desjobert, C.; de Soultrait, V.R.; Faure, A.; Parissi, V.; Litvak, S.; Tarrago-Litvak, L.; Fournier, M. 
Identification by phage display selection of a short peptide able to inhibit only the strand transfer Int. J. Mol. Sci. 2012, 13  4786 
 
 
reaction  catalyzed  by  human  immunodeficiency  virus  type  1  integrase.  Biochemistry  2004,  43, 
13097–13105. 
106.  Pilkington, G.R.; Duan, L.; Zhu, M.; Keil, W.; Pomerantz, R.J. Recombinant human Fab antibody 
fragments to HIV-1 Rev and Tat regulatory proteins: Direct selection from a combinatorial phage 
display library. Mol. Immunol. 1996, 33, 439–450. 
107.  Bai, J.; Sui, J.; Zhu, R.Y.; Tallarico, A.S.; Gennari, F.; Zhang, D.; Marasco, W.A. Inhibition of  
Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. 
Chem. 2003, 278, 1433–1442. 
108.  Kolb, G.; Boiziau, C. Selection by phage display of peptides  targeting the  HIV-1  Tar  element.  
RNA Biol. 2005, 2, 28–33. 
109.  Lener, D.; Benarous, R.; Calogero, R.A. Use of a constrain phage displayed-peptide library for the 
isolation of peptides binding to HIV-1 nucleocapsid protein (NCp7). FEBS Lett. 1995, 361, 85–88. 
110.  Pustowka, A.; Dietz, J.; Ferner, J.; Baumann, M.; Landersz, M.; Konigs, C.; Schwalbe, H.; Dietrich, U. 
Identification of peptide ligands for target RNA structures derived from the HIV-1 packaging signal 
ψ by screening phage-displayed peptide libraries. ChemBioChem 2003, 4, 1093–1097. 
111.  Dietz, J.; Koch, J.; Kaur, A.; Raja, C.; Stein, S.; Grez, M.; Pustowka, A.; Mensch, S.; Ferner, J.; 
Moller, L.; et al. Inhibition of HIV-1 by a peptide ligand of the genomic RNA packaging signal ψ. 
ChemMedChem 2008, 3, 749–755. 
112.  Park,  M.Y.;  Kwon,  J.;  Lee,  S.;  You,  J.;  Myung,  H.  Selection  and  characterization  of  peptides 
specifically binding to HIV-1 ψ (ψ) RNA. Virus Res. 2004, 106, 77–81. 
113.  Yoshikawa, M.; Mukai, Y.; Tsunoda, S.; Tsutsumi, Y.; Yoshioka, Y.; Okada, N.; Nakagawa, S. 
Modifying  the  antigen-immunization  schedule  improves  the  variety  of  monoclonal  antibodies 
obtained from immune-phage antibody libraries against HIV-1 Nef and Vif. J. Biosci. Bioeng. 2011, 
111, 597–599. 
114.  Bouchet, J.; Basmaciogullari, S.E.; Chrobak, P.; Stolp, B.; Bouchard, N.; Fackler, O.T.; Chames, P.; 
Jolicoeur,  P.;  Benichou,  S.;  Baty,  D.  Inhibition  of  the  nef  regulatory  protein  of  HIV-1  by  a  
single-domain antibody. Blood 2011, 117, 3559–3568. 
115.  Nunoya, J.; Nakashima, T.; Kawana-Tachikawa, A.; Kiyotani, K.; Ito, Y.; Sugimura, K.; Iwamoto, A. 
Short communication: Generation of recombinant monoclonal antibodies against an immunodominant 
HLA-A*2402-restricted HIV type 1 CTL epitope. AIDS Res. Hum. Retrovir. 2009, 25, 897–904. 
116.  Yang, S.; Sun, Y.; Zhang, H. The multimerization of human immunodeficiency virus type I Vif 
protein: A requirement for Vif function in the viral life cycle. J. Biol. Chem. 2001, 276, 4889–4893. 
117.  Yang, B.; Gao, L.; Li, L.; Lu, Z.; Fan, X.; Patel, C.A.; Pomerantz, R.J.; DuBois, G.C.; Zhang, H. 
Potent  suppression  of  viral  infectivity  by  the  peptides  that  inhibit  multimerization  of  human 
immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 2003, 278, 6596–6602. 
118.  Ohba, H.; Soga, T.; Tomozawa, T.; Nishikawa, Y.; Yasuda, A.; Kojima, A.; Kurata, T.; Chiba, J.  
An immunodominant neutralization epitope on the ―thumb‖ subdomain of human immunodeficiency 
virus type 1 reverse transcriptase revealed by phage display antibodies. J. Gen. Virol. 2001, 82, 813–820. Int. J. Mol. Sci. 2012, 13  4787 
 
 
119.  Chiba, J.; Yamaguchi, A.; Suzuki, Y.; Nakano, M.; Zhu, W.; Ohba, H.; Saito, A.; Shinagawa, H.; 
Yamakawa, Y.; Kobayashi, T.; et al. A novel neutralization epitope on the ―thumb‖ subdomain of 
human immunodeficiency virus type 1 reverse transcriptase revealed by a monoclonal antibody.  
J. Gen. Virol. 1996, 77 (Pt 12), 2921–2929. 
120.  Herschhorn,  A.;  Admon,  A.;  Hizi,  A.  Recombinant  human  antibodies  against  the  reverse 
transcriptase of human immunodeficiency virus type-1. Biochim. Biophys. Acta 2003, 1648, 154–163. 
121.  Jensen, A.; Jensen, T.H.; Kjems, J. HIV-1 Rev nuclear export signal binding peptides isolated by 
phage display. J. Mol. Biol. 1998, 283, 245–254. 
122. Vercruysse, T.; Pawar, S.; de Borggraeve, W.; Pardon, E.; Pavlakis, G.N.; Pannecouque, C.; Steyaert, 
J.;  Balzarini,  J.;  Daelemans,  D.  Measuring  cooperative  Rev  protein-protein  interactions  on  rev 
responsive RNA by fluorescence resonance energy transfer. RNA Biol. 2011, 8, 316–324. 
123.  Vercruysse, T.; Pardon, E.; Vanstreels, E.; Steyaert, J.; Daelemans, D. An intrabody based on a 
llama single-domain antibody targeting the N-terminal α-helical multimerization domain of HIV-1 
Rev prevents viral production. J. Biol. Chem. 2010, 285, 21768–21780. 
124.  Stahl,  S.J.;  Watts,  N.R.;  Rader,  C.;  DiMattia,  M.A.;  Mage,  R.G.;  Palmer,  I.;  Kaufman,  J.D.;  
Grimes,  J.M.;  Stuart,  D.I.;  Steven,  A.C.;  et  al.  Generation  and  characterization  of  a  chimeric 
rabbit/human fab for co-crystallization of HIV-1 Rev. J. Mol. Biol. 2010, 397, 697–708. 
125.  Sticht, J.; Humbert, M.; Findlow, S.; Bodem, J.; Muller, B.; Dietrich, U.; Werner, J.; Krausslich, H.G.  
A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 2005, 12, 671–677. 
126.  Huang, L.; Zhang, L.; Chen, C.H. Potential drug targets on the HIV-1 envelope glycoproteins, gp120 
and gp41. Curr. Pharm. Des. 2003, 9, 1453–1462. 
127.  Kadow, J.; Wang, H.G.; Lin, P.F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: 
An emerging opportunity for drug development. Curr. Opin. Investig. Drugs 2006, 7, 721–726. 
128.  Koefoed,  K.;  Farnaes,  L.;  Wang,  M.;  Svejgaard,  A.;  Burton,  D.R.;  Ditzel,  H.J.  Molecular 
characterization of the circulating anti-HIV-1 gp120-specific b cell repertoire using antibody phage 
display libraries generated from pre-selected HIV-1 gp120 binding PBLs. J. Immunol. Methods 2005, 
297, 187–201. 
129.  Parren, P.W.; Gauduin, M.C.; Koup, R.A.; Poignard, P.; Fisicaro, P.; Burton, D.R.; Sattentau, Q.J. 
Relevance  of  the  antibody  response  against  human  immunodeficiency  virus  type  1  envelope  to 
vaccine design. Immunol. Lett. 1997, 57, 105–112. 
130.  Bermas,  B.L.;  Petri,  M.;  Berzofsky,  J.A.;  Waisman,  A.;  Shearer,  G.M.;  Mozes,  E.  Binding  of 
glycoprotein  120  and  peptides  from  the  HIV-1  envelope  by  autoantibodies  in  mice  with 
experimentally induced systemic lupus erythematosus and in patients with the disease. AIDS Res. 
Hum. Retrovir. 1994, 10, 1071–1077. 
131.  Zhou,  Y.X.;  Karle,  S.;  Taguchi,  H.;  Planque,  S.;  Nishiyama,  Y.;  Paul,  S.  Prospects  for 
immunotherapeutic proteolytic antibodies. J. Immunol. Methods 2002, 269, 257–268. 
132.  Paul,  S.;  Tramontano,  A.;  Gololobov,  G.;  Zhou,  Y.X.;  Taguchi,  H.;  Karle,  S.;  Nishiyama,  Y.; 
Planque, S.; George, S. Phosphonate ester probes for proteolytic antibodies. J. Biol. Chem. 2001, 
276, 28314–28320. Int. J. Mol. Sci. 2012, 13  4788 
 
 
133.  Paul, S.; Karle, S.; Planque, S.; Taguchi,  H.; Salas, M.; Nishiyama, Y.; Handy, B.; Hunter, R.; 
Edmundson, A.; Hanson, C. Naturally occurring proteolytic antibodies: Selective immunoglobulin 
m-catalyzed hydrolysis of HIV gp120. J. Biol. Chem. 2004, 279, 39611–39619. 
134.  Paul,  S.;  Nishiyama,  Y.;  Planque,  S.;  Taguchi,  H.  Theory  of  proteolytic  antibody  occurrence. 
Immunol. Lett. 2006, 103, 8–16. 
135.  Gao, Q.S.; Sun, M.; Rees, A.R.; Paul, S. Site-directed mutagenesis of proteolytic antibody light 
chain. J. Mol. Biol. 1995, 253, 658–664. 
136.  Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; 
Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363, 
446–448. 
137.  Vanlandschoot, P.; Stortelers, C.; Beirnaert, E.; Ibanez, L.I.; Schepens, B.; Depla, E.; Saelens, X. 
Nanobodies(r): New ammunition to battle viruses. Antiviral Res. 2011, 92, 389–407. 
138.  Biorn, A.C.; Cocklin, S.; Madani, N.; Si, Z.; Ivanovic, T.; Samanen, J.; van Ryk, D.I.; Pantophlet, R.; 
Burton,  D.R.;  Freire,  E.;  et  al.  Mode  of  action  for  linear  peptide  inhibitors  of  HIV-1  gp120 
interactions. Biochemistry 2004, 43, 1928–1938. 
139.  Garg, R.; Juncadella, I.J.; Ramamoorthi, N.; Ashish; Ananthanarayanan, S.K.; Thomas, V.; Rincon, M.; 
Krueger, J.K.; Fikrig, E.; Yengo, C.M.; et al. Cutting edge: CD4 is the receptor for the tick saliva 
immunosuppressor, Salp15. J. Immunol. 2006, 177, 6579–6583. 
140.  Juncadella, I.J.; Garg, R.; Bates, T.C.; Olivera, E.R.; Anguita, J. The ixodes scapularis salivary 
protein, Salp15, prevents the association of HIV-1 gp120 and CD4. Biochem. Biophys. Res. Commun. 
2008, 367, 41–46. 
141.  Llorente,  M.;  Sanchez-Palomino,  S.;  Manes,  S.;  Lucas,  P.;  Kremer,  L.;  de  Alboran,  I.M.;  
Toran, J.L.; Alcami, J.; Del Real, G.; Martinez, A.C. Natural human antibodies retrieved by phage 
display libraries from healthy donors: Polyreactivity and recognition of human immunodeficiency 
virus type 1gp120 epitopes. Scand. J. Immunol. 1999, 50, 270–279. 
142.  Berberian, L.; Valles-Ayoub, Y.; Sun, N.; Martinez-Maza, O.; Braun, J. A VH clonal deficit in 
human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood 1991, 
78, 175–179. 
143.  David, D.; Demaison, C.; Bani, L.; Zouali, M.; Theze, J. Selective variations in vivo of VH3 and 
VH1 gene family expression in peripheral B cell igM, igD and igG during HIV infection. Eur. J. 
Immunol. 1995, 25, 1524–1528. 
144.  Toran, J.L.; Kremer, L.; Sanchez-Pulido, L.; de Alboran, I.M.; del Real, G.; Llorente, M.; Valencia, A.; 
de Mon, M.A.; Martinez, A.C. Molecular analysis of HIV-1 gp120 antibody response using isotype 
igM and igG phage display libraries from a long-term non-progressor HIV-1-infected individual.  
Eur. J. Immunol. 1999, 29, 2666–2675. 
145.  Toran,  J.L.;  Sanchez-Pulido,  L.;  Kremer,  L.;  del  Real,  G.;  Valencia,  A.;  Martinez,  A.C. 
Improvement  in  affinity  and  HIV-1  neutralization  by  somatic  mutation  in  the  heavy  chain  first 
complementarity-determining region of antibodies triggered by HIV-1 infection. Eur. J. Immunol. 
2001, 31, 128–137. Int. J. Mol. Sci. 2012, 13  4789 
 
 
146.  Chen,  W.;  Zhu,  Z.;  Liao,  H.;  Quinnan,  G.V.,  Jr.;  Broder,  C.C.;  Haynes,  B.F.;  Dimitrov,  D.S.  
Cross-reactive human igm-derived monoclonal antibodies that bind to HIV-1 envelope glycoproteins. 
Viruses 2010, 2, 547–565. 
147.  Chen, W.; Streaker, E.D.; Russ, D.E.; Feng, Y.; Prabakaran, P.; Dimitrov, D.S. Characterization of 
germline  antibody  libraries  from  human  umbilical  cord  blood  and  selection  of  monoclonal 
antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and 
design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2012, 417, 1164–1169. 
148.  Zhu, Z.; Qin, H.R.; Chen, W.; Zhao, Q.; Shen, X.; Schutte, R.; Wang, Y.; Ofek, G.; Streaker, E.; 
Prabakaran, P.; et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified 
from a patient with 2F5-like antibodies. J. Virol. 2011, 85, 11401–11408. 
149.  Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; DeMasi, R.; Bolognesi, D. Enfuvirtide: The first 
therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 2004, 3, 
215–225. 
150.  Schumacher,  T.N.;  Mayr,  L.M.;  Minor,  D.L.,  Jr.;  Milhollen,  M.A.;  Burgess,  M.W.;  Kim,  P.S. 
Identification of D-peptide ligands through mirror-image phage display. Science 1996, 271, 1854–1857. 
151.  Root,  M.J.;  Kay,  M.S.;  Kim,  P.S.  Protein  design  of  an  HIV-1  entry  inhibitor.  Science  2001,  291,  
884–888. 
152.  Fellouse,  F.A.;  Li,  B.;  Compaan,  D.M.;  Peden,  A.A.;  Hymowitz,  S.G.;  Sidhu,  S.S.  Molecular 
recognition by a binary code. J. Mol. Biol. 2005, 348, 1153–1162. 
153.  Luftig,  M.A.;  Mattu,  M.;  di  Giovine,  P.;  Geleziunas,  R.;  Hrin,  R.;  Barbato,  G.;  Bianchi,  E.;  
Miller,  M.D.;  Pessi,  A.;  Carfi,  A.  Structural  basis  for  HIV-1  neutralization  by  a  gp41  fusion 
intermediate-directed antibody. Nat. Struct. Mol. Biol. 2006, 13, 740–747. 
154.  Lu, M.; Ji, H.; Shen, S. Subdomain folding and biological activity of the core structure from human 
immunodeficiency virus type 1 gp41: Implications for viral membrane fusion. J. Virol. 1999, 73, 
4433–4438. 
155.  Knappik, A.; Ge, L.; Honegger, A.; Pack, P.; Fischer, M.; Wellnhofer, G.; Hoess, A.; Wolle, J.; 
Pluckthun, A.; Virnekas, B. Fully synthetic human combinatorial antibody libraries (HuCAL) based 
on modular consensus frameworks and cdrs randomized with trinucleotides. J. Mol. Biol. 2000, 296, 
57–86. 
156.  Louis, J.M.; Nesheiwat, I.; Chang, L.; Clore, G.M.; Bewley, C.A. Covalent trimers of the internal  
N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of 
HIV envelope-mediated cell fusion. J. Biol. Chem. 2003, 278, 20278–20285. 
157.  Louis, J.M.; Bewley, C.A.; Clore, G.M. Design and properties of N(CCG)-gp41, a chimeric gp41 
molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 2001, 276, 29485–29489. 
158.  Bewley, C.A.; Louis, J.M.; Ghirlando, R.; Clore, G.M. Design of a novel peptide inhibitor of HIV 
fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 2002, 277, 14238–14245. 
159. Montefiori, D.C.; Pantaleo, G.; Fink, L.M.; Zhou, J.T.; Zhou, J.Y.; Bilska, M.; Miralles, G.D.; Fauci, 
A.S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus 
type 1 in long-term nonprogressors. J. Infect. Dis. 1996, 173, 60–67. Int. J. Mol. Sci. 2012, 13  4790 
 
 
160.  Agostini,  I.; Navarro, J.M.; Rey, F.;  Bouhamdan, M.; Spire, B.; Vigne, R.; Sire, J. The human 
immunodeficiency  virus  type  1  Vpr  transactivator:  Cooperation  with  promoter-bound  activator 
domains and binding to TFIIB. J. Mol. Biol. 1996, 261, 599–606. 
161.  Stewart, S.A.; Poon, B.; Jowett, J.B.; Chen, I.S. Human immunodeficiency virus type 1 Vpr induces 
apoptosis following cell cycle arrest. J. Virol. 1997, 71, 5579–5592. 
162.  Cohen,  E.A.;  Dehni,  G.;  Sodroski,  J.G.;  Haseltine,  W.A.  Human  immunodeficiency  virus  Vpr 
product is a virion-associated regulatory protein. J. Virol. 1990, 64, 3097–3099. 
163.  Cohen,  E.A.;  Terwilliger,  E.F.;  Jalinoos,  Y.;  Proulx,  J.;  Sodroski,  J.G.;  Haseltine,  W.A. 
Identification of HIV-1 Vpr product and function. J. Acquir. Immune Defic. Syndr. 1990, 3, 11–18. 
164.  Bouhamdan,  M.;  Benichou,  S.;  Rey,  F.;  Navarro,  J.M.;  Agostini,  I.;  Spire,  B.;  Camonis,  J.; 
Slupphaug, G.; Vigne, R.; Benarous, R.; et al. Human immunodeficiency virus type 1 Vpr protein 
binds to the Uracil DNA glycosylase DNA repair enzyme. J. Virol. 1996, 70, 697–704. 
165.  Refaeli, Y.; Levy, D.N.; Weiner, D.B. The glucocorticoid receptor type II complex is a target of the 
HIV-1 Vpr gene product. Proc. Natl. Acad. Sci. USA 1995, 92, 3621–3625. 
166.  Wang, L.; Mukherjee, S.; Jia, F.; Narayan, O.; Zhao, L.J. Interaction of virion protein Vpr of human 
immunodeficiency virus type 1 with cellular transcription factor sp1 and trans-activation of viral 
long terminal repeat. J. Biol. Chem. 1995, 270, 25564–25569. 
167.  Nissim, A.; Hoogenboom, H.R.; Tomlinson, I.M.; Flynn, G.; Midgley, C.; Lane, D.; Winter, G. 
Antibody fragments from a ―single pot‖ phage display library as immunochemical reagents. EMBO J. 
1994, 13, 692–698. 
168.  Garber, M.E.; Wei, P.; Jones, K.A. HIV-1 tat interacts with cyclin t1 to direct the p-TEFb CTD 
kinase complex to TAR RNA. Cold Spring Harb. Symp. Quant. Biol. 1998, 63, 371–380. 
169.  Druillennec, S.; Dong, C.Z.; Escaich, S.; Gresh, N.; Bousseau, A.; Roques, B.P.; Fournie-Zaluski, M.C. 
A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. 
Proc. Natl. Acad. Sci. USA 1999, 96, 4886–4891. 
170.  Druillennec, S.; Caneparo, A.; de Rocquigny, H.; Roques, B.P. Evidence of interactions between  
the nucleocapsid protein ncp7 and the reverse transcriptase of HIV-1. J. Biol. Chem. 1999, 274, 
11283–11288. 
171.  Frankel, A.D.; Young, J.A. HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67,  
1–25. 
172.  Cimarelli, A.; Sandin, S.; Hoglund, S.; Luban, J. Basic residues in human immunodeficiency virus 
type  1  nucleocapsid  promote  virion  assembly  via  interaction  with  RNA.  J.  Virol.  2000,  74,  
3046–3057. 
173.  Hashiguchi,  S.;  Nakashima,  T.;  Nitani,  A.;  Yoshihara,  T.;  Yoshinaga,  K.;  Ito,  Y.;  Maeda,  Y.; 
Sugimura,  K.  Human  Fc  epsilon  rialpha-specific  human  single-chain  Fv  (ScFv)  antibody  with 
antagonistic activity toward igE/Fc epsilon Rialpha-binding. J. Biochem. 2003, 133, 43–49. 
174.  Gargano,  N.;  Biocca,  S.;  Bradbury,  A.;  Cattaneo,  A.  Human  recombinant  antibody  fragments 
neutralizing human immunodeficiency virus type 1 reverse transcriptase provide an experimental 
basis for the structural classification of the DNA polymerase family. J. Virol. 1996, 70, 7706–7712. Int. J. Mol. Sci. 2012, 13  4791 
 
 
175.  Heaphy, S.; Finch, J.T.; Gait, M.J.; Karn, J.; Singh, M. Human immunodeficiency virus type 1 
regulator of virion expression, Rev, forms nucleoprotein filaments after binding to a purine-rich 
―Bubble‖ Located within the Rev-responsive region of viral mRNAs. Proc. Natl. Acad. Sci. USA 
1991, 88, 7366–7370. 
176.  De  Haard,  J.J.;  Kazemier,  B.;  Oudshoorn,  P.;  Boender,  P.;  van  Gemen,  B.;  Koolen,  M.J.;  
van  der  Groen,  G.;  Hoogenboom,  H.R.;  Arends,  J.W.  Selection  of  human  anti-human 
immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based 
phage repertoire. J. Gen. Virol. 1998, 79 (Pt 12), 2883–2894. 
177.  Khurana, S.; Needham, J.; Mathieson, B.; Rodriguez-Chavez, I.R.; Catanzaro, A.T.; Bailer, R.T.; 
Kim, J.; Polonis, V.; Cooper, D.A.; Guerin, J.; et al. Human immunodeficiency virus (HIV) vaccine 
trials: A novel assay for differential diagnosis of HIV infections in the face of vaccine-generated 
antibodies. J. Virol. 2006, 80, 2092–2099. 
178.  Vyroubalova,  E.C.;  Hartley,  O.;  Mermod,  N.;  Fisch,  I.  Identification  of  peptide  ligands  to  the 
chemokine  receptor  CCR5  and  their  maturation  by  gene  shuffling.  Mol.  Immunol.  2006,  43,  
1573–1578. 
179.  Wang, F.Y.; Zhang, T.Y.; Luo, J.X.; He, G.A.; Gu, Q.L.;  Xiao, F. Selection of CC chemokine 
receptor 5-binding peptide from a phage display peptide library. Biosci. Biotechnol. Biochem. 2006, 
70, 2035–2041. 
180.  Mirzabekov, T.; Kontos, H.; Farzan, M.; Marasco, W.; Sodroski, J. Paramagnetic proteoliposomes 
containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat. Biotechnol. 
2000, 18, 649–654. 
181.  Zhang, Y.; Pool, C.; Sadler, K.; Yan, H.P.; Edl, J.; Wang, X.; Boyd, J.G.; Tam, J.P. Selection of 
active  ScFv  to  g-protein-coupled  receptor  CCR5  using  surface  antigen-mimicking  peptides. 
Biochemistry 2004, 43, 12575–12584. 
182.  Chevigne, A.; Fischer, A.; Mathu, J.; Counson, M.; Beaupain, N.; Plesseria, J.M.; Schmit, J.C.; 
Deroo, S. Selection of a CXCR4 antagonist from a human heavy chain CDR3-derived phage library. 
FEBS J. 2011, 278, 2867–2878. 
183.  Huang, Y.; Paxton, W.A.; Wolinsky, S.M.; Neumann, A.U.; Zhang, L.; He, T.; Kang, S.; Ceradini, D.; 
Jin, Z.; Yazdanbakhsh, K.; et al. The role of a mutant CCR5 allele in HIV-1 transmission and 
disease progression. Nat. Med. 1996, 2, 1240–1243. 
184.  Steinberger, P.; Sutton, J.K.; Rader, C.; Elia, M.; Barbas, C.F., 3rd. Generation and characterization 
of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody 
humanization. J. Biol. Chem. 2000, 275, 36073–36078. 
185.  Hartley, O.; Dorgham, K.; Perez-Bercoff, D.; Cerini, F.; Heimann, A.; Gaertner, H.; Offord, R.E.; 
Pancino,  G.;  Debre,  P.;  Gorochov,  G.  Human  immunodeficiency  virus  type  1  entry  inhibitors 
selected on living cells from a library of phage chemokines. J. Virol. 2003, 77, 6637–6644. 
186.  Gaertner,  H.;  Cerini,  F.;  Escola,  J.M.;  Kuenzi,  G.;  Melotti,  A.;  Offord,  R.;  Rossitto-Borlat,  I.; 
Nedellec, R.; Salkowitz, J.; Gorochov, G.; et al. Highly potent, fully recombinant anti-HIV chemokines: 
Reengineering a low-cost microbicide. Proc. Natl. Acad. Sci. USA 2008, 105, 17706–17711. Int. J. Mol. Sci. 2012, 13  4792 
 
 
187.  Jahnichen,  S.;  Blanchetot,  C.;  Maussang,  D.;  Gonzalez-Pajuelo,  M.;  Chow,  K.Y.;  Bosch,  L.;  
de Vrieze, S.; Serruys, B.; Ulrichts, H.; Vandevelde, W.; et al. CXCR4 nanobodies (VHH-based 
single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.  
Proc. Natl. Acad. Sci. USA 2010, 107, 20565–20570. 
188.  Ellmark, P.; Andersson, H.; Abayneh, S.; Fenyo, E.M.; Borrebaeck, C.A. Identification of a strongly 
activating human anti-CD40 antibody that suppresses HIV type 1 infection. AIDS Res. Hum. Retrovir. 
2008, 24, 367–373. 
189.  Ellmark, P.; Ottosson, C.; Borrebaeck, C.A.; Malmborg Hager, A.C.; Furebring, C. Modulation of 
the  CD40-CD40  ligand  interaction  using  human  anti-CD40  single-chain  antibody  fragments 
obtained from the n-coder phage display library. Immunology 2002, 106, 456–463. 
190.  Garbelli, A.; Beermann, S.;  di Cicco, G.; Dietrich, U.; Maga, G. A motif unique to the human  
dead-box  protein  DDX3  is  important  for  nucleic  acid  binding,  ATP  hydrolysis,  RNA/DNA 
unwinding and HIV-1 replication. PLoS One 2011, 6, doi:10.1371/journal.pone.0019810. 
191.  Chevigne, A.; Fievez, V.; Schmit, J.C.; Deroo, S. Engineering and screening the  N-terminus  of 
chemokines for drug discovery. Biochem. Pharmacol. 2011, 82, 1438–1456. 
192.  Tamamura, H.; Fujii, N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV 
infection, cancer metastasis and rheumatoid arthritis. Expert Opin. Ther. Targets 2005, 9, 1267–1282. 
193.  Steen,  A.;  Schwartz,  T.W.;  Rosenkilde,  M.M.  Targeting  CXCR4  in  HIV  cell-entry  inhibition.  
Mini Rev. Med. Chem. 2009, 9, 1605–1621. 
194.  Deroo,  S.;  Fischer,  A.;  Beaupain,  N.;  Counson,  M.;  Boutonnet,  N.;  Pletinckx,  J.;  Loverix,  S.; 
Beirnaert, E.; de Haard, H.; Schmit, J.C.; et al. Non-immunized natural human heavy chain CDR3 
repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin 
epitope. Mol. Immunol. 2008, 45, 1366–1373. 
195.  Rubinstein,  D.B.;  Leblanc,  P.;  Wright,  D.G.;  Guillaume,  T.;  Strotchevoi,  A.;  Boosalis,  M.  
Anti-CD34+  fabs  generated  against  hematopoietic  stem  cells  in  HIV-derived  combinatorial 
immunoglobulin library suggest antigen-selected autoantibodies. Mol. Immunol. 1998, 35, 955–964. 
196.  Abayneh, S.A.; Ellmark, P.; Karlsson, U.; Andersson, H.; Borrebaeck, C.A.; Karlsson, I.; Fenyo, E.M. 
Sensitivity of HIV type 1 primary isolates to human anti-CD40 antibody-mediated suppression is 
related to coreceptor use. AIDS Res. Hum. Retrovir. 2008, 24, 447–452. 
197.  Matthews, D.J.; Wells, J.A. Substrate phage: Selection of protease substrates by monovalent phage 
display. Science 1993, 260, 1113–1117. 
198.  Beck, Z.Q.; Lin, Y.C.; Elder, J.H. Molecular basis for the relative substrate specificity of human 
immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J. Virol. 2001, 75, 
9458–9469. 
199.  Beck, Z.Q.; Hervio, L.; Dawson, P.E.; Elder, J.H.; Madison, E.L. Identification of efficiently cleaved 
substrates  for  HIV-1  protease  using  a  phage  display  library  and  use  in  inhibitor  development. 
Virology 2000, 274, 391–401. 
200.  Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. 
Commun. 1967, 27, 157–162. Int. J. Mol. Sci. 2012, 13  4793 
 
 
201.  Tozser, J.; Weber, I.T.; Gustchina, A.; Blaha, I.; Copeland, T.D.; Louis, J.M.; Oroszlan, S. Kinetic 
and modeling studies of s3-s3' subsites of HIV proteinases. Biochemistry 1992, 31, 4793–4800. 
202.  Kleinschmidt, W.J.; Douthart, R.J.; Murphy, E.B. Interferon production by t4 coliphage.  Nature 
1970, 228, 27–30. 
203.  Clark, J.R.; March, J.B. Bacterial viruses as human vaccines? Expert Rev. Vaccines 2004, 3, 463–476. 
204.  Jepson, C.D.; March, J.B. Bacteriophage lambda is a highly stable DNA vaccine delivery vehicle. 
Vaccine 2004, 22, 2413–2419. 
205.  Minenkova, O.O.; Ilyichev, A.A.; Kishchenko, G.P.; Petrenko, V.A. Design of specific immunogens 
using filamentous phage as the carrier. Gene 1993, 128, 85–88. 
206.  De  Berardinis,  P.;  Sartorius,  R.;  Fanutti, C.; Perham,  R.N.; Del  Pozzo, G.; Guardiola, J. Phage 
display of peptide epitopes from HIV-1 elicits strong cytolytic responses. Nat. Biotechnol. 2000, 18, 
873–876. 
207.  Di Marzo Veronese, F.; Willis, A.E.; Boyer-Thompson, C.; Appella, E.; Perham, R.N. Structural 
mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage. 
The V3 loop of HIV-1 gp120. J. Mol. Biol. 1994, 243, 167–172. 
208.  Cano,  A.;  Viveros,  M.;  Acero,  G.;  Govezensky,  T.;  Munguia,  M.E.;  Gonzalez,  E.;  Soto,  L.; 
Gevorkian,  G.;  Manoutcharian,  K.  Antigenic  properties  of  phage  displayed  peptides  comprising 
disulfide-bonded loop  of the immunodominant region  of  HIV-1  gp41.  Immunol. Lett.  2004,  95,  
207–212. 
209.  Majumdar, S.; Hajduczki, A.; Mendez, A.S.; Weiss, G.A. Phage display of functional, full-length 
human and viral membrane proteins. Bioorg. Med. Chem. Lett. 2008, 18, 5937–5940. 
210.  Perham,  R.N.;  Terry,  T.D.;  Willis,  A.E.;  Greenwood,  J.;  di  Marzo  Veronese,  F.;  Appella,  E. 
Engineering a peptide epitope display system on filamentous bacteriophage. FEMS Microbiol. Rev. 
1995, 17, 25–31. 
211.  Ren, Z.; Black, L.W. Phage T4 SOC and HOC display of biologically active, full-length proteins on 
the viral capsid. Gene 1998, 215, 439–444. 
212. Peabody, D.S.; Manifold-Wheeler, B.; Medford, A.; Jordan, S.K.; do Carmo Caldeira, J.; Chackerian, 
B.  Immunogenic  display  of  diverse  peptides  on  virus-like  particles  of  RNA  phage  MS2.  
J. Mol. Biol. 2008, 380, 252–263. 
213.  Mattiacio, J.; Walter, S.; Brewer, M.; Domm, W.; Friedman, A.E.; Dewhurst, S. Dense display of 
HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved 
antibody responses to HIV-1 Env. Vaccine 2011, 29, 2637–2647. 
214.  Ren, Z.J.; Lewis, G.K.; Wingfield, P.T.; Locke, E.G.; Steven, A.C.; Black, L.W. Phage display of 
intact domains at high copy number: A system based on soc, the small outer capsid protein of 
bacteriophage T4. Protein Sci. 1996, 5, 1833–1843. 
215.  Pedroza-Roldan, C.; Charles-Nino, C.; Saavedra, R.; Govezensky, T.; Vaca, L.; Avaniss-Aghajani, E.; 
Gevorkian, G.; Manoutcharian, K. Variable epitope library-based vaccines: Shooting moving targets. 
Mol. Immunol. 2009, 47, 270–282. Int. J. Mol. Sci. 2012, 13  4794 
 
 
216.  Sathaliyawala,  T.;  Rao,  M.;  Maclean,  D.M.;  Birx,  D.L.;  Alving,  C.R.;  Rao,  V.B.  Assembly  of 
human immunodeficiency virus (HIV) antigens on bacteriophage T4: A novel in vitro approach to 
construct multicomponent HIV vaccines. J. Virol. 2006, 80, 7688–7698. 
217.  Caldeira Jdo, C.; Medford, A.; Kines, R.C.; Lino, C.A.; Schiller, J.T.; Chackerian, B.; Peabody, D.S. 
Immunogenic  display  of  diverse  peptides,  including  a  broadly  cross-type  neutralizing  human 
papillomavirus l2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010, 28, 
4384–4393. 
218.  Charles-Nino, C.; Pedroza-Roldan, C.; Viveros, M.; Gevorkian, G.; Manoutcharian, K. Variable 
epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency 
virus type 1-neutralizing antibody response. Vaccine 2011, 29, 5313–5321. 
219.  Ishii, T.; Yanagida, M. The two dispensable structural proteins (soc and hoc) of the T4 phage capsid; 
their purification and properties, isolation and characterization of the defective mutants, and their 
binding with the defective heads in vitro. J. Mol. Biol. 1977, 109, 487–514. 
220.  Zhu,  P.;  Liu,  J.;  Bess,  J.,  Jr.;  Chertova,  E.;  Lifson,  J.D.;  Grise,  H.;  Ofek,  G.A.;  Taylor,  K.A.;  
Roux, K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 
2006, 441, 847–852. 
221.  Deroo,  S.;  Muller,  C.P.  Antigenic  and  immunogenic  phage  displayed  mimotopes  as  substitute 
antigens: Applications and limitations. Comb. Chem. High Throughput Screen. 2001, 4, 75–110. 
©  2012  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 